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Abstract
The immune system’s vitality and function is of the upmost importance in the
human body. The ingenuity and performance of this defence mechanism also
plays a role in the prevention of mutated, transformed cells becoming malig-
nant tumours (cancers). More recently, the subject of cancer immunology has
been concerned with examining the local effects the immune system has on
a pre-angiogenic tumour site. A recent immunological review article - “The
Three Es of Cancer Immunoediting” - discusses the way the immune system
interacts with cancer cells: elimination, equilibrium, and escape. This bio-
logical explanation underpins the mathematical modelling in this PhD thesis
where mathematical models of pre-angiogenic immune-tumour interactions
are presented and analysed. Chapter two develops an individual-based model
of immune-cancer cell interactions using the computational simulation plat-
form, CompuCell3D, to extend an earlier spatio-temporal model of tumour
dormancy (Matzavinos et al. [2004]). Chapter three investigates and analyses
an ODE model of the interaction of two immune cells and two tumour cells.
This model is extended to include spatial movement terms for the tumour
and immune cells (in both one and two dimensions) and investigates the rich
heterogeneous spatio-temporal dynamics of the system in the presence of a
7
limit cycle in the reaction kinetics. Finally, chapter four extends the models
in the previous two chapters by examining an individual based model of two
immune cell populations interacting with two tumour cell populations.
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Chapter 1
Introduction
A tumour can be described as: an abnormal mass of tissue whose growth ex-
ceeds that of normal tissue, is uncoordinated with that of the normal tissue,
and persists in the same excessive manner after cessation of the stimuli which
evoke the change (MacSween and Whaley [1992]). Cancer growth has three
stages: avascular, angiogenesis and metastasis and invasion. Each of these
cancer growth stages have their own dynamics, however this thesis will be
concerned with the avascular stage of growth. Here, the tumour mass is in its
infancy, and has a maximum size of around 106 cells in volume. It does not
have a blood network and therefore survives only on the nutrient that is avail-
able to it in the local tissue. The theory of immunoediting, developed to try
and categorise tumour-immune interactions has become quite popular within
the literature, and this thesis will aim to explore it. There are three stages,
named the three Es of immunoediting, which are: elimination, equilibrium
and escape. Equilibrium can persist for a number of years; a phenomenon
deemed “cancer dormancy”. The exploration of the immune system’s abil-
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ity to fight cancer is extremely important for the destruction of the disease,
however the complex nature of cancer continues to elude researchers. To aid
in the pursuit of a cure, mathematical modelling is an advantageous tool,
which can be used to predict and examine the most important aspects of the
disease. This thesis has therefore aimed to mathematically model important
aspects of the immune-tumour environment.
This thesis investigates multiple models that explore the immune system’s
defence against malignant growth. Sections 1.1, 1.2 and 1.3 give relevant bi-
ological and mathematical backgrounds. Chapter 2 develops an individual
based model of CD8+ T-cells when in interaction with a tumour population.
These cells, often called cytotoxic T-cells, are immune cells that have vast
targets and are potent to tumour cells. The uptake of oxygen by the cancer
cells and immune cells is also modelled. The aim is to try and model the Es of
immunoediting to better understand the dynamics which govern each stage.
Chapter 3 is concerned with exploring the interaction of tumour cells with
both cytotoxic T-lymphocytes and T-helper cells. Although, traditionally,
cytotoxic lymphocytes have been thought of as the “gold standard” cells in
the tumour-immune microenvironment, more recently, the CD4+ T-cell has
been shown to provide better immunological defence against tumours in cer-
tain situations. Moreover, this chapter will also examine different phenotype
of cancer cells, whereby one tumour cell is more potent than the other. Chap-
ter 4, extends both of the previous chapter’s models, by utilising a discrete
model to investigate different tumour phenotypes and the Warburg effect.
Finally, Chapter 5 explores the improvement and possible extensions of the
mathematical models developed in this thesis.
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1.1 Cancer Immunology
This section discusses the immune system’s ability to destroy cancer cells.
An overview of the immune system is examined in the first section, focusing
on different types of immune cells and their functions within the body. The
second section explores the hypothesis of “immunoediting”, which describes
the process by which tumour cells can be eliminated by the immune sys-
tem, kept at an equilibrium state by the immune system, or evade immune
destruction. Moreover, this chapter then examines the role different pheno-
types of tumours and immune cells play in the microenvironment. The last
section explores the “Warburg Effect” and how this fuels cancer cell growth
and their ability to evade immune detection.
1.1.1 The Immune System
In a world teeming with hostile, subtle, and rapidly evolving pathogens, how
does a fragile and slowly evolving human survive? Like all other multicellular
organisms, we have evolved several different mechanisms to resist infection by
pathogens (Alberts et al. [2008]). The immune system is the body’s natural
defence mechanism against any foreign attack. Through something called
the immune response, the body is able to attack these foreign invaders and
destroy them. In the case of humans, there are two different types of barriers,
namely, the innate and adaptive immune systems. Each of these has its own
individual methods and abilities to help our bodies stay healthy, interacting
with one another to kill harmful invaders. It has also become evident that
the immune system plays some sort of role in the protection of the body from
11
cancerous cells. However, both the functioning of the immune system and
the growth of tumours involve highly complex processes, and coupled, the
tumour-immune interactions form an elaborate system that is not yet fully
understood by either experimentalists or theoreticians (Malet and de Pillis
[2006]).
The innate immune system is present in all animals and is the first line of
defence against pathogens. It has three levels of protection against pathogens.
Firstly, there are physical barriers, such as the skin, and chemical barriers,
such as the acid in the stomach. The second line of defence comprises cell-
intrinsic response, by which an individual cell recognises that it has been
infected and takes measures to kill or cripple the pathogen (Alberts et al.
[2008]). Finally, the innate immune system can activate specific cells and
proteins against invaders. This includes: professional phagocytes, natural
killer cells (NK) and the complement system.
The complement system is composed of about 20 different proteins, made
mainly by the liver, that interact with one another to kill any foreign invaders
and signal to the other cells of the immune system. This type of immune
defence is extremely old and can be observed in sea urchins, which evolved
approximately 700 million years ago (Sompayrac [2012]). There are three
different pathways by which the complement system can be activated: the
classical pathway, the lectin pathway and the alternative pathway. Essen-
tially, these three different pathways activate C3, which then in turn then
signals to professional phagocytes and NK cells to kill the invader.
NK cells are part of a class of white blood cells called lymphocytes. They
are generally found in the blood, where they can be called upon, and then
12
rapidly proliferate in the problem area. When NK cells receive signals from
other immune system cells, they can give off cytokines, which in turn signals
other immune cells to come and help defend an infected area. Also, natural
killer cells can destroy tumour cells, virus infected cells, bacteria, parasites
and fungi. NK cells kill these cells by forcing them to undergo apoptosis
(Sompayrac [2012]).
The “professional phagocytes” consist of different types, for example neu-
trophils, dendritic cells and macrophages. Each of these types of cell start as
monocytes, which are produced by stem cells in the bone marrow. The mono-
cytes then enter the blood stream where they travel to the capillaries and try
to penetrate any holes in the endothelial wall. After they enter the tissue they
then mature into different types of white blood cells. Neutrophils, are cells
which are short lived and like NK cells are “on call” when there is an attack.
They exit the blood stream, navigating their way to the issue where they
proliferate and kill the pathogen. Macrophages are the most famous of the
professional phagocytes. Their name comes from the Greek word “phage”,
meaning “to eat”, and “macro”, meaning “big”, therefore macrophages are
“big eaters”. Macrophages recognise invaders by using their receptors to
search for anything unusual. When a bacterium, for example, is present in
the body it will display foreign carbohydrates and fats on their cell wall. The
macrophages’ receptors can recognise these, move towards it and kill it by a
process called “phagocytosis”.
Phagocytosis is the method macrophages, and indeed other phagocytes,
employ to kill an invader. Firstly it will produce a phagosome, a vesicle,
which will encase the bacterium. It then binds the phagosome with a lyso-
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some, a vesicle which contains very powerful enzymes and chemicals, to kill
the bacterium. Whilst undergoing phagocytosis a macrophage will also se-
crete proteins called cytokines, which alert other cells of the immune system
to traverse to the affected area. Neutrophils also secrete cytokines.
Macrophages have three different types of states. The first is when they
lie dormant in the system, mainly cleaning up internal debris. Secondly, a
macrophage can act as an antigen presenting cell. When the defences are put
under pressure and a macrophage has engulfed an invader, it presents class II
MHC proteins on its surface. Helper T-cells can read these “billboards” and
activate to help. Finally, the third state of a macrophage is “hyperactiva-
tion”. In this case, for example, a macrophage can be activated by molecules
that are secreted by a bacterium called lipopolysaccharide, a component of
the outer cell wall of Gram-negative bacteria, or by a carbohydrate, that is
an ingredient of the cell walls in many pathogens, called mannose. When the
macrophage receives these signals, it goes into a heightened state of alert.
This in turn stops the macrophages proliferating in order to focus on killing.
Moreover, in this state the macrophages do not only increase their size and
their phagocytic abilities, but they can secrete something called a tumour
necrosis factor (TNF). This is a cytokine, which can kill tumour cells and
virus infected cells, as well as activate other immune cells (Sompayrac [2012]).
In summary, the innate immune system is the first line of defence against
pathogens. Its tools consist of three different types: the complement sys-
tem, professional phagocytes and natural killer cells. However, sometimes
the innate system cannot neutralise the problem on its own, for example
the innate system is not good at destroying viruses, and therefore, it must
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activate the adaptive immune system. Before discussing how the innate sys-
tem actives the adaptive, the different cells and responses that govern the
adaptive immune system must first be addressed.
Whereas the innate immune responses are general defence reactions, the
adaptive responses are highly specific to the particular pathogen that in-
duced them, and they provide long-lasting protection (Alberts et al. [2008]).
Any substance capable of eliciting an adaptive immune response is called an
antigen. If one contracts something like the measles then, after the virus
has been killed, the adaptive immune system will remember it and therefore,
provide long lasting immunity against it. This is why vaccination works. The
cells that make up the adaptive immune system retain some mature cells that
have knowledge of this encounter, which are aptly named “memory cells”.
It is also necessary to point out that the adaptive immune system is very
destructive and therefore this is why it lies dormant until activated. If this
does not happen, and the immune system is in a hyperactive state, it will
try to kill normal tissue cells and conditions like autoimmune disease arise.
White blood cells, called lymphocytes, are what the adaptive immune
system uses to kill antigens. There are two classes of response: antibody
response, in the form of B-cells from the bone marrow; and T-cell medi-
ated responses from the thymus. B-cells and T-cells are extremely similar
in appearance and cannot be differentiated under a microscope; it is only
when activated their guise becomes apparent. They do, however, have some
distinct differences, which will come to light later.
B-cells mature in the bone marrow and act as antibody factories. Anti-
bodies are made up of two different proteins, the heavy chain (Hc) and the
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light chain (Lc). Due to this structure each molecule has two identical Fab
Regions that can bind to antigens. The Fab regions of each antibody are
designed to bind to a specific type of antigen, even if the host has not been
exposed to it. To generate all of these different types of antibodies, B-cells
have been found to change their DNA structure to accommodate the millions
of types of antibodies needed, which is called “modular design”. In addition
to this, the antibody also has a constant region “tail” (Fc) that can bind to
Fc receptors on cells of the innate immune system (Sompayrac [2012]). The
purpose of antibodies is to find an invader and bind to it. This does two
things: it prevents the antigen from binding to the cells of normal tissue and
it also allows cells like macrophages to bind to the tail of the antibody. This
then elicits a phagocytic response from the phagocyte. When an antibody
binds to a phagocyte, it essentially acts as a bridge between an immune cell
and an antigen, tagging it for destruction. In the case, where the antibody
binds to a macrophage, it increases the appetite of the macrophage making
it more phagocytic and allows it to bind to a bigger pool of antigens, making
the macrophage more potent. Unfortunately, once an antigen has entered a
normal cell, the antibodies become obsolete and a different type of immune
cell is needed.
T-cells, from the thymus, consist of three distinct groups: the helper
T-cell, the cytotoxic T-cell (CTL) and the regulatory T-cells. The helper
T-cell activates macrophages, dendritic cells, B-cells and CTLs by secreting
a variety of cytokines, like interleukin 2 (IL-2) and interferon gamma (IFN-
γ), and displaying a variety of co-stimulatory proteins on their surface. The
CTL, or killer T-cell, directly kills a virus infected cell by programming it for
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apoptosis. The third type of T-cell, the regulatory T-cell, suppresses other
cells of the immune system, preventing them from attacking normal tissue.
There are also distinct differences between B-cells and T-cells other than
where they mature. A B-cell can secrete its receptors, but a T-cell’s remain
on its surface. Moreover, antibodies can recognise any organic molecules,
whereas T-cells specialise in recognising antigens. Also, B-cells can act over
distance, whereas T-cells act locally. More importantly, B-cells can identify
an antigen without any other form of communication, whereas a T-cell relies
on other cells of the immune system. In order for a T-cell to direct a response
at a target, there is a mechanism that must first active them.
Dendritic cells provide the link between the innate and adaptive immune
system. Dendritic cells cleave the proteins of the pathogens into peptide
fragments, which then bind with the MHC proteins, that then carry the
fragments to the cell surface (Alberts et al. [2008]). They also display cell-
surface co stimulatory proteins. This in turn activates the T-cells where
cytokines, secreted by the dendritic cells, determine an effective response.
The way an antigen cell is presented to a T-cell is different depending on
the type of T-cell. Proteins called major histocompatibility complex proteins
(MHC), using peptides, present to T-cells. There are two classes of MHC
molecules: class I and class II. Class I MHC molecules are “billboards” that
display, on the surface of a cell, fragments of proteins manufactured by that
cell called “endogenous proteins”. They act as information ports for the
CTLs, declaring if there is a problem and activating them. Class II MHC
molecules are only found on specific cells namely, antigen presenting cells
(APCs). APCs are cells that display foreign antigen complexed with an
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MHC protein on the cell surface for presentation to lymphocytes. These
APCs can be, for example, macrophages and dendritic cells, whose role is to
internalise and destroy the invader. When, for example, a macrophage has
internalised an antigen, it will load peptides onto class II MHC molecules for
display on their surface. The class II MHC molecules are utilised by both
helper T-cells and regulatory T-cells. They then “read” this information and
alert other cells of the immune system. In summary, class I MHC molecules
activate killer T-cells and class II MHC molecules, by way of an antigen
presenting cell, activate helper T-cells which initiates a response from other
immune cells. However, to activate the adaptive immune system there is one
more mechanism that needs to be triggered.
As previously discussed, the adaptive immune system is very destructive;
therefore a secondary safety tool has been employed. B-cells and T-cells
require another signal to activate them. For a helper T-cell it must first
recognise its cognitive antigen displayed by class II MHC molecules on the
surface of a dendritic cell (acting as an APC). The second signal is the same
for any antigen and it involves a protein, e.g. B7, on the surface of an
APC, which plugs into its receptor, e.g. CD28, on the surface of a helper
T-cell. After this has happened, the helper T-cell can then proliferate, whose
receptors recognise the same antigen (Sompayrac [2012]). The activation of
B-cells is slightly different. It activates by cross-linking its receptors and then
receiving a co-stimulatory signal. It can do this on its own or by way of a
helper T-cell. The activation of killer T-cells is not quite fully understood,
but it appears that dendritic cells directly activate them. They recognise
their cognitive antigen, displayed by MHC class I molecules on the dendritic
18
cell and then they also receive the co-stimulation they need from the same
dendritic cell. Therefore, an activated dendritic cell is all that is necessary
to activate a killer T-cell. In summary, the dendritic cell plays a key role in
the activation of the adaptive immune system, but it also shows that extra
precautions have been put in place to make sure the immune system does
not attack the host.
In conclusion, the innate and the adaptive immune systems are powerful
weapons against many pathogens that a human is exposed to. The innate im-
mune system, through activation of phagocytes, the complementary system
and the NK cell, provides the second line of defence against foreign invaders
that get past the initial physical and chemical barrier the body provides.
This system copes very well and provides a broad spectrum of protection,
activating extremely quickly. However, if the innate system is overwhelmed
it will activate the adaptive immune system through a series of mechanisms.
The adaptive immune system, by way of the lymphocytes, provides further
protection from more powerful pathogens, called antigens. However, the ac-
tivation of this system, takes some time and therefore, the innate system
must hold until then. As previously discussed, there are certain measures
within the immune system that can deal with cancer cells, which is the focus
of this thesis.
1.1.2 Immunoediting
A neoplasm (solid tumour) may be defined as an abnormal mass of tissue
whose growth exceeds that of normal tissue, and is uncoordinated with that
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of the normal tissue (Matzavinos et al. [2004]). Cancer has three key stages:
avascular tumour growth, angiogenesis, and invasion and metastasis. The
avascular stage of growth reaches a steady state at roughly 1-3mm in diam-
eter (approximately 106 cells in total). There are over 100 types of cancer,
whether being viral, blood based or solid. Many cancer studies, whether clin-
ical or theoretical, have, in recent years, been greatly influenced by Hanahan
and Weinberg [2000]. This paper proposes six hallmarks of cancer and dis-
cusses what their roles are in helping to promote tumour growth. These are:
self-sufficiency in growth signals, insensitivity to antigrowth signals, tissue
invasion and metastasis, limitless replicative potential, sustained angiogen-
esis and evading apoptosis. Recently, the original six hallmarks have been
updated and several new ones have been added in a “next generation paper”
(Hanahan and Weinberg [2011]). Most interestingly, one of the new hallmarks
was identified to be when the tumour mass “evades immune destruction”.
The long standing theory of immune surveillance proposes that cells and
tissues are constantly monitored by an ever alert immune system, and that
such immune surveillance is responsible for recognising and eliminating the
vast majority of incipient cancer cells and thus nascent tumours (Hanahan
and Weinberg [2011]). This was first proposed in 1909 (Ehrlich [1909]), where
it was hypothesised that one of the functions of the immune system is to elim-
inate cancerous cells. However, this could not be tested experimentally at
the time due to the lack of immunological knowledge and technology. Good
review of the history behind immunosurveillence can be found in Dunn et al.
[2002] and Dunn et al. [2004b]. It wasn’t until the 1950s, when a better
understanding of immune and transplantation theories were available, when
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meaningful experiments were conducted in order to create the theory of im-
mune surveillance. It was postulated that immune cells, attracted by tumour
antigens, attacked and attempted to destroy nascent tumours (Burnet [1957,
1964, 1970]). However, the type of mice that were used in the experiments
were only immunocompromised not immunodeficient, therefore the experi-
ments did not produce enough evidence for the theory to be widely accepted.
In 1990s, the theory of immune surveillance was revisited and two impor-
tant discoveries were made, due to advances in monoclonal antibody produc-
tion and the use of “knock out” mice, a type of mouse whose genes can be
altered, to deem them immunoincompetent. Firstly, endogenously produced
interferon-γ (IFN-γ) was shown to protect the host against transplanted tu-
mours and the formation of primary chemically induced and spontaneous
tumours (Street et al. [2001a,b]; Kaplan et al. [1998]; Dighe et al. [1994]).
IFN-γ is thought to induce cytokines, which help the host immune system tar-
get the tumour, by sending a signal to produce more immune cells. Secondly,
mice lacking in perforin, a cytolytic protein found in the granules of Cyto-
toxic T-lymphocytes (CTLs) and NK cells, were found to be more susceptible
to MCA-induced and spontaneous tumour formation (Street et al. [2001b,a];
van den Broek et al. [1996]; Smyth et al. [2000a,b]; Russell and Ley [2002]).
Since then many studies have been conducted, producing data from experi-
ments with mice, along with correlative clinical human data, strengthening
the theory of immune surveillance, reviewed in Dunn et al. [2002, 2004a,b];
Swann and Smyth [2007]. Immunosurveillence has also been observed in
viral cancers, such as cervical cancer related to HPV. Further proof can
also be gained from AIDs victims who are more likely to contract certain
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types of cancer (O’Byrne and Dalgleish [2001]). This would seem intuitive
as the adaptive immune system is excellently equipped to deal with viruses.
Therefore, if impaired the host system will not respond in the correct man-
ner. Weighing up all of the new breakthroughs in immunology, the original
theory of immunosurveillance does not fully encompass all of the biological
processes that take place in the different stages a tumour goes through to
evade immune destruction.
A new theory, which includes immunosurveillance, has been proposed
namely, “Cancer Immunoediting” (Dunn et al. [2004b]). Immunoediting, es-
sentially an extension to immunosurveillence, proposes three different stages
of the immune response to cancer: elimination, equilibrium and escape.
These stages have been named the “three Es of cancer immunoediting”.
Elimination refers to the inflammatory response of the immune system to
cancer and subsequent destruction of a tumour mass; the original immune
surveillance theory. If the tumour mass is able to evade immune destruction
in the elimination stage, it enters the equilibrium stage. Here, the tumour is
kept at roughly the same size and is prevented from inducing an angiogenic
response.
“Cancer dormancy” has been widely proposed, whereby a tumour is
thought to be at near steady state size, for an explanation to something
that occurs in oncology. From experimental data, it has become apparent
that defective immunological surveillance of tumours leads to a higher fre-
quency of tumours arising in the host (Vajdic and van Leeuwen [2009]). In
the past, dormancy has been indirectly evident in experiments in mice trans-
plants (Teng et al. [2008]). A good overview of other equilibrium models
22
containing data on mice and humans can be found in Teng et al. [2008].
Tiny solid tumours have also been found in humans, who have died, leading
clinicians to theorise that tumours can persist for long periods of time in a
dormant state. Sometimes patients can also relapse after being in clinical
remission for at least ten years. In fact, even after long periods of clinical
remission greater than 10 years, patients are still found to have some cir-
culating, disseminated tumour cells (Stewart et al. [1991]; Sagalowsky and
Molberg [1999]; Herrlinger et al. [2005]; Demicheli et al. [1996]; Callaway and
Briggs [1989]; Matsui et al. [2006]; Meng et al. [2004]). Also, in donor patients
there is evidence that a defective immune system can result in transplanted
tumour cells being grown in a new host even if the donor has never had the
disease or has been in clinical remission for many years (Teng et al. [2008];
Ryungsa et al. [2007]). But what drives this dormant state?
The mechanisms that govern cancer dormancy are poorly understood.
There are a few theories that have been proposed aside from the immune
response: cellular intrinsic and angiogenic extrinsic dormancy. Cellular dor-
mancy occurs when the tumour cells enter a quiescent stage and angiogenic
dormancy is where apoptosis and proliferation of cancer cells are in balance,
preventing vascularisation. It is unknown how these systems work or even if
they work independently or together, however, it is known that good cancer
prognosis is correlated with detection of circulating cancer CTLs (Montagna
et al. [2006]; Pages et al. [2010]; Nelson [2008]). A recent mouse model has
attempted to validate this clinical observation, detecting small, inert lesions,
containing tumour cells in an equilibrium state (Koebel et al. [2007]). Here,
it is suggested that highly specific adaptive T-cell immunity is the component
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of the immune system that maintains equilibrium. Specifically, mice deficient
in the production of CD8+ cytotoxic T-lymphocytes, CD4+ Th1 helper T-
cells and natural killer cells have been found to be much more susceptible to
nascent tumours (Teng et al. [2008]; Ryungsa et al. [2007]).
The last “E” of immunoediting is escape. Whilst in the equilibrium stage,
it is thought that the interactions of the tumour cells and immune cells pro-
duce two eventual outcomes: cancer elimination or cancer escape. In the
first, the cancer is eliminated by the immune system, making this outcome
equivalent to the immunosurveillence stage, albeit over a longer period of
time. The second outcome is when the cancer cells have managed to, through
different factors, supersede the immune system. It is thought that the in-
teraction of the immune cells and tumour cells over a long period of time
creates a “Darwinian” selective process, whereby the immune system kills
more immunogenic tumour cells leaving the less immunogenic tumour cells
to proliferate and grow, essentially changing the phenotype of the cancer
cells and creating a less immunogenic tumour. Therefore, the immune sys-
tem attack is neutralised and the tumour can secrete growth factors to gain
a regulatory blood network.
The focus of these investigations has been on the ability of cytotoxic T-
lymphocytes to kill tumour cells. However, CTLs may not be a viable killer
on their own against solid tumours. CTLs are mainly found throughout
the blood system, the lymph and secondary lymphoid organs. Therefore,
if a tumour appears in the lung, for example, normally CTLs will not be
in the area to react and provide the necessary surveillance of the tumour
cells. Moreover, if a CTL does encounter a tumour cell in the tissue of the
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lung, and is activated by a tumour antigen presenting cell, it requires co-
stimulation from the cell that presents the antigen. The tumour cell will not
provide this co-stimulation, therefore the CTL would most likely be killed
or anergised. Unfortunately, there is a third problem. Naive T-cells are
prevented from entering the tissues, unless there is an attack, to prevent
them from attacking normal tissue cells. This makes it unlikely that the
naive T-cells would ever encounter tumour antigens expressed in the lung
(Sompayrac [2012]). However, there are other cells that, when introduced
into the system, could help CTLs.
Macrophages and natural killer cells could provide some defence against
tumour cells. As previously discussed, macrophages when in a hyper acti-
vated state, secrete a cytokine called “tumour necrosis factor” (TNF). Es-
sentially this chemical attacks the blood vessels that support the nutrients to
the tumour, causing the tumour to become necrotic. Macrophages are also
found throughout the tissue, therefore can provide immediate surveillance
against the tumour. There has been some success in activating macrophages
with vaccinations. For example, in the treatment of bladder cancer, a cousin
of tuberculosis is injected into the tumour causing the macrophages to be-
come hyperactive and subsequently destroying the tumour. In the case of
NK cells, they target cells that express low levels of class I MHC proteins
and cells that indicate that they are stressed. Collectively, both macrophages
and NK cells are part of the innate immune system, therefore they can be
instantly activated, unlike CTLs that may take a week to activate. Both NK
cells and macrophages collectively also recognise diverse targets, therefore the
chances of them being fooled a single small mutation is minimal (Sompayrac
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[2012]). This provides some motivation for using macrophages in mathemat-
ical models, along with other types of cells of the immune system, in future
work.
1.1.3 Tumour cell heterogeneity
Historically, a cancer mass has been thought of as a homogeneous collection
of mutated cells. This in fact could not be further from the truth as tu-
mour cell variation within a neoplasm is vast. The mutations a cancer cell
develops from, is handed down the generation by means of cellular division
where further mutations are created as the tumour grows. It has also been
argued that cancer cells are derived from different cancer stem cells, creat-
ing subpopulations, which through self-renewing, create vast differences in
daughter cells (Hanahan and Weinberg [2011]). It is this heterogeneity that
often protects it from destruction.
Not only do cancer cells form spontaneous mutations, but they are also
very versatile. Tumour cells are extremely well suited to many situations
that a healthy cell is not, such as a low pH environment, and expression of
enzymes which deplete important amino acids, managing to overcome many
biological fail safes in order to continue aggressive proliferation and survive to
invade and metastasise. In fact, cancer, although a clever disease, is actually
the bane of its own existence, killing the host and therefore killing itself.
These adaptive subpopulations of cancer cells are called phenotypes.
This unique ability also allows the cancer cells to elude the immune sys-
tem. As the immune system attacks a tumour, the hypothesis is that the
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tumour cells become more immunogenic, evading immune destruction by dis-
abling components of the immune system that have been dispatched to elim-
inate them (Hanahan and Weinberg [2011]; Mattes et al. [2003]). The way
in which cancer cells do this is not fully understood but can be attributed to
certain processes. The cancer cell can secrete chemicals, such as the tumour
growth factor, TGF-β. This chemical has the ability to immobilise cytotoxic
T-lymphocytes and NK cells. The recruitment of certain cells, called inflam-
matory immune cells, can also promote tumour growth by means of clearing
the local environment of debris, allowing more space and nutrient for growth.
Hanahan and Weinberg [2011] notes that, “inflammation can contribute to
multiple hallmark capabilities by supplying bioactive molecules to the tumor
microenvironment, including growth factors that sustain proliferative signal-
ing, survival factors that limit cell death, proangiogenic factors, extracellular
matrix-modifying enzymes that facilitate angiogenesis, invasion, and metas-
tasis, and inductive signals that lead to activation of epithelial-mesenchymal
transition (EMT) and other hallmark-facilitating programs”. It has also been
noted that cells such as tumour infiltrating macrophages promote tumour
growth and cancer cells can change the immune cell’s phenotype (Wang et al.
[2000]). Indeed, tumour-infiltrating macrophages are associated with a poor
prognosis in melanoma and breast cancer (Mattes et al. [2003]).
In normal circumstances, healthy tissues express antigens on their surface
that the immune cells can understand, allowing them to act on the healthy
cell’s needs and requirements. Tumour cells also express antigens that the
cells of the adaptive immune system can recognise (Mattes et al. [2003]; Melief
et al. [2000]). The activation of the immune system and subsequent clearing
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of nascent tumours is still debated, however there is growing evidence that
supports this theory (Haabeth et al. [2014]; Koebel et al. [2007]). It is even
thought that the immune system can target more established tumour cells
(Haabeth et al. [2014]; Dudley et al. [2002]; Quezada et al. [2010]). The
main players of the immune system that play an important role in target-
ing cancer cells are CD8+ and CD4+ T-cells. As previously discussed, MHC
protein pathways act as the guide to which the immune cells can recog-
nise and eradicate tumour cells, through peptide antigens and the colonially
distributed T-cell receptor (TCR). In experiments, it has been shown that
cancer cells in MHC 1 positive mice are directly targeted by CD8+ T-cells
and can work even in the absence of CD4+ T-cells. Moreover, there is a
vast amount of evidence supporting the importance of CD8+ T-cells, with
support from CD4+ T-cells, as overall patient survival is better when a high
number of CD8 memory T-cells are present. Unfortunately tumour cells can
downgrade their MHC protein pathways in order to evade the immune re-
sponse (Mattes et al. [2003]; Marincola et al. [2000]). More specifically, the
down regulation of MHC I tumours effectively makes CD8+ T-cells impotent
within the immune response, therefore, CD4+ T-cells become the dominant
cancer killer. However, most studies on the immune response to cancer have
focused on the cytotoxic ability of CD8+ T-cells and the CD4+ T-cells role
in improving their ability. However, as previously discussed, the immunose-
lection of tumour cells can help to promote tumour growth by evading these
cells, therefore further investigation on how to boost the immune system is
required.
CD4+ T-cell’s role within the body is to help other cells of the immune
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system, for example when an antigen-presenting cell expresses an antigen on
MHC class II, a CD4+ T-cell will aid those cells through a combination of
cell to cell interactions. It has also been noted that CD4+ T-cell activation
is essential in the initiation of the immune reaction even in the presence of
CD8+ T-cells (Ossendorp et al. [1998]). CD4+ T-cells can be subcategorised
into two different cell types: Th1 and Th2. Th1 cells mainly partner with
macrophages and CD8+ T-cells and produce the cytokines: interferon-γ, the
tumour necrosis factor-β and interleukin 2 (IL-2). Conversely, Th2 cells
manage recruit B-cells and eosinophils and produce IL-4, IL-5 and IL-10.
The study of CD4+ T-cells, in association with cancer has mainly focused
on a supporting role, providing a boost to CD8+ T-cells (Kern et al. [1986];
Ossendorp et al. [1998]; Mattes et al. [2003]). It has always been thought
that Th1 cells only provided this supporting role to CD8+ T-cells, although
this has been challenged of late. It has been suggested that both types of
CD4+ T-cells act independently of CD8+ T-cells and that they may in fact
play a much more direct role in eradicating neoplasms than first thought
(Mattes et al. [2003]; Hung et al. [1998]; Nishimura et al. [1999]; Mumberg
et al. [1999]; Quezada et al. [2010]).
There are two ways in which it is thought that CD4+ T-cells can actively
eliminate a tumour. Firstly, as previously mentioned, the secretion of cy-
tokines by immune cells are very important to tumour clearance as certain
types are cytotoxic to cancer cells. In this case, the CD4+ T-cells would se-
crete a cytokine in the presence of a tumour cell, rendering it immobile. The
second way would be through the active recruitment of different immune cells
to target the tumour cells. The down regulation of the MHC I protein path-
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way by cancer cells does not seem to effect the cytotoxic ability of the CD4+
T-cells (Mattes et al. [2003]; Haabeth et al. [2014]; Quezada et al. [2010];
Ossendorp et al. [1998]; Wang et al. [2000]; Hanahan and Weinberg [2011];
Perez-Diez et al. [2007]). However, many report that the cells still utilise
the MHC II protein pathway, and recruit immune cells such as eosinophils
(Mattes et al. [2003]) and NK cells (Perez-Diez et al. [2007]). However, there
is some research that suggests even without the MHC II protein pathway, the
CD4+ T-cell can still mount an effective immune attack (Ossendorp et al.
[1998]).
In this thesis, the interplay between CD4+ T-cells and CD8+ T-cells will
investigated, through mathematical models. This is to try and understand
the underlying eccentricities of the system.
1.1.4 The Warburg Effect
Energy supply for cells is intrinsic to all life. In a newly formed earth, oxygen
was not as abundant as it is today and cells gained energy by the process
known as “glycolysis”. Evolution and rising oxygen levels shifted the way en-
ergy was gained for certain organisms. In multicellular organisms, but more
importantly mammals, cells primarily rely on mitochondrial oxidative phos-
phorylation (OXPHOS) in order to generate energy (Zheng [2012]). This
metabolic pathway uses enzymes to oxidise cells in order to release energy.
The process takes place in the mitochondria; an area deemed “the power
house” of the cell. The main ingredient in the process of OXPHOS is glu-
cose, which is harnessed to produce adenosine 5’ triphosphate (ATP). This
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acts as a chemical carrier for metabolic processes such as cell motility and
proliferation. In fact, glycolysis is used in conjunction with OXPHOS in or-
der to gain the optimal amount of energy for a specific cell. In the presence of
oxygen, most cells will primarily metabolise glucose in this way. The process
begins by oxidation of the glycolytic pyruvate, which is produced by glycol-
ysis in the cytoplasm, in the mitochondrial tricarboxylic acid cycle (TCA).
This produces nicotinamide adenine dinucleotide (NADH), which then pro-
duces ATP through oxidative phosphorylation (Van der Heiden et al. [2009]).
It should also be noted that this process produces minimal lactate. If there
is no oxygen available the cell will be under anaerobic conditions and the
pyruvate is reduced to lactate, which is then excreted into the extracellular
space (Van der Heiden et al. [2009]; Zheng [2012]; Bartrons and Caro [2007];
Lu et al. [2015]; Liberti and Locasale [2016]; Wu and Zhao [2013]; Upadhyay
et al. [2013]). OXPHOS is also much more efficient at producing energy than
glycolysis as it produces 36 ATPs whereas, glycolysis only produces 2. How-
ever, glycolysis is still used in certain areas of the body such as the liver,
brain and muscles( Zheng [2012]; Brooks [2009]; Vaishnavi et al. [2010]).
Tumour cells have the unique ability to adapt to their surroundings. By
changing their phenotype they can survive even in the most hostile of envi-
ronments, and indeed, are therefore, very hard to destroy. In normal cells
many fail-safes are put into place to ensure that no mutations form during
the cell cycle. If one of the processes goes wrong the cell will go into arrest
and subsequently undergo apoptosis. Moreover, there are control systems
that are put into place to prevent uncontrollable cell growth, as nutrient is
available in constant supply to most cells in the body. Healthy cells are only
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triggered to grow when indicated to by growth factors. However, in contrast,
cancer cells do not have these mechanisms in place and are allowed to mutate
and grow at an exponentially high rate and uptake glucose indefinitely.
The metabolic phenotype has been well known now for over a century
and is considered a “hallmark of cancer”. In the 1920s, Otto Warburg ob-
served that cancer cells seem to take up unusually large amounts of glucose
and exhibit anaerobic glycolysis to produce energy (Warburg et al. [1924];
Warburg [1925]; Warburg et al. [1927]). Additionally, it was also observed
that this continued even if the cells had enough oxygen to sustain OXPHOS
(Warburg et al. [1956]; Liberti and Locasale [2016]), deemed aerobic glycoly-
sis i.e. glycolysis in the presence of oxygen. This phenomenon, in the 1970s,
was dubbed “The Warburg Effect” (Racker [1972]). Although there is no
clear answer as to why this happens, it is thought that it is the combined
result of many different reasons such as tumour hypoxia, mutated mtDNA,
tumour suppressors and oncogenes, among others. Warburg attributed this
to an anomaly in the mitochondria; however, this was disproved as many
cancer cell’s mitochondria function normally. Furthermore, Warburg’s dis-
covery was over looked for a long period of time and has only recently, over
the last 15 years, come into light again through the discovery of proton emis-
sion tomography (PET), whereby the Warburg Effect formed the basis of the
research. Here, 18-fluorode-oxyglucose (FDG) accumulates in tumour cells
due to the rapid uptake of glucose, which can then be imaged using a PET
scan (Lu et al. [2015]). Interestingly, as previously mentioned, aerobic gly-
colysis is an inefficient way of producing ATP, however glucose is produced
at a much higher rate than by OXPHOS.
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Cancer spreads often in a finger like fashion, and is well known not to
have just one specific cell type, but is heterogeneous by nature. Just as in the
human body, a multitude of cells are required for many biological processes.
Each tumour mass, depending upon where it is located within the body,
will have its own set of nutritional needs. Even if the cancer is of the same
type, each neoplasm will be completely different to the next, subsequently
making the tumour hard to kill. If OXPHOS is available why would cancer
use glycolysis if it is an inefficient way of producing ATP?
Cancer has many different attributes such as fast cellular motility, poorly
formed tumour boundaries, different cellular shapes, but, most importantly,
for the sake of this section, uncontrollable growth. The changing of receptor-
initiated signalling pathways in tumour cells seem to activate the uptake and
metabolism of nutrients that both promote cell survival and fuel cell growth
(Van der Heiden et al. [2009]). For cells to divide, it is necessary to uptake
enough energy for the parent cell to pass onto the daughter cells i.e. the
passing of enough metabolic intermediaries to form a new cell. Therefore, by
switching to glycolysis, the promotion of cell proliferation and cell survival is
more maintainable even if it an inefficient way to produce ATP. It is impor-
tant to note however, that glycolysis is also used by lymphocytes when rapid
growth is required, boosting evidence of the Warburg hypothesis. Moreover,
It is well known that cancer cells exhibit hypoxia when there is little oxygen
available in the microenvironment. In this situation, it seems prudent for
cancer cells to switch on anaerobic glycolysis as a way to survive in this very
arid environment. As a direct result of this, lactate is excreted into the mi-
croenvironment. Lactate is very acidic, and the drop in pH allows the cancer
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cells to thrive. Normal cells cannot survive in an acidic environment. The
host immune system is evaded and healthy tissue degrades, promoting cancer
invasion and metastasis (Pederson [2007]). Van der Heiden et al. [2009] also
attributes the excretion of lactate by the cancer cells to allow a faster uptake
of nutrients into the biomass, which facilitates rapid proliferation. Lastly,
glycolysis produces less reactive oxygen species (ROS). ROS, are chemically
reactive molecules which contain oxygen and have substantial roles in both
homeostasis and cell signalling. The damage these molecules can inflict on
tumour cells, if at a high enough concentration, is divisive and cell death will
occur.
However, there is an argument that glycolysis is used in co-ordination
with OXPHOS. Zheng [2012], attributes some reasoning as to why cancer
cells may use both. Firstly, the authors hypothesises that as the need for
nutrients for cancer growth is paramount, the cells can gain energy from
both glycolysis and the TCA cycle, in order to have enough metabolic in-
termediaries to divide. Secondly, the rapid production of ATP can have a
knock on effect. ADP can be converted to ATP, which, through the inhi-
bition of phosphofructokinase 1 (PFK1) and pyruvate kinase 1 (PK1), will
inhibit glycolysis. As previously discussed, anaerobic glycolysis also causes
the production of an acidic environment by way of lactate. In this hypoxic
situation, lactic acidosis inhibits glycolysis and favours OXPHOS as a means
of energy generation.
The biological processes and dynamics behind the Warburg effect is not
yet clear. To elucidate this, more scientific research is needed in order to
discover more compatible therapies, which can target and destroy cancer. In
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this thesis, the hypoxic generation of anaerobic glycolysis will be investigated.
As one can see, the biology of immunoediting is extremely complex and
full of uncertainties. One tool to aid in the understanding of these intricate
processes is mathematical modelling.
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1.2 Mathematical Modelling of Cancer and
Immunotherapy
This section will discuss the literature on mathematical models produced in
relation to cancer immunology. It will examine different types of models in-
cluding homogeneous and spatial models, as well as individual based models.
The first section is a general overview of cancer modelling and the second
section focuses on the literature that explores the interaction between the
immune system and cancer.
1.2.1 Mathematical Cancer Modelling
The use of mathematical models for cancer research has become increasingly
popular and is used as a tool to aid in the understanding of cancer envi-
ronments. Biological processes within the body, in relation to cancer, have
mostly been modelled using the classical techniques: Ordinary (ODE) and
Partial (PDE) Differential Equation systems.
A system of homogeneous ordinary differential equations is used to show a
change in reaction kinetics between different variables, utilising an investiga-
tion of parameter values in order to understand the dynamics of the system.
The earliest use of modelling, within an ODE setting, in terms of mathemat-
ical biology was in genetics and evolution, but has recently exploded into all
aspects of the biological world. This type of equation system often allows
the modeller to investigate the importance of certain underlying dynamics,
for example cell-cell interactions. Although a simplified process, it allows the
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user to mathematically investigate, through analytical or numerical means,
a system to elucidate only the most important factors in that environment;
a good aid if the cancer system is very complex. The technique assumes
the cancer environment is a “well mixed vat”, covering different spatial and
temporal scales. The law of mass action, whereby different reaction rates
between individual elements may be modelled, then governs the dynamics of
the system.
ODE systems are of great use when modelling tumour growth, as they
may be able to tell if there are any interesting phenomena within the system,
such as Hopf bifurcations or chaotic behaviour. For the purpose of this
thesis, the Hopf bifurcation is of significant importance. These tools can
lead to a greater understanding of the intricate interactions between species
or indeed other activities within the cancer environment. Matzavinos et al.
[2004] utilises a homogeneous system of differential equations in order to
investigate the presence of a traveling wave solution. It was found that
a Hopf bifurcation was present within the system, which was driving the
oscillatory behaviour. However, the need to understand the spatial habits of
cells and chemicals calls for a different technique.
Partial differential equation systems allow for the inclusion of more biolog-
ically relevant features and can portray additional variables such as chemical
diffusion. The equations are concerned with the rates of change with respect
to continuous variables and can model cellular and chemical concentration
at given times. Some of the earliest influential PDE cancer models were pro-
duced in the 1970s. In Greenspan 1972, the growth of a tumour spheroid
in the avascular stage of development was modelled by the diffusion of a
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nutrient and an internal pressure. A tumour spheroid is thought to consist
of many different internal layers and Greenspan’s model, after a certain pe-
riod of time, developed three different layers: a necrotic core, where cells are
starved of nutrient; a quiescent zone, which surrounds the internal necrotic
core; and a proliferating zone, where there is a thin layer of cells around the
edge. The internal pressure was used to try and represent cell-cell adhesion.
This paper shows that if the nutrient concentration goes below a certain crit-
ical threshold, then proliferating cells will become quiescent, then necrotic if
the nutrient level continues to fall. Cells in the quiescent zone are unable to
divide and are said to be in a “resting state”. Proliferating cells, at the rim of
the tumour mass have access to all the available nutrient within the system
and therefore can divide, increasing the tumour size. The internal pressure
was added to try and maintain the different tumour zones and the results
show an inward motion of cells, which constituted a possible hypothesis as
to why an avascular tumour mass has a maximum size.
Greenspan (1976) then extended this work in order to investigate the per-
turbations of the tumour spherical shape under steady state conditions. As
before, the tumour mass consists of a proliferating ring, quiescent zone and
necrotic core, each governed by nutrient concentration and an internal pres-
sure, representing the surface tension of the tumour and cell-cell adhesion.
The results showed, as the tumour size increased, the tumour shape became
less stable. This was an important result as perturbations in the tumour
shape may allow an investigation as to why a tumour can become invasive.
Over the years, these models have been explored and extended into many
different systems, such as Byrne and Chaplain [1996], and have been utilised
38
in many different fields associated with mathematical cancer systems, such
as immune-cancer cell modelling.
1.2.2 Mathematical Immune Cancer Modelling
There have been many attempts over the years to model the interaction of the
immune system and cancer to try and help clinicians and experimentalists
drive their studies. These include deterministic models, in the form of spatial
and non spatial studies, and stochastic models. Most of the scientific research
conducted on studies of the immune system and cancer has been based on
white blood cells, and hence most of the modelling is based on the interaction
of white blood cells with tumour cells. Specifically, many studies focus on
CD8+ killer cells, natural killer cells and macrophages, as they have been
shown to successfully lyse tumour cells (Quesnel [2008]), such as Boon and
van der Bruggen [1996], Khar [1997], Kuznetsov et al. [1994] and Lejeune
and El Akili [2008].
In terms of deterministic non spatial models, these have incorporated
many different aspects of the immune-tumour environment such as: cy-
tokines/chemokines (Kirschner and Panetta [1998], Arciero et al. [2004],
Byrne et al. [2004]); multiple immune cell co-operation (de Pillis et al. [2003],
Owen and Sherratt [1998], de Pillis et al. [2005], Eftimie et al. [2010]); tumour
antigens (Joshi et al. [2009], Fishman and Perelson [1993]); and interactions
with normal tissue (Owen and Sherratt [1998], Radunskaya and de Pillis
[2003], de Pillis and Radunskaya [2001], Byrne et al. [2004]). There has also
been a growing number of models based on the effect of immunotherapy
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drugs by direct injection of T-cells or cytokines, and also the investigation
of T-cell tumour regression and chemotherapy (Kuznetsov and Knott [2001],
Kirschner and Panetta [1998], Kogan et al. [2010], d’Onofrio [2008]). More-
over, Gu et al. [2006] have modelled the effects of combining immunotherapy
and chemotherapy. The tumour-immune mathematical models tend to have
up to four differential equations that govern the system. Models with larger
numbers of elements will require more estimation in terms of parameter val-
ues as well as the obligatory time element in solving the system numerically.
It is also more difficult to find certain mathematical aspects of the system,
for example hopf bifurcations, which provide vital clues as to the nature of
the system. However, there are a few papers that have successfully stud-
ied larger ODE models of immune-cancer interaction such as Deboer et al.
[1985], Cappuccio et al. [2006], Kronik et al. [2008] and Kronik et al. [2010].
A good review of non spatial models that study interactions between immune
and cancer cells can be found in Eftimie et al. [2011]. While ODE models
are a good basis for modelling research, it is also prudent to model spatial
movement. This can be accomplished at cellular and sub cellular level. A
good example of the need for a spatial model would be when trying to study
a tumour mass which consists of different tumoral cellular zones. It would
also possibly need to incorporate the movement of fields associated with the
growing tumour mass.
Deterministic spatial models using partial differential equations to mimic
the biological processes in immunoediting have also been undertaken. Here,
spatial aspects of the immune tumour environment can be examined and
studied, for example, through the investigation of travelling waves and the
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utilisation of differing tumour geometries. This includes the modelling of,
cytotoxic T-cells with chemoattractants (Kuznetsov and Stepnova [1992]
Matzavinos et al. [2004], Matzavinos and Chaplain [2004]); the effects of the
immune system on the tumour phenotype (Al-Tameemi et al. [2012]); inter-
actions between cancer promoting chemicals, tumour cells and immune cells
(Wang et al. [2009]); tumour cells, Th1 cells and IL-27 (Laio et al. [2014]);
tumour cells and macrophages (Owen and Sherratt [1997], Owen and Sher-
ratt [1999], Webb et al. [2007]); and macrophage targeted gene therapy with
chemotherapy (Owen et al. [2011]). Numerical and bifurcation analysis of
these models have demonstrated diverse patterns of spatio temporal dynam-
ics of the immune and tumour cells within tumour tissue, even in dormant
tumours, which are being controlled by cyctotoxic lymphocytes (Matzavinos
et al. [2004]). The “gold standard” of immune modelling has utilised the
effects of CD8+ T-lymphocytes on the tumour bulk, however there is ample
evidence, as discussed in section 1.1.3, that CD4+ T-cells may also play a
bigger role than first thought in immune-cancer interactions.
The modelling of CD4+ T-cells in mathematics is somewhat in its infancy,
however there are models which encompass the idea that CD4+ T-cells can
recruit other cells to inflict damage on the tumour mass. One such model is
that of Nwabugwu et al. [2013], extended from Nwabugwu et al. [2012], where
the inactivation of the MYC oncogene is modelled using ODEs. It shows that
the cellular senescence of tumour cells is dependent on CD4+ T-cells, leading
to relapse of tumours in immunocompromised hosts. The introduction of
macrophages, recruited by the T-helper cells was shown to achieve sustained
tumour regression if in the presence of an immunocompetent individual. An-
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other model is that of Eftimie et al. [2010], where the modelling of Th1 and
Th2 cells are investigated in relation to the rejection of melanoma by way
of an ODE model. It was found that neither the Th1 nor Th2 cells could
clear the cancer alone, however cancer clearance was observed when the Th2
cells recruited eosinophils. It is also noted in Eftimie et al. [2011], that the
development of these models would allow a better understanding of this type
of biological system, providing evidence to support experimental studies in
order to elucidate the underlying dynamics that exist between CD4+ T-cells
and the tumour environment.
Among other types of techniques there are stochastic and discrete (indi-
vidual) based models. Stochasticity may arise from genetic mutations that
occur during the evolution of cancer cells or from variations in the environ-
ment (Eftimie et al. [2011]). This includes: models of a deterministic origin,
which have had stochastic elements added (Bose and Trimper [2009]); and
individual agent based models (Lollini et al. [2006]; Pappalardo et al. [2006]).
Moreover, discrete based modelling arises from two separate modelling tech-
niques: cellular automata and agent based models, which normally focus on
the interactions of cancer cells and the local tumour environment (Malet and
de Pillis [2006]; Mansury et al. [2006]). These attempt to describe how cells
behave by either specifying rules to each individual cell (agent based), or by
defining specific rules associated with a grid system, in which each grid may
contain one or more cells (cellular automata). Agent based models can also
be subdivided into two different categories based on their geometry: on lat-
tice and off lattice. When utilising an off lattice model, cells are not confined
by grid restriction allowing a more biologically relevant geometrical repre-
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sentation. On lattice models can be thought of as an extension of cellular
automata models because cells are represented by a grid system.
An extension to the cellular automata model has been created in the
form of a cellular potts model. Here, the model is comprised of pixels with
each cell, or cellular compartment, made up of several connecting pixels.
Therefore, the cells are no longer modelled as single points, but as spatial
objects whose size and shape can be altered. The simulation progresses
through a series of monte carlo steps (MCS), which attempt to minimise the
overall effective energy within the system. At each MCS, attempts are made
to transform neighbouring pixels at the boundary of each cell to increase
its volume. If the transformation, known as a “flip”, reduces the overall
effective energy then the pixel in question will be changed. The use of this
type of model allows for much more biologically relevant models, in that each
individual element of the system can be modelled actively using numerous
different rules. This type of model has been successfully transformed into
user friendly software. CompuCell3D is one of these programmes.
CompuCell3D is a very useful tool when modelling tumour immune inter-
actions. It allows the user to easily model an idealistic tumour environment
where individual cells interact with one another. Numerous different ad-
ditions to the software can be implemented using python coding, allowing
the modelling, for example, of: chemical fields, cell structure, cell size, cell
shape and cell-cell adhesion. It is also relatively easy to formulate, for a
simple system, not only a two dimensional model but a three dimensional
model. One very complex model, in CompuCell3D, is Hester et al. [2011]. In
this paper, a model of somitogeneis is undertaken, which is observed in the
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development of all vertebrate embryos and results in segmentation, requir-
ing a enormous amount of co-ordination between different biological process
on multiple scales. Tumour growth has also been modelled and includes the
modelling of: avascular tumour growth in gliomas in 2-D and 3-D (Poplawski
et al. [2009] Poplawski et al. [2010]); vascular tumour growth (Merks and
Glazier [2006], Merks et al. [2008], Bauer et al. [2007], Bauer et al. [2009],
Shirinifard et al. [2009]); and tumour invasion (Andasari et al. [2012]). Com-
puCell3D has also been used to model cell cycle heterogeneity among cells
and how this can affect how a tumour responds to chemotherapeutic drugs
(Powathil et al. [2014]). It has also been used to model selection pressures
in somatic evolution leading to the development of tumour cell aggression in
solid tumours in Swat et al. [2015].
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1.3 Mathematical Methods
Understanding mathematical numerical methods, including their advantages
and limitations, is essential knowledge for anyone using computer software
environments. Therefore, this section aims to ‘tease away’ the underlying
mathematical methods that are utilised for the inbuilt tools in numerical
software packages relevant to this thesis. The first section describes the
methods used to solve ODE and PDE models and the second section focuses
on the tools used to solve individual based models.
1.3.1 Numerical methods of ODEs and PDEs
It is prudent to point out that there are many excellent inbuilt numerical
tools in different computing environments of which many academics have
spent years working on. For the everyday user, these tools will be sufficient
for most of their needs however, choosing the right inbuilt tool depends on
their ability to mathematically determine the right package for their problem.
It is only when one of these tools does not ‘fit the bill’ that writing a new
method is necessary and should be undertaken. In this thesis Matlab will be
the main programme used for 1-D systems and Comsol for 2-D.
Matlab, based on C, has the ability to numerically solve mathematical
models using different inbuilt tools. For all of the ODE models in this report,
ODE45, has been used which is Runge-Kutta method. The Runge-Kutta
method is a one step approximation scheme, whereby each step is determined
by the previous step i.e. it is an explicit method. The order of the method
that should be used depends on the problem, but in general the higher the
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order of the method the more accurate the system. Issues arise when the
problem is too stiff for the method and explicit methods simply do not work,
e.g. there maybe large differences in time scales in the problem, and therefore
the ability of the method is damaged by the amount of time the solver takes
to solve the system. Matlab, therefore, has different solvers for this e.g.
ODE15s, which is essentially a linear multistep backward difference method.
However, for the purposes of the models in this report a 4th order Runge-
Kutta method, in the form of ODE45, is used and the general method is
formulated by:
u′ = f(t,u), u(0) = u0 (1.3.1)
k1 = ∆tf(tn,un)
k2 = ∆tf
(
tn + c2∆t,u
n + a2,1k
1
)
,
k3 = ∆tf
(
tn + c3∆t,u
n + a3,1k
1 + a3,2k
2
)
, (1.3.2)
...
ks = ∆tf
(
tn + cs∆t,u
n + as,1k
1 + ...+ as,s−1ks−1
)
,
un+1 = un +
s∑
i=1
bik
i.
This can be also written as part of a Butcher tableau (Griffiths and Higham
[2011]).
The RK method uses intermediate steps namely ki to determine the value
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of the system at the next time step. To compute the approximate answer,
uu+1 ≈ u(tn), one simply needs to compute the values of the intermediate
values, ki, to get the next time step. This is an explicit method as the method
uses the initial condition u0, along with the time step ∆t, to compute the
first point k1. Then, k1 is used, again with ∆t and u
1, to compute k2 and
so on until the next time step is achieved depending on the order of the
method (Griffiths and Higham [2011]). The classical fourth order Runge
Kutta Method is shown in system (1.3.3) (Griffiths and Higham [2011]) :
k1 = ∆tf (tn,un)
k2 = ∆tf
(
tn +
1
2
∆t,un +
1
2
k1
)
,
k3 = ∆tf
(
tn +
1
2
∆t,un +
1
2
k2
)
, (1.3.3)
k4 = ∆tf
(
tn + ∆t,un + k3
)
,
uu+1 = un +
(
1
6
k1 +
1
3
k2 +
1
3
k3 +
1
6
k4
)
.
After solving a non-dimensionalised ODE system, spatial elements will be
added to give a PDE system. This requires a different tool in Matlab, namely
PDEPE. PDEPE solves initial-boundary value problems for parabolic-elliptic
PDEs in 1-D. The ODEs resulting from discretisation in space are integrated
to obtain approximate solutions within a given time range. What is pro-
duced, in models in this report, are cells densities over the domain. One
would have to integrate over the domain to get the concentrations of cells at
a point.
For 2-D PDE time independent simulations, the computer programming
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package“Comsol” will be used. Comsol, formerly “Femlab”, has many dif-
ferent uses within engineering, physics and mathematics. For the purposes
of this report, the computer environment is utilised to implement the finite
element method in time independent PDE systems, over given domains, to
approximate the solutions over a set time. The PDEs may be entered directly
or in their ‘weak form’. Again, it is best to understand the inner workings
of such a method before proceeding with a computer package.
Fundamentally, the finite element method is a way to solve boundary
value problems. Unlike the finite difference method, a collection of small
triangular domains is used to approximate the given domain and minimise
the error. This would be used when working with shapes like circles that
are difficult to approximate at their boundary due to their curved nature. A
generalisation of the process one has to carry out to solve a BVP with the
FEM is:
1. Reformulate the PDE to give a weak form.
2. “Triangulate” the domain i.e. divided the domain into triangles and/or
quadrilaterals.
3. Define a general continuous piecewise polynomial on the triangulation.
4. Use the weak form to generate a system of linear algebraic equations
in the coefficients in the piecewise polynomial representation of the
approximate solution. It is at this stage that the Dirichlet boundary
conditions are enforced.
5. Solve the algebraic system to generate a finite element approximation.
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6. Post-process the solution to extract the required information.
This process can become exceptionally difficult, especially in large problems
at step five above, and therefore, specialised linear algebra packages like
Comsol are required.
1.3.2 CompuCell3D
In order to numerically solve individual based models, within this thesis,
CompuCell3D has been utilised. CompuCell3D, as previously discussed in
Chapter 1.2, is an open source solver, which uses the Cellular Potts Method
or Glazier-Graner-Hogeweg (GGH) model (Glazier et al. [2007] and reviewed
in Rejniak and Anderson [2011]). It was developed to allow the modelling
of a large number of cells and their interactions. The system was created
in the programming language C++, but allows models to be created in a
user-friendly manner in the XML and Python languages. The CPM also
makes use of PDEs to represent non-discrete fields. CompuCell3D models
have a range of different uses within mathematical biology, whereby each
simulation can model varying biological processes and objects such as cells
and chemicals.
Firstly, spatially operative generalised cells are created, which can repre-
sent clusters of cells, single cells, sub compartments of cells or indeed small
subdomains of non-cellular materials (Izaguirre et al. [2004]). Each model is
made up of objects, a description of their interactions and appropriate initial
conditions. The power of CompuCell3D is its ability to create models in two
or three dimensions. The objects in each model are comprised of lattice sites,
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called pixels in 2D and voxels in 3D. Each cell is assigned a type and each
lattice site is represented by a vector of integers, i. The cell index, occupying
pixel i, is σ(i) (generalised cell) and the cell type is referred to as τ(σ(i)).
Either increasing or decreasing the number of pixels it contains can change
the size of the cell. Alternatively, groups of cells may be clustered together
to simulate, for example, a tumour. Cell shape, polarity, intracellular mem-
branes and cell-shape changes can also be modelled. A cell type may have
many attributes associated with it such as surface area, volume, adhesion
and motility.
The solver uses the “effective energy” to describe the interactions between
cells. This determines many characteristics such as cell size, shape, motility,
adhesion strength and the reaction to gradients of chemotactic fields. It
is these interaction descriptions and dynamics that define how the objects
behave both biologically and physically. The user defines the parameters for
the effective energy for each cell type and these determine the characteristics
of each cell. During a simulation, cells will attempt to extend their boundaries
to minimise the effective energy. This happens through a series of index-copy
attempts, whereby a lattice site will “flip” to belong to a different cell if it
is favourable to do so. The success of an index-copy attempt is governed
by the Boltzmann acceptance function, and if it is successful the cell will
increase in volume by a lattice site and the neighbouring cell will decrease in
volume. Once all of the boundary pixels in the simulation have performed
an index-copy attempt, a Monte Carlo Step has been completed.
As previously discussed, CompuCell3D can also adequately model nutri-
ents, chemical gradients or the extra cellular matrix by using a field compo-
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nent. Partial differential equations are used to describe the fields and most
simulations require secretion, absorption, diffusion and decay components.
For these, simple ODE forward Euler methods can be employed to solve the
discretised PDEs. This type of method means that the parameter values
must be chosen carefully, in order to ensure the stability of the solution.
Auxiliary equations describe cells’ absorption and secretion of chemical dif-
fusants and extracellular materials, e.g. their interactions with fields, state
changes within the cells, mitosis and cell death. These can be simple, using
Euler methods, or complex, utilising RK solvers.
1.3.3 Compucell3D model makeup
Effective energy
Cellular Potts Models, as mentioned above, employ the effective energy to
describe cell behaviour and interactions. All equations in the section can be
found in more detail in (Izaguirre et al. [2004]). There are two different ways
to portray the energy in the model: boundary energy or constraints. It is
first prudent to look at the mechanism that describes cell adhesion. This is
one of the most important descriptions in the model, as if cells did not bind
together then complex structures and indeed intelligent life as we know it
would not exist. Adhesion is defined by the boundary energy J(τ(σ), τ(σ′)),
which is the boundary energy per unit area between two cells, (σ, σ′), of given
types (τ(σ), τ(σ′)), at the boundary between two neighbouring pixels. This
is then calculated by summing over all neighbouring pairs of lattice sites, i
and j:
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Hboundary =
∑
i, j
neighbours
J(τ(σ(~i)), τ(σ(~j)))(1− δ(σ(~i), σ(~j))). (1.3.4)
The second method of energy use in the model is by way of constraints
on cell behaviour. Constraints are written in a general elastic form and are
represented by:
Hconstraints = λ(value− targetvalue)2. (1.3.5)
As one can see, if the value = targetvalue then the energy is zero and
the constraint, known as the equilibrium condition, has been satisfied. The
exponent, 2, establishes the elasticity of the constraint. This creates an ideal
spring, which pushes on the cells’ effective energy. By minimising the effec-
tive energy and utilising this idealised spring, CompuCell3D will drive the
constraint to equilibrium. However, due to the stochastic nature of the sim-
ulations, the condition does not always have to be met, creating two or more
possible constraint conflicts where the constraints are partially met, result-
ing in random fluctuations. The spring constraint (a positive real number),
represented by λ, determines how far the value can deviate from the target.
Large values of λ will result in a larger effective energy change, essentially
preventing a flip, whereas small values allow for much more deviation from
the equilibrium condition.
Constraint energy has also been implemented to restrict the size of a
52
cell to a specified target volume. CompuCell3D models cells’ volume at any
given time, as well as their surface area. A volume constraint is employed
to restrict volume variations of generalised cells from their target volumes,
modelled by:
Hvol =
∑
σ
λvol(σ)(v(σ)− Vt(σ))2, (1.3.6)
where λvol(σ) is the inverse compressibility of the cell, v(σ) is the number
of pixels in the cell and Vt(σ) is the cell’s target volume in pixels. The internal
pressure inside the cell is P ≡ −2λ(v(σ)−vt(σ)). A positive internal pressure
in a cell is produced when v < Vt whereas, when v > Vt there is a negative
internal pressure.
The surface area constraint is given by:
Hsurf =
∑
σ
λsurf (σ)(s(σ)− St(σ))2, (1.3.7)
where; s(σ) is the surface area of the cell, σ; Dt is the cell’s target surface
area; and λsurf(σ) is its inverse membrane compressibility.
By adding together the boundary and volume constraints, from equations
(1.3.4) and (1.3.6), the basic GGH effective energy is obtained:
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HGGH =
∑
i, j
neighbours
J(τ(σ(~i)), τ(σ(~j)))(1− δ(σ(~i), σ(~j)))
+
∑
σ
λvol(σ)(v(σ)− Vt(σ))2. (1.3.8)
A Monte-Carlo step
CompuCell3D measures time in a simulation by Monte-Carlo Steps, which
indicate when every pixel on the lattice has made an index-copy attempt.
Each index-copy attempt begins by the software randomly selecting a lattice
site, which is chosen as the target pixel,~i. A neighbouring lattice site is then
chosen to be a source pixel, namely ~i′. An attempt is then made to flip the
target pixel, governed by the effective energy, to the same generalised cell as
the source pixel, increasing the volume of the source cell and decreasing the
volume of the target cell. Cells that belong to the same cell, i.e. σ(~i) = σ(~i′),
do not need to attempt a flip and the effective energy will not be calculated.
Index copies are governed by a probability where:
P (σ(~i)→ σ(~i′) =
 exp(−∆H/Tm), ∆H > 0,1, ∆H ≤ 0, (1.3.9)
where ∆H is the change in effective energy and Tm is the effective cell
motility (or the amplitude of cell membrane fluctuations). The classical GGH
implements a modified version of a classical stochastic Monte-Carlo pattern-
evolution dynamics, called Metropolis dynamics with Boltzmann acceptance
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function, displayed in equation 1.3.9. If the change in the effective energy is
less than or equal to zero, then the index copy attempt will be successful.
Moreover, if it is greater than zero the attempt may still be successful with
the probability exp(−∆H/Tm). Time can be converted here from the MCS
by the average of parameters, ∆H and Tm.
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Chapter 2
A Mathematical Model of
Immune and Tumour Cell
Interactions
2.1 Introduction
In this chapter, an individual-based mathematical model of a simplified bi-
ological process, whereby a nascent tumour, attacked by a host immune
system, will be examined. Specifically, the potency of tumour infiltrating cy-
totoxic lymphocytes (TICLS) will be investigated when in interaction with
a tumour population. This work will be based on Kuznetsov and Step-
nova [1992]; Matzavinos et al. [2004]; Matzavinos and Chaplain [2004]; Al-
Tameemi et al. [2012].
Having studied the models by Matzavinos et al. [2004]; Matzavinos and
Chaplain [2004]; and Al-Tameemi et al. [2012], what can be seen is that the
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use of ODE and PDE models, give an overall assessment of the underlying
kinetics in a given system. However, both of these have weaknesses. In an
ODE model there are no spatial components therefore everything is assumed
to be well mixed, causing a lack of cell structure. Although PDE models
include a spatial awareness, they do not incorporate important biological
features such as cell-cell interactions, intracellular behaviour and individual
cell properties. When numerically solving a PDE model, the results give an
overall approximation of cell density throughout the whole domain, however
they do not indicate key tumour-immune cell interactions. However, ODE
and PDE models are a viable approach for mathematicians and biologists to
replicate long term effects in a biological system, if armed with the correct
mathematical structure.
An example of this is in Matzavinos et al. [2004], where the presence of
a limit cycle gives the appearance of a dormant steady state and drives the
results. However, this is a quite well known phenomenon within reaction-
diffusion equations, therefore is this of biological relevance or is it a result of
the mathematics? To answer this question, and to try and include more of
the tumour-immune micro-environment, a good approach would be to create
an individual-cell based model.
Individual based models enable the tracking of individual cells and key
aspects of cellular behaviour. They allow the inclusion of: adhesion; motil-
ity; mitosis; growth; competition for space; shape; size; interactions between
cells; intracellular signalling; secretion of chemoattractants and chemorepel-
lents; and the effects of oxygen concentrations e.g. hypoxia and epithelial
mesenchymal transition. The individual based model will be analysed using
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“CompuCell3D”, a modelling software environment and PDE solver. The
software was developed to help researchers model materials without having
to create their own code. CompuCell3d competently models key aspects of
tumour-immune interactions. Therefore, in this chapter, an individual based
model will be undertaken, giving a better understanding of the biological
properties in cancer dormancy.
2.2 Mathematical model
This section will discuss the original findings from Matzavinos et al. [2004]
and the formulation of the individual based model. It is hoped that the
CompuCell3D model will be able to mimic the results of the PDE model
found in Matzavinos et al. [2004], showing the three Es of immunoediting:
elimination, equilibrium and escape.
Matzavinos et al. [2004] investigated the use of tumour infiltrating cy-
totoxic T-lymphocytes (TICLs) to eliminate a nascent tumour, using both
homogeneous and heterogeneous equation systems. The original model in-
volved a chemokine, which elicited a chemotactic response by the immune
cells towards the tumour cells. The model was based on the schematic in
Figure (2.1).
Figure (2.1) shows the original model kinetics where, a TICL (E) binds
with a tumour cell (T) to form a TICL-tumour cell complex (C) at rate k1,
with the reverse reaction at rate k−1. The complex (C) then breaks down to
leave either a tumour cell and an inactivated TICL (E∗), at rate k2(1 − p),
or a TICL and a ‘programmed for lysis’ tumour cell (T ∗), at rate k2p. Using
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Figure 2.1: Schematic of local interactions between the TICLs and tumour
cells in vivo. Taken from Matzavinos et al. [2004] whereby full details can be
found in Kuznetsov [1991]; Kuznetsov et al. [1994].
the law of mass action on the scheme in Figure (2.1), adding spatial elements
and non-dimensionalising, the heterogeneous PDE system was derived in
Matzavinos et al. [2004] as:
∂E
∂t
=
random motility︷︸︸︷
∇2E −
chemotaxis︷ ︸︸ ︷
γ∇(E∇α) +
supply︷ ︸︸ ︷
σh(x) +
proliferation︷ ︸︸ ︷
ρC
η + T
−
decay︷︸︸︷
σE − (2.2.1)
local kinetics︷ ︸︸ ︷
µET + C,
∂α
∂t
=
diffusion︷ ︸︸ ︷
δ∇2α +
production︷︸︸︷
κC −
decay︷︸︸︷
α , (2.2.2)
∂T
∂t
=
random motility︷ ︸︸ ︷
ω∇2T +
logistic growth︷ ︸︸ ︷
β1(1− β2T )T −
local kinetics︷ ︸︸ ︷
φET + λC, (2.2.3)
∂C
∂t
=
local kinetics︷ ︸︸ ︷
µET − ψC . (2.2.4)
Zero flux boundary conditions were imposed and further details of the initial
conditions can be found in Matzavinos et al. [2004].
When solving the PDE system numerically, using the computer solver
“PDEPE” in “Matlab”, a train of solitary like waves of tumour cells, was
seen to be invading the tissue. This occurred when the probability of a TICL
killing a tumour cell, p, was in a certain range. Moreover, a linear stability
59
analysis of the homogeneous system (from system (2.2.1)-(2.2.4)) was un-
dertaken and a limit cycle was found. A bifurcation analysis was performed
to investigate the appearance of the limit cycle. By solving numerically the
ODE system, it was found that for p less than a critical value (approximately
0.9906), the limit cycle will disappear and all the orbits that correspond to
non-heterogeneous solutions converge to a tumour invasive steady state. If
p is above the critical value, the limit cycle becomes apparent through a
subcritical Hopf birfurcation, common to dynamical systems (Sherratt et al.
[1997]). In a follow up paper, Matzavinos and Chaplain [2004], a travelling
wave analysis of system (2.2.1)-(2.2.4) was undertaken and a 1-D heteroclinic
connection was found using the transversality theorem of Guckenheimer and
Holmes (Guckenheimer and Holmes [1983]).
2.2.1 Individual-based model
This chapter will focus on an individual mathematical model, implemented to
investigate the individual interactions of TICLs and tumour cells, to try and
get similar qualitative results as the findings of the PDE model in Matzavinos
et al. [2004]. It will have similar basic kinetics as the one shown in Figure
(2.1). The extension of this work into an individual-based model allows the
introduction of more biologically relevant information with a hope to enrich
the validation of the results.
The technique that will be implemented to analyse the model will be the
Cellular Potts Model (CPM) (or Glazier-Graner-Hogeweg (GGH) Model). It
is important to realise that there is a force (F) and cell velocity (v) relation-
60
ship in the cell environment due to its highly viscous nature. The cellular
potts model embeds a linear F − ν relation into a stochastic computational
algorithm by minimising energy through the use of the Modified Metropolis
Algorithm, and allows the use of experimental data to be used as parameter
values (Powathil et al. [2013]). Further details of the workings of Compu-
Cell3D can be found in Chapter 1.3.
The CPM was implemented in the computer software system Compu-
Cell3D, an open source computer system (Swat et al. [2012]). In the simula-
tion a 200x200 pixel 2D grid lattice has been utilised. The model represents
each cell by a user defined set of pixels which contain the same index at-
tributed to the specific cell type.
In order to mimic the dynamics of the system in Matzavinos et al. [2004],
the CPM model utilises different aspects of CompuCell3D. Cells that are
involved in this model are immune cells and tumour cells. Within the model,
healthy tissue, represented by a block of cells, which are called “medium
cells”, is considered to be homogeneous. It is known that a cell is roughly
between 10µm-20µm in diameter (Alberts et al. [2008]). A newly divided
cell is determined to be 10µm and will not be allowed to divide until it has
reached 20µm. Each pixel in CompuCell3D can belong to any cell type. The
size of each cell in CompuCell3D is modelled by first assuming that each
newly divided cell is made up of 5x5 pixels, and that each pixel represents a
square element of a cell that is 2µm x 2µm, giving a total area of 4µm2. The
model begins with a central 5x5 cell tumour mass and 4 randomly placed
single immune cells in the domain. It also has a nutrient that would be
available within the biological domain, such as oxygen, for the cells to feed
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from. It is important to note that there are no chemotactic effects in this
model, and therefore, cellular motility is random.
Mitosis occurs when a proliferating tumour cell grows to a critical size
and then divides along a randomly orientated axis. Tumour cells try to reach
maximum size of 50 pixels, before they divide into two daughter cells. This,
however, is determined by how much available oxygen there is for the tumour
cell. The tumour cell grows every Monte Carlo Step, by a different amount
each time, determined by how much oxygen is available within the tumour
cell. The oxygen concentration is calculated and the result is then added
to the size of the tumour cell × 0.1. The tumour growth rate (TGR) is,
therefore:
TGR = 0.1× concentration of oxygen at proliferating tumour cell core.
(2.2.5)
This allows tumour cells at the edge of the proliferating rim to grow much
faster than those in the middle. If the oxygen goes below a critical level, the
proliferating tumour cells turn quiescent. In this state, they have the ability
to turn back into a proliferating cell if they can gain enough oxygen but
they do not divide. If the quiescent cell’s oxygen level falls below a level
to which the cell cannot sustain its functions, the cell becomes necrotic and
is allowed to disintegrate. Dead cells only disintegrate when in exposure
with the medium. Initially, when the model was first written, the tumour
cells were allowed to grow by one pixel every MCS, as long as the oxygen
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at their core was enough to be a tumour cell. It provided no relationship
between the oxygen level and cell growth and created exponential tumour
cell proliferation, leading to the oxygen level being implemented as described
above.
Immune cells do not divide and are supplied to the domain at a constant
rate of 1 per 25 MCS, provided there is enough space in the medium. This is
meant to mimic the process, in the body, where cytokines are sent by immune
cells to signal and recruit more immune cells, in order to target the foreign
object.
The migration rate in CompuCell3D determines how far a cell can move
in each MCS, corresponding with the parameter µ. Each cell has a random
orientation for each individual cell type, with immune cells having a faster
capability than tumour cells. Quiescent and necrotic cells do not move unless
pushed by a different cell type or by adhesion.
The nutrient in the model is represented by a partial differential equa-
tion, which is solved using the DiffusionSolverFE steppable in CompuCell3D.
Nutrient in this model has been identified as oxygen and is supplied to the
domain at a constant rate, secreted by the medium cells. Oxygen diffusion
in the domain is “zero flux” at the boundary and is modelled by the PDE:
∂c
∂t
= D∇2c− kc+ secrection,
where D is the diffusion rate and k is the decay rate. k represents the uptake
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of oxygen in a given cell with rates:
k =

0.5, in the tumour cells
0.25, in the quiescent cells
0.5, in the immune cells
0, in the necrotic cells
0, in the dead immune and dead tumour cells.
(2.2.6)
Within proliferating tumour and immune cells, the uptake of oxygen is
much higher than quiescent tumour cells. The tissue, in this model, does not
uptake oxygen but instead secretes it. Necrotic cells do not uptake oxygen.
Hypoxic and necrotic effects of cells are not taken into consideration.
CompuCell3D allows the user to specify adhesion properties of cells. In
this model, immune cells do not adhere to one another, whereas medium
cells adhere strongly. Proliferating tumour cells adhere to each other, but
not as strongly as immune cells adhere to proliferating tumour cells, allowing
tumour cells to break free and form new tumour masses, locally. Immune
cells do not adhere to necrotic and quiescent cells, however, tumour cells do,
but much less than they do to themselves. Cells lysed by either tumour or
immune cells adhere weakly to tumour cells. This can sometimes create a
small wall of debris for the immune cell to have to work its way through
before getting to a proliferating tumour cell, enhancing tumour cell growth.
When an immune cell comes into contact with a proliferating tumour
cell there are two different outcomes: the immune cell kills the proliferating
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tumour cell or the proliferating tumour cell kills the immune cell. This is the
same basic killing method that is utilised in Matzavinos et al. [2004]. The
dead cell is then allowed to disintegrate, again only when in contact with the
medium. The control parameter p from Matzavinos et al. [2004] has been
implemented into this model and is used to determine the probability of an
immune cell killing a tumour cell. The age of the tumour cells does not come
into consideration, as one of the main trademarks of cancer is that tumour
cells evade apoptosis. This mechanism in cells is very important. When
“healthy” cells go through the cell cycle, if there are issues at any of the
stages, the cell will undergo programmed death, preventing any mutations
that may arise. However, because cancer cells are able to avoid apoptosis the
tumour cells will be able to divide, despite damage to DNA, into mutated
daughter cells. In this model, therefore, the only way a tumour cell can be
killed is by an immune cell or by cellular degradation, known as “necrosis”.
Necrosis occurs when there is a lack of oxygen for the cancer cell to survive.
Immune cell death by lysis has been omitted in order to understand the
underlying dynamics, however this would be a good extension to the model.
The simulations will run for a maximum of 50,000 MCS. The simulations,
however, will stop if the immune cell kills all of the tumour cells and there
are no quiescent cells left. It will also stop when the tumour cells kill all
of the immune cells. Moreover, time can be implemented in a number of
different ways. The most appropriate way for this model would be to take
into consideration the average mitotic rate of a cancer cell. This is in the
region of around 18-34 hours. For the purpose of this model, time is generic.
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2.3 Results
The inidividual-based model, will aim to investigate the potency of T-lymphocytes,
without chemotactic effects, on a latent tumour mass. As discussed in the
previous section, oxygen will be made available in the tumour environment
by tissue. When the oxygen levels in the tumour mass fall lower than certain
threshold values, the tumour mass will form different “tumoural zones”: the
proliferating tumour rim, quiescent zone and necrotic zone.
Matzavinos et al. [2004] investigated a model, which described a pre-
angiogenic tumour without a central necrotic core. The findings of this PDE
model indicate that a dormant state can be found when the immune cells
(CD8+ T-lymphocytes) are suitably efficient at killing tumour cells. In using
CompuCell3D, the hope is to get similar results qualitatively as the PDE
model in Matzavinos et al. [2004], whereby a tumour mass is to be kept
dormant by immune cells. However, by using an individual-based approach
it allows the model to include more biological features of the tumour immune
environment. The following results will again use CD8+ T-lymphocytes as
the effector cell. This section will focus on the results when implementing
the model using CompuCell3D. The three elements of immunoediting will be
investigated. This will be done by varying the success rate of the immune
cells lysing tumour cells.
As one can see, from the previous section, there are slight differences in
the basic model set up. Matzavinos et al. [2004] does not include different
states of tumour cells and omits a central necrotic core. A tumour cell, in
the individual-based model, also grows in relation to the amount of oxygen
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concentration found at its core. The term in the model for the growth rate is
multiplied by the oxygen concentration to determine how much the cell will
expand by, at each growth step. This means that the cells on the outer rim
of the proliferating tumour zone will grow much faster than the proliferating
tumour cells on the border of the quiescent zone. In doing this, it adds a
little more to the model, as rather than having a tumour cell constantly
grow, no matter how much oxygen is available to it, it will have an added
constraint. Also, this could be important if the model were to include the
effects of hypoxia, however this has been omitted. For the figures in the
results section, the colours of the cells are indicated next to their description
in the following synopsis of the model in the next paragraph.
Initially, the model starts out with a central tumour mass (red) with four
randomly placed immune cells (blue). The tumour mass is allowed to grow
in relation to the oxygen level at its core and immune cells are constantly
added to the system every 25MCS. Oxygen is secreted, at a constant rate,
from the medium cells (grey) that represent the host tissue. As the model
progresses, oxygen is used by the immune and tumour cells. Once the oxy-
gen concentration goes below a threshold, the tumour cells turn quiescent
(purple). Then, the quiescent cells either turn back to being proliferative,
if the local tumour environment improves, or necrotic (black) if the oxygen
levels are no longer sufficient to support it. It should also be noted, that
the quiescent cells take up oxygen at half the rate of tumour cells. When
an immune cell and tumour cell come into contact, their random motility
is switched off, as is their ability to bind to another cell, meaning that the
immune cells can only interact with one tumour cell at a time. Depending
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on the outcome of this interaction, there will either be a dead immune cell
(green) or a dead tumour cell (yellow). All dead cells disintegrate when they
come into contact with the medium. It should also be pointed out that since
this modelling technique is stochastic, results will vary every time a new
simulation is undertaken, however a range of values will be given, showing a
guide for each of the three sections of immunoediting.
2.3.1 Elimination-Immune destruction
In solving the model, cancer destruction by the immune system is possible
in this idealised environment. As previously discussed, this is known as the
elimination stage within the immunoediting description of immune-cancer
interactions. In order for this to happen, the immune system needs to be
very efficient at killing tumour cells. The results suggest that the immune
cells must have a success rate of roughly 80% or more. This can be seen in
Figures 2.2, 2.3 and 2.4.
At 80% immune success rate the immune cells seem to have the advan-
tage over the tumour cells and usually kill off the tumour mass. Figure 2.2
represents the concentration of immune (blue) and tumour cells (red), Figure
2.3 shows the tumour and immune interactions, and Figure 2.4 represents the
oxygen evolution over time. In Figure 2.2, the immune cells almost increase
linearly, whereas the tumour cells have an oscillatory nature. Figure 2.3(a)
depicts the tumour and immune cells at 200MCS, where a central cancer
mass is present with surrounding immune cells. The tumour cells then grow
and interact with the immune cells. This can be seen in Figures 2.3(b)-2.3(e).
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Looking at Figures 2.3(b) and 2.3(c), the oscillatory nature of the tumour
cell concentration can be seen, which is due to the tumour cells managing to
regrow after waves of immune attack. By 10000MCS, in Figure 2.3(f), the
immune cells have nearly successfully killed all the tumour cells and Figure
2.2 shows that the tumour cells’ number are reduced to zero just after this
Montecarlo Step. Figure 2.4 portrays the role oxygen concentration plays in
this model. Initially, the tumour mass has enough oxygen to grow (Figure
2.4(a)), but as it gets larger, the tumour cells progress into a quiescent and
then necrotic state, as the tumour environment can no longer support them
(Figures 2.4(b)-2.4(e)). However, as the necrotic cells come into contact with
the medium, they disintegrate and allow oxygen to flow into that area again.
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Figure 2.2: Graph showing the total number of tumour and immune cells
for 80% immune kill rate.
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(a) (b)
(c) (d)
(e) (f)
Figure 2.3: Plots showing the growth of a tumour mass interacting with a
host immune system. The types of cells and their corresponding colours in
Figures 2.3(a)-2.3(f) are as follows: proliferative tumour cells in red, quies-
cent tumour cells in purple, necrotic cells in black, medium cells in grey, im-
mune cells in blue, dead immune cells in green and lysed tumour cells in yel-
low, with the immune rate at 80%. Figures 2.3(a)-2.3(f) represent the model
at 200MCS, 2000MCS, 4000MCS, 6000MCS, 8000MCS and 10000MCS re-
spectively. The growth and oscillatory nature of the tumour mass is evident
in Figures 2.3(b)-2.3(e). By 10000MCS the tumour mass is under control
and will eventually be killed by the immune cells.
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(a) (b)
(c) (d)
(e) (f)
Figure 2.4: Plots showing the oxygen concentration at times 200MCS,
2000MCS, 4000MCS, 6000MCS, 8000MCS and 10000MCS respectively with
the immune rate at 80%. The oxygen concentration is high when it is red and
low when it is blue. A bar on the left hand side of each picture represents the
oxygen concentration. Oxygen is used up by the immune, tumour and quies-
cent cells, leaving areas where tumour cells can longer be supported, leading
to necrosis. Once the necrotic cells have disintegrated, oxygen can flow into
the area again via the medium cells.
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When building this model, the tumour cells, although adhering to each
other, have been allowed to have random motility, in order for them to branch
out and create new tumour mass sites. This is important as cancer does not
follow a strict growth pattern nor does it stay uniform in nature, making re-
sections and patient care plans very difficult. Looking at 2.5, it can be seen
that for 80% to 83% immune success rate, elimination is possible. However,
even at this high percentage, it isn’t unusual for tumour cells to overcome
the immune cells producing a cancerous state. As the results are stochastic
in nature, there will be a new simulation with a new outcome every time,
however the hope was to find a spectrum of results for each area of immu-
noediting. This unfortunately will not always bring about the correct results,
as errors will always be found.
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Figure 2.5: Plots showing the total number of tumour and immune cells for
80-83% immune kill rate.
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2.3.2 Oscillatory Dynamics
The second type of dynamic, which the model is able to mimic, is tumour-
immune equilibrium. Here, the tumour and immune cells have oscillatory
dynamics. This is meant to represent the period of malignant dormancy
within a patient. In order to obtain these dynamics, the success rate of the
immune cells has been increased. What is evident from the results, is that
there is a switching effect going on for certain values. At 72%, the tumour
cells are still evading immune destruction, but then the dynamics change. At
73%, there is a slight tendency towards oscillatory dynamics, seen in Figure
2.6. The same can be said in Figure 2.7, for 77-80% immune kill success rate.
Here, the dynamics are displaying similar results to Matzavinos et al. [2004].
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Figure 2.6: Plots showing the total number of tumour and immune cells for
74-76% immune kill rate.
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Figure 2.7: Plots showing the total number of tumour and immune cells for
78-81% immune kill rate.
It seemed prudent to look closer at the 75-78% immune success rate, in
Figures (2.8)-(2.15), to see if a dynamic equilibrium can be found. These
values were chosen as the system oscillates for a longer amount of MCS.
What can be seen, is that the oscillatory dynamics last over a wide range
of percentages. Looking at Figures 2.8-2.15, however, this does not always
happen, as the tumour mass can often win, creating no oscillations. The 75-
78 percentage range does yield the most abundant amount of equilibrium like
dynamics however, even at 80 % immune success rate, this type of result can
be seen. Looking at 75.9 % immune success rate in Figure 2.10, the simulation
actually stops, however the immune and tumour cells are still battling each
other. This could be seen as a possible steady state like dynamic. Another
observation is that the oscillatory dynamics give a much better outlook for
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the immune system, where the immune cells often win the battle. However,
it is much nicer to look at some pictures of tumour cell growth to illustrate
these points, captured in the next section.
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Figure 2.8: Plots showing the total number of tumour and immune cells for
75-75.3% immune kill rate.
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Figure 2.9: Plots showing the total number of tumour and immune cells for
75.4-75.7% immune kill rate.
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Figure 2.10: Plots showing the total number of tumour and immune cells
for 75.8-76.1% immune kill rate.
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Figure 2.11: Plots showing the total number of tumour and immune cells
for 76.2-76.5% immune kill rate.
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Figure 2.12: Plots showing the total number of tumour and immune cells
for 76.6-76.9% immune kill rate.
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Figure 2.13: Plots showing the total number of tumour and immune cells
for 77-77.3% immune kill rate.
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Figure 2.14: Plots showing the total number of tumour and immune cells
for 77.4-77.7% immune kill rate.
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Figure 2.15: Plots showing the total number of tumour and immune cells
for 77.8-78% immune kill rate.
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Dormancy investigation
To look more closely at the dynamics needed for a equilibrium state to
emerge, this section will focus on the values that show the change from
tumour success to immune success. At 74% immune success rate, the im-
mune cells and tumour cells are oscillatory in nature. The immune cells are
mounting an attack, but unfortunately here the tumour growth is just too
quick. This can be seen in Figures 2.16 and 2.17. At 77 % immune success
rate however, the immune cells manage to overcome the tumour mass, seen
in Figures 2.19 and 2.20.
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Figure 2.16: Plots showing the total number of tumour and immune cells
for 74% immune kill rate.
While conducting these simulations, some observations were found re-
garding oxygen use and spatial restriction. Figures 2.18 and 2.21 represent
oxygen concentration over time. In terms of space, the tumour can only use
the oxygen available to it within the given domain. This has repercussions for
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the tumour cells, as without a blood supply it will become necrotic, however,
it also has negative effects for the immune assault.
What can be seen is that often the proliferating tumour cells are killed
or nearly killed by the immune cells, however there is still a large residual
quiescent and necrotic population, depicted in Figure 2.17(c) and 2.17(d), but
more solidly in Figure 2.20(e). As oxygen is constantly supplied through the
medium cells, the quiescent mass will be able to gain enough oxygen in order
for them to become viable tumour cells again. This gives the tumour another
lifeline, as the immune cells do not recognise, in this model, a quiescent cell
as a threat. This quiescent mass can also prevent immune cells travelling
to a more remote area of the domain, where tumour cells are proliferating,
as they create a wall that the immune cell would find difficult to penetrate.
Figure 2.20(c) is a good example of this. It is only when either the quiescent
cells give way, by either creating a space due to their random motility or by
becoming proliferative tumour cells again, that the immune cells can gain
access to the tumour cells and attack. Therefore, the tumour has the ability
to grow in a different region, which is slightly protected by either quiescent
or necrotic cells, creating a new local tumour mass. If hypoxia were included
in this model, the oxygen starved tumour would send signals in order to gain
a blood supply. It also shows that it only takes either one quiescent cell
or tumour cell to escape from the immune system, in a patient’s body, for
the tumour to re-grow and gain a hold. Even after resection, chemotherapy,
radiotherapy or therapeutic drug therapy this may also be the case. In
understanding this, patients who have been in remission for years, may not
know their cancer is spreading and that the immune system is trying to
81
combat it, as small avascular tumours are undetectable. There is also the
possibility that the tumour cells who have survived the first attack by the
immune system, may undergo some phenotypic changes in order to avoid
immune detection, leading to an advanced sub population of tumour cells.
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(a) (b)
(c) (d)
(e) (f)
Figure 2.17: Plots showing the growth of a tumour mass interacting with
a host immune system. The types of cells and their corresponding colours
in Figures 2.17(a)-2.17(f) are as follows: proliferative tumour cells in red,
quiescent tumour cells in purple, necrotic cells in black, medium cells in grey,
immune cells in blue, dead immune cells in green and lysed tumour cells in
yellow, with the immune rate at 74%. Refer to Figure 2.16 for the overall
cell concentrations. Figures 2.17(a)-2.17(f) represent the model at 200MCS,
1500MCS, 5000MCS, 10000MCS, 15000MCS and 20000MCS, respectively.
Oscillatory dynamics are depicted here, whereby the tumour and immune
cells try to battle for control. Here, the tumour completely floods the domain
and evades the immune system.
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(a) (b)
(c) (d)
(e) (f)
Figure 2.18: Plots showing the oxygen concentration at times 200MCS,
1500MCS, 5000MCS, 10000MCS, 15000 MCS and 20000 MCS, respectively.
Refer to Figure 2.16 for the overall cell concentrations where the immune cell
success rate is 74%. The oxygen concentration is high when it is red and low
when it is blue. A bar on the left hand side of each picture represents the
oxygen concentration. Here, the tumour completely floods the domain and
evades the immune system.
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Figure 2.19: Plots showing the total number of tumour and immune cells
for 77% immune kill rate.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 2.20: Plots showing the growth of a tumour mass interacting with
a host immune system. The types of cells and their corresponding colours
in Figures 2.20(a)-2.20(i) are as follows: proliferative tumour cells in red,
quiescent tumour cells in purple, necrotic cells in black, medium cells in grey,
immune cells in blue, dead immune cells in green and lysed tumour cells in
yellow. Figures 2.20(a)-2.20(i) represent the model at 200MCS, 1000MCS,
5000MCS, 10000MCS, 13700MCS, 20000MCS, 25000MCS, 27700MCS and
313000MCS, respectively. Refer to Figure 2.19 for the overall cell concen-
trations when the immune success rate is at 77%. Oscillatory dynamics are
depicted here, whereby the tumour and immune cells try to battle for con-
trol. However, this time the tumour cells are destroyed by the host immune
system.
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(g) (h) (i)
Figure 2.21: Plots showing the oxygen concentration at times 200MCS,
2000MCS, 5000MCS, 10000MCS, 13700MCS, 20000MCS, 27700MCS AND
31300MCS, respectively. The oxygen concentration is high when red and low
when blue. A bar on the left hand side of each picture represents the oxygen
concentration. Refer to Figure 2.19 for the overall cell concentrations when
the immune success rate is at 77%. Oscillatory dynamics are depicted here,
whereby the tumour and immune cells try to battle for control. However, this
time the tumour cells are destroyed by the host immune system.
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2.3.3 Immune evasion
The last “E” in immunoediting is “Immune Evasion”. Here, the tumour cells
successfully evade immune destruction when the success rate of the immune
cells is roughly less than 73%, shown in Figure 2.22. Figures 2.23, 2.24 and
2.25 represent the model at 70% immune success rate. It is important to
note that, looking at Figure 2.23, the tumour cells (red) peak to a certain
level and then start to decrease. This is due to the domain being filled by
tumour cells, which then turn quiescent, due to the lack of oxygen within
the system. If no tumour cells, quiescent cells or immune cells remain in the
domain the simulation stops. If the immune cells go to zero, the tumour has
gained control. If a blood supply was added it would continue to grow, enter
the blood stream and possibly begin to metastasise within the body.
Figure 2.24 shows the growth of a tumour mass over time while under
attack from a host immune system. Here, the immune system does not have
sufficient enough power to overcome the tumour and it floods the domain.
In this figure, one can see the different zones of the tumour very well. As
the tumour growth progresses, a quiescent zone forms, followed by a necrotic
core. Once all the oxygen has been used up in the system, all the cells will
become necrotic. In reality this wouldn’t happen, as the tumour mass would
try and gain a blood supply to fuel its growth. Oxygen evolution can also be
seen in Figure 2.25.
88
0 1000 2000 3000 4000 5000
MCS
0
200
400
600
800
To
ta
l n
um
be
r o
f c
el
ls
70 Percent Immune Success Rate
immune
tumour
0 2000 4000 6000
MCS
0
100
200
300
400
500
600
700
To
ta
l n
um
be
r o
f c
el
ls
71 Percent Immune Success Rate
immune
tumour
0 5000 10000 15000
MCS
0
200
400
600
800
To
ta
l n
um
be
r o
f c
el
ls
72 Percent Immune Success Rate
immune
tumour
0 0.5 1 1.5 2
MCS
×104
0
100
200
300
400
500
To
ta
l n
um
be
r o
f c
el
ls
73 Percent Immune Success Rate
immune
tumour
Figure 2.22: Plots showing the total number of tumour and immune cells
for 70-73% immune kill rate.
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Figure 2.23: Plots showing the total number of tumour and immune cells
for 74% immune kill rate.
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(a) (b)
(c) (d)
(e) (f)
Figure 2.24: Plots showing the growth of a tumour mass interacting with
a host immune system. The types of cells and their corresponding colours
in Figures 2.24(a)-2.24(f) are as follows: proliferative tumour cells in red,
quiescent tumour cells in purple, necrotic cells in black, medium cells in grey,
immune cells in blue, dead immune cells in green and lysed tumour cells in
yellow. Figures 2.24(a)-2.24(f) represent the model at 200MCS, 1000MCS,
2000MCS, 3000MCS, 4000MCS and 4400MCS, respectively at 70% immune
success rate. The growth of the tumour mass is evident in Figures 2.24(a)
and 2.24(f). By 4400MCS the tumour mass has completely taken control.
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(a) (b)
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(e) (f)
Figure 2.25: Plots showing the oxygen concentration at times 200MCS,
1000MCS, 2000MCS, 3000MCS, 4000MCS, and 4400 MCS, respectively at
70% immune success rate. By 4400MCS the tumour mass has completely
taken control.
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2.4 Conclusion
The model in this chapter has investigated, in a novel way, the impact CD8+
T-cells have on a tumour mass before angiogenesis. It was based on the
spatial model in Matzavinos et al. [2004], whereby the results showed the
exhibition of a dormant cancer state, by way of a Hopf bifurcation identified
in the homogenous model. Using CompuCell3d, the spatial system has been
extended into an individual based model and the resulting simulations have
tried to portray the three Es of immunoediting: elimination, equilibrium and
escape. This model is stochastic in nature and, therefore, produces different
results each time a new simulation is started. The model begins with a
central tumour mass, which is attacked by immune cells. The tumour cells
are allowed to divide when they reach a certain size, determined by how much
oxygen is available to them. This creates different tumoural zones, whereby
the tumour mass forms a proliferating rim, quiescent zone and necrotic core.
The immune cells are constantly supplied to the domain at a rate of one
every twenty-five MCS. For the killing mechanism, the immune cells are
given a percentage of success rate against the tumour cells, mimicking the
Hopf bifurcation control parameter from Matzavinos et al. [2004]. As this
success rate is varied the three Es of immunoediting are realised.
Firstly, the elimination stage, where the immune cells are able to overcome
the cancer cells, is simulated. Provided the success rate is over roughly 80%
this state can be exhibited. However, as the model is stochastic in nature, the
system can produce the opposite result. This is also due to other dynamics
in the way in which the simulation progresses. The tumour cells are allowed
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to break off from the main mass, and grow in a location where there maybe
a larger abundance of oxygen, creating a new local tumour mass. This may
also be twinned with the fact that often when the tumour cells go quiescent
they can change back into a tumour cell when their oxygen is at a sufficient
enough level. As the immune cells do not recognise quiescent cells as a threat,
the tumour mass is often left undetected, sometimes hidden behind a wall of
quiescent cells and necrotic material, promoting cancer growth. The second
E of immunoediting, equilibrium, is exhibited when the immune success rate
is roughly between 75 − 77%. This period is recognised when oscillatory
dynamics are present over a significant number of time steps. Again as this
system is stochastic in nature, one cell type will eventually win out, but the
equilibrium dynamics are present here. Lastly, the escape stage is realised
when the immune success rate is below 73%. This means that the cancer
cells have sufficient enough leverage over the immune cells to gain a hold and
possibly promote tumour growth factors to gain a regulatory blood network.
In conclusion, this system has provided a good snap shot of immunoedit-
ing and has attempted to mimic the dynamics produced in Matzavinos et al.
[2004]. Further discussions and future work on the model can be found in
Chapter 5.
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Chapter 3
Modelling Multiple Cancer and
Immune Cell Phenotypes
3.1 Introduction
The previous chapter modelled the interaction between a host immune system
and a tumour population in an individual based model using the computer
platform CompuCell3D. The model consisted of only one tumour and immune
cell type, supplied by oxygen. The tumour mass was allowed to grow and
the immune cells were introduced at a constant rate into the domain. The
tumour and immune cells killed one another using a probability, inputed
by the user, to favour one or the other. However, one of the hallmarks of
cancer is that a tumour mass contains many different cells and phenotypes,
as well as a host immune system that consists of different immune cells. This
heterogeneity is discussed in section 1.1.3. It therefore seemed prudent to
extend the model in order to capture more of the tumour microenvironment.
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The previous model was based on the paper Matzavinos et al. [2004],
whereby a partial differential equation system was introduced to try and
describe the interactions between immune and tumour cells. This included
an investigation on an ordinary differential equation system, whereby the
authors removed the spatial elements in the PDE system, to better under-
stand the underlying oscillatory dynamics. This paper was then extended,
in Matzavinos and Chaplain [2004], to show that the oscillations, driven by
a Hopf bifurcation, exhibited travelling wave solutions by way of a 1-D hete-
roclinic connection. Utilising these techniques, the model in this chapter has
extended the model in chapter 2.
The biological focus of the previous model was on cytotoxic T lympho-
cytes, more specifically, CD8+ cells, as it was thought that they produced
the most effective means of clearance of nascent tumours. More recently
however, it is thought that the T-helper cell or CD4+ T-cell has the ability
to target tumours, which have down graded their MHC I protein pathways.
This down-regulation allows the tumour cells to elude the CD8+ T-cells. As
previously discussed, in section 1.1.3, the MHC protein pathways allow im-
mune cells to recognise tumours by way of antigen presenting cells (APCs).
CD4+ T-cells indirectly kill tumour cells by either recruiting other immune
cells, such as macrophages or eosinophils, to kill the tumour cells or will
release cytokines, in the presence of a tumour cell, which are toxic.
There are two models in this chapter. One was developed to try and
extend de Pillis et al. [2005], which ultimately failed. Tactics were changed
and the model evolved into one that investigates the underlying dynamics
of a tumour-immune system. This uses an ODE model, which will then be
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extended to include more biological features and spatial interactions, in 1-D
and 2-D. Although the individual based model can portray more biological
features, it is also an advantage to work with PDE and ODE systems. More
mathematical analysis can be done and the parameters that ultimately con-
trol the dynamics of the system can be more easily accessed. Modelling more
and more interactions and dynamics is not always a benefit and can often
prevent any findings due to the increasing complex nature of the model.
The next model has utilised some modelling techniques from de Pillis et al.
[2005]. In this paper, a model of CD8+ T-cells, NK cells and an immune pop-
ulation has been developed. The model uses experimental mice (Diefenbach
et al. [2001]) and human data (Dudley et al. [2002]) and, therefore, has good
quantitative results. The model is used to try and find “best fit” functional
forms for the interaction terms between tumour and immune cells and to try
and establish the underlying dynamics for tumour clearance. It is hoped that
the model could aid in the development of therapeutic vaccines. The model
is as follows:
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dT
dt
=
logistic growth︷ ︸︸ ︷
aT (1− bT )−
death by NK︷︸︸︷
cNT −
death by CD8+︷︸︸︷
D, (3.1.1)
dN
dt
=
supply︷︸︸︷
σ −
death rate︷︸︸︷
fN +
recruitment tumour︷ ︸︸ ︷
gT 2
h+ T 2
−
death by tumour︷ ︸︸ ︷
pNT, (3.1.2)
dL
dt
= −
death rate︷︸︸︷
mL +
recruitment tumour︷ ︸︸ ︷
jD2
k +D2
−
death by tumour︷︸︸︷
qLT +
boost by NK︷ ︸︸ ︷
rNT, (3.1.3)
where, D = d
(L/T )λ
s+ (L/T )λ
T. (3.1.4)
Here, the tumour population is represented by the variable T , and the
dynamics are described in equation (3.1.1); the NK cells’ population is rep-
resented by the variable N , and described by equation (3.1.2); and the CD8+
cells are represented by the variable L, and the dynamics are shown in equa-
tion (3.1.3). The model employs basic, but well used, mathematical mod-
elling techniques for cell growth, supply and death, however, it uses more
complex methods for recruitment and killing. The recruitment of immune
cells are also represented by Michaelis Menten dynamics, utilised due to the
term’s saturation effects (Kirschner and Panetta [1998]). The CD8+ T-cell
equation, in (3.1.3), also contains the term rNT , that boosts the recruitment
of the CD8+ T-cells. As NK cells interact with the tumour cells, this initi-
ates the activation of the CD8+ T-cells. As the CD8+ T-cells are activated
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in this way, this prevents the activation of the CD8+ T-cells prior to innate
immunity.
The results of the investigation into finding a curve of “best fit”, deduce
that there is a distinct difference in the way an NK cell and CD8+ T-cell
interact with a tumour cell. While the dynamics of an NK cell killing a
tumour can be described by a simple mathematical product interaction term,
it was surmised that a CD8+ T-cell’s behaviour should be mathematically
represented by a fractional response term. D denotes this fractional response
term in equation (3.2.7). Here, λ represents how the lysis rate depends on
the effector/target ratio, s allows a change in the steepness of the curve, and
d is the maximum lysis rate/effectiveness of the immune cells.
In practice, saturation of the NK cells is not reached. Conversely, it is
argued that the T-cells may require this type of saturation curve, represented
by the fractional term, as they are targeting a specific tumour type and are,
therefore, more effective in terms of cell-cell interactions. The results show
that the experimental data can be replicated in the mathematical model. In
light of this model, this thesis has tried to build on the dynamics and extend
them.
3.2 Mathematical Model
This section will focus on the interactions between a host immune population,
tumour cells and antigen presenting cells (APCs). As previously discussed, in
section 1.1, the activation of immune cells is fulfilled by loaded APCs. These
antigens are deemed loaded, as they have come into contact with a tumour
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cell, and will display foreign antigen complexed with an MHC protein on the
cell surface, for presentation to lymphocytes. APCs can be, for example,
macrophages and dendritic cells. These cells can then be “read” by T-helper
cells, by way of an epitope, which can elicit an immune response to the cancer
cells.
The model has five variables: T , the tumour cell population; Eh, the
T-helper or CD4+ T-cell population; El, the CD8
+ T-cell population; Au
the inactivated/unloaded APCs; and Aa, the activated/loaded APCs. The
dynamics are represented by system (3.2.1)-(3.2.6):
dT
dt
=
logistic growth︷ ︸︸ ︷
a1(1− a2T )T −
death by CD4+︷ ︸︸ ︷
cEhT −
death by CD8+︷︸︸︷
D, (3.2.1)
dEh
dt
=
supply︷︸︸︷
u1 −
decay︷︸︸︷
fEh +
Activation by APC︷ ︸︸ ︷
gA2a
h+ A2a
Eh −
death by tumour︷ ︸︸ ︷
cEhT, (3.2.2)
dEl
dt
=
supply︷︸︸︷
u2 −
decay︷︸︸︷
mEl +
activation by tumour︷ ︸︸ ︷
jD2
k +D2
El +
activation by CD4+︷ ︸︸ ︷
rEhEl (3.2.3)
−
death by tumour︷ ︸︸ ︷
nElT, (3.2.4)
dAu
dt
=
production inactivated︷︸︸︷
α −
decay︷︸︸︷
vAu −
removed class︷ ︸︸ ︷
qAuT, (3.2.5)
dAa
dt
=
activated by tumour︷ ︸︸ ︷
qAuT −
decay︷︸︸︷
σAa, (3.2.6)
where, D = d
(El/T )
λ
s+ (El/T )λ
T, (3.2.7)
The idea behind the above system was to incorporate certain methods,
used in de Pillis et al. [2005], to model different biological features. The
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terms are described by the over-brace brackets above each term. Again,
growth, supply and decay are all modelled by well known practices, however
recruitment and immune cell kill rate are modelled differently. The inacti-
vated APCs are activated, at rate q, this then activates the CD4+ T-cells, at
rate g, shown in equation (3.2.2), using a saturation type term. The CD4+
T-cells can then go onto kill the tumour cells, at rate c. In turn, the tumour
cells can also mount an attack on the CD4+ T-cells. Both of these killing
mechanisms, however, are simplified. It is thought, as discussed in section
1.1.3, that CD4+ T-cells indirectly kill tumour cells by way of either released
cytokines or by activating different cells of the immune system. The tumour
cells also release enzymes, which are toxic to immune cells. The other im-
mune cell in this model is the CD8+ T-cell. Looking at equation (3.2.4), the
CD8+ T-cells are activated by the presence of the tumour cells, at rate j, util-
ising similar Michaelis Menten dynamics as de Pillis et al. [2005]. Moreover,
the CD8+ cells are enhanced by the presence of CD4+ T-cells, at rate r. The
CD8+ T-cells kill the tumour cells, represented by the term D, in equation
(3.2.1), using the same fractional response term developed in de Pillis et al.
[2005]. The model was then non-dimensionalised, by setting:
T ∗ =
T
T0
, t∗ =
t
τ
, E∗h =
Eh
Eh0
, E∗l =
El
El0
,
A∗u =
Au
Au0
, A∗a =
Aa
Aa0
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The new dimensionless system is:
dT
dt
= δ(1− T )T − ηEhT −D1, (3.2.8)
dAu
dt
= α1 − α2AuT − v1Au, (3.2.9)
dAa
dt
= α2α3AuT − σ1Aa (3.2.10)
dEh
dt
= u1 − f1Eh + g1 A
2
a
h1 + A2a
− ωEhT, (3.2.11)
dEl
dt
= −m1El + j1 D
2
1
k1 +D21
+ r1EhEl − n1EhT. (3.2.12)
where
a1t0 = δ, a2T0 = , t0cEh0 = η,
s
θλ
= s1,
dt0 = d1,
El0
T0
= θ,
αt0
Au0
= α1, t0v = v1
qT0t0 = α2,
Au0
Aa0
= α3, σt0 = σ1,
t0f = f1, gt0 = g1,
h
A2a0
= h1, pT0t0 = ω,
mt0 = m1, jt0 = j1, rEh0t0 = r1, nT0t0 = n1,
ut0
Eh0
= u1
k
T 20
= k1. (3.2.13)
After finding and linearising around the steady states, bifurcation dy-
namics have remained elusive for this model. Discussions on possible ways
to remedy this issue will be conveyed in the future work chapter.
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3.3 The Basic Mathematical Model
Previously, a system that focused on CD8+ T-cells and CD4+ T-cells, in
section 3.2, was developed, which ultimately proved too difficult to find any
bifurcations. To try and investigate some sort of multiple immune/tumour
cell modelling, the system in this section will be more general, and quali-
tative rather than quantitative. System (3.3.1)-(3.3.4), describes a host im-
mune system in interaction with a tumour mass. The role of the APCs has
been removed and it was decided it would be interesting to investigate two
tumour populations, where one is deemed to have evolved into a more potent
tumour phenotype. The evolution of tumour phenotypes has been discussed
in this thesis in the immunoediting section, 1.1.2, whereby it is thought that
the tumour cells evade immune destruction by the selective process of the
immune system’s killing; the immune system kills the more immunogenic
cells, leaving a more powerful cancer mass. Moreover in section 1.1.3, it
is argued that the tumour cells downgrade their MHC protein pathways in
order to prevent immune cells recognising them. Both of these postulations
are well known within theoretical biology, providing further reasoning behind
the development of this system.
The model contains four variables: T1, the tumour type one population;
T2, the tumour type two population; E1, the immune type one population;
and E2 the immune type two population. The model is described by equa-
tions (3.3.1)-(3.3.4):
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Tumour 1︷︸︸︷
dT1
dt
= r1T1
(
1− T1
K1
)
− a1E1T1
1 + T1
− a4E2T1
1 + T1
, (3.3.1)
Tumour 2︷︸︸︷
dT2
dt
= r2T2
(
1− T2
K2
)
− a2E1T2
1 + T2
− a3E2T2
1 + T2
, (3.3.2)
Immune 1︷︸︸︷
dE1
dt
= b1 +
e1a1E1T1
1 + T1
+
e2a2E1T2
1 + T2
− d1E1, (3.3.3)
Immune 2︷︸︸︷
dE2
dt
= b2 +
e3a3E2T2
1 + T2
+
e4a4E2T1
1 + T1
− d2E2, (3.3.4)
where, K1, K2, a1, a2, a3 a4, e1, e2, e3, e4, b1, b2, d1 and d2 are all positive
parameters. Equation (3.3.1) represents the dynamics of the T1 population.
The growth and decay is represented by logistic growth, where K1 is the
carrying capacity, and the T1 population is attacked by both E1 and E2 cells
at rate a1 and a4 respectively. Equation (3.3.2) describes the evolution of the
T2 tumour cells. Logistic growth is again used to model growth and decay,
with carrying capacity K2 and the population is attacked by the E1 and E2
cells at rate a2 and a3. As in de Pillis et al. [2005], the use of a Hill function
has been employed here to elucidate the killing mechanism of the immune
cells. Further discussions on the derivation of Michaelis Menten techniques,
in relation to the recruitment of immune cells, can be found in Kuznetsov
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et al. [1994].
Moreover, equation (3.3.3) represents the E1 population. The supply
rate is constant and is represented by parameter b1. The immune cells are
enhanced by the presence of the tumour cells and their recruitment is repre-
sented by the terms e1a1E1T1
1+T1
and e2a2E1T2
1+T2
. The E1 population also decays at
rate d1 due to lysis. Similarly, equation (3.3.4) elucidates the E2 population’s
dynamics where, b2 is the constant supply rate and d2 is the decay rate due
to lysis. As in the E1 equation, the immune cells interact with the tumour
cells in terms e3a3E1T1
1+T1
and e4a4E1T2
1+T2
. The aim of this model is to try and
understand the dynamics which will allow the model to move into different
cancerous states. The hope is to be able to capture dormancy steady states
and try and explain the situations where these states disappear. In order to
investigate this system the model has been deconstructed into three separate
models.
Section 3.4 will concern a shortened version of system (3.3.1)-(3.3.4),
whereby only the E1 cells will attack the T1 cells and the supply terms will
be omitted. After non-dimensionalising, steady states and their stability will
be examined in section 3.4.1. The results of this model, using ODE45 in
matlab, will be discussed in section 3.4.4, along with bifurcation analysis.
This is then extended into spatial models in 1-D, in section 3.5, and 2-D, in
section 3.6, with their corresponding results in sections 3.5.2 and 3.6.1.
System (3.3.1)-(3.3.4), is then further investigated by removing only the
E2 immune cells ability to attack the T1 cells in section 3.7. Again, steady
states and their stability will be deduced, in section 3.7.1, and the results,
along with bifurcation analysis, will be investigated in section 3.7.2. The
104
model is then extended into a spatial system in section 3.8, with the results
in section 3.8.1.
The full system, displayed in (3.3.1)-(3.3.4), is explored in section 3.9 and,
as before, any steady states, along with their stability, are examined, with
results and bifurcation analysis displayed in section 3.9.2. Furthermore, the
model is extended into a 1-D spatial model, in section 3.10, and the results
are investigated in section 3.10.1.
3.3.1 Non-dimensionalisation
System (3.3.1)-(3.3.4) can be non-dimesionalised by letting:
t∗ =
t
τ
, T ∗1 =
T1
T10
, T ∗2 =
T2
T20
, E∗1 =
E1
E10
,
E∗2 =
E2
E20
,
where:
τ =
1
r1
, T10 = K1, T20 = K2, E10 = K1 and E20 = K2.
The non-dimensional system is therefore:
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dT1
dt
= T1(1− T1)− γ1 E1T1
s1 + T1
− γ4 E2T1
s4 + T1
, (3.3.5)
dT2
dt
= α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s3 + T2
, (3.3.6)
dE1
dt
= z1 +
ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1, (3.3.7)
dE2
dt
= z2 +
ψ3E2T2
s3 + T2
+ ψ4
E2T1
s4 + T1
− ω2E2, (3.3.8)
where:
a1
r1
= γ1,
1
K1
= s1,
r2
r1
= α2,
a2K1
r1K2
= γ2,
a3
r1
= γ3
1
K2
= s2, τe1a1 = ψ1, τe2a2 = ψ2,
d1τ = ω1, τe3a3 = ψ3, d2τ = ω2, z1 =
b1
r1K1
,
z2 =
b2
r1K2
, γ4 =
a4K2
r1K1
, ψ4 = τe4a4, s3 =
1
K2
,
s4 =
1
K1
.
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3.4 Shortened model of cancer and immune
cells
This shortened model of system (3.3.5)-(3.3.8) has omitted the supply terms,
z1 and z2, for both immune types. Moreover, the E2 cells attack on the T1
tumour population has also been removed. It can be argued that the supply
terms can be removed as the cells could already be present in the tumour
microenvironment, although not practical. However, by scaling back on the
model, it will allow more investigation into what dynamics change if the
model is extended. It will show the most important influences within the
model and how they effect any of the cell types. Setting γ4=z1=z2=0 in
system (3.3.5)-(3.3.8), the system now becomes:
dT1
dt
= T1(1− T1)− γ1 E1T1
s1 + T1
, (3.4.1)
dT2
dt
= α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s3 + T2
, (3.4.2)
dE1
dt
=
ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1, (3.4.3)
dE2
dt
=
ψ3E2T2
s3 + T2
− ω2E2. (3.4.4)
Looking at the non-dimensional parameters, it can be seen that the E1
immune cells kill the T1 cancer cells at a faster rate than the E2 cells. The
107
E2 cells however kill the T2 cells at a much faster rate than the T1 cells do,
but do not attack the T1 population. The T1 cells can be seen as mutated
cancer cells, in the sense that they are phenotypically different to the T2 cells.
While the T1 cells are being attacked by the E1 cells, they have managed to
evade detection by the E2 cells and therefore can be classed as a more potent
phenotype. It may become apparent in a clinical situation that the immune
system would manage to thwart the T2 cell population while allowing the
T1 cell population to grow “unchecked” by all but one type of immune cell,
whose best efforts may not be enough to clear the tumour bulk, leading to
metastasis and invasion. The two different types of immune cells could be,
for example, a CD8+ T-cell for the E2 population and an NK cell for the
E1 population. This is a reasonable choice as the NK cells are part of the
innate immune system and have vast targets. Similarly, the two immune
cells could be a CD8+ T-cell for the E2 population and a CD4
+ T-cell for the
E1 population. In this scenario, the T1 population may have down-regulated
their MHC I protein pathway, evading immune detection by the CD8+ T-
cells, however the CD4+ T-cells can still recognise them, as discussed in
section 1.1.3. Moreover, Eftimie et al. [2010] recognises the difference between
the action of Th1 and Th2 immune cells in relation to cancer rejection. Here,
it was necessary for both immune cells to work together in order to kill the
tumour.
The values of γ1, γ2 and γ3 are important as they determine the saturation
point of the cells i.e. if one were to plot the function where the E1 cells are
attacking the T1 cells the curve would tend toward s1. The gradient of the
curve is influenced by the parameters s1, s2 and s3. If these parameters are
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decreased, the curve will become steeper, leading the immune cells to reach
saturation point at a much faster rate, however increasing the parameters
will have the opposite effect. It is now necessary to look at the number of
steady states within the system and determine their stability.
3.4.1 Steady states and stability
Steady states are found by setting:
dT1
dt
= T1(1− T1)− γ1 E1T1
s1 + T1
= 0, (3.4.5)
dT2
dt
= α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s2 + T2
= 0, (3.4.6)
dE1
dt
=
ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1 = 0, (3.4.7)
dE2
dt
=
ψ3E2T2
s2 + T2
− ω2E2 = 0. (3.4.8)
It is easy to see that the trivial steady state (0, 0, 0, 0) exists. The other
steady states are equated by setting:
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T1(1− T1)(s1 + T1)− γ1E1T1 = 0, (3.4.9)
α2T2(1− T2)(s2 + T2)(s3 + T2)− γ2E1T2(s3 + T2)
− γ3E2T2(s2 + T2) = 0, (3.4.10)
ψ1E1T1(s2 + T2) + ψ2E1T2(s1 + T1)− ω1E1(s2 + T2)(s1 + T1) = 0, (3.4.11)
ψ3E2T2 − ω2E2(s3 + T2) = 0. (3.4.12)
There are nine steady states: the trivial steady state, discussed previously;
seven semi trivial steady states; and one coexistence steady state.
3.4.2 Numerical values of steady states
The numerical values of steady states are found using the parameter values
as below:
γ1 = 0.7778 s1 = 0.65, α2 = 0.7778, s4 = 0.5,
γ2 = 0.2222, γ3 = 0.7778, s2 = 0.5, s3 = 0.65,
ψ1 = 0.3111, ψ2 = 0.0044, ω1 = 0.1778, ψ3 = 0.2333
ω2 = 0.1333, z1 = 0.1778, z2 = 0.1333, γ4 = 0.1111
ψ4 = 0.0022.
These parameter values are generic. It is prudent to point out that gaining
experimental data for these types of systems is difficult. One could use
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a number of different values from numerous academic materials, but this
chapter is concerned with achieving a qualitative picture of the system and
to examine the dynamics that can be achieved here. Time has been scaled
in reference to the mitotic rate of the T1 cells. Again different cancer cell
types have different proliferation rates, however a cancer cell normally has a
mitotic rate of somewhere between 18-34 hours.
s1 = (0, 0, 0, 0), s2 = (1, 0, 0, 0) , (3.4.13)
s3 = (0, 1, 0, 0) , s4 = (1, 1, 0, 0), (3.4.14)
s5 = (0.867, 0, 0.259, 0), (3.4.15)
s6 = (0, 0.866, 0, 0.203), (3.4.16)
s7 = (1, 0.866, 0, 0.203), (3.4.17)
s8 = (0.835, 0.937, 0.315, 0), (3.4.18)
s9 = (0.836, 0.866, 0.314, 0.103). (3.4.19)
3.4.3 Linear stability analysis
To further investigate the dynamics of the system it is prudent to examine
the stability of the steady states by carrying out a linear stability analysis.
After finding the steady states one now needs to work out the determinant
of the Jacobian Matrix equal to zero, in order to investigate the eigenvalues.
The Jacobian is worked out as follows:
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J =

∂f1
∂T1
∂f1
∂T2
∂f1
∂E1
∂f1
∂E2
∂f2
∂T1
∂f2
∂T2
∂f2
∂E1
∂f2
∂E2
∂f3
∂T1
∂f3
∂T2
∂f3
∂E1
∂f3
∂E2
∂f4
∂T1
∂f4
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where
f1 =
dT1
dt
= T1(1− T1)− γ1 E1T1
s1 + T1
, (3.4.20)
f2 =
dT2
dt
= α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s2 + T2
, (3.4.21)
f3 =
dE1
dt
= z1 +
ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1, (3.4.22)
f4 =
dE2
dt
= z2 +
ψ3E2T2
s2 + T2
− ω2E2. (3.4.23)
Now it is necessary to work out:
detJ(T ∗1 ,T ∗2 ,E∗1 ,E∗2 ) − λI = 0, (3.4.24)
where stability is determined by examining the eigenvalues (λ) of the steady
state. The steady state is asymptotically stable if and only if all the real
parts of the eigenvalues are less than zero i.e. Re(λ) < 0 as t→∞. If any of
the eigenvalues have Re(λ) > 0 the steady state is unstable, provided each
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eigenvalue exists.
The trivial steady state, (0, 0, 0, 0), is unstable determined by
detJ(0,0,0,0) − λI = 0 and λ = 0.7778, 1,−0.1333,−0.1778. (3.4.25)
There are seven semi-trivial steady states. The stability of each is de-
termined by the sign of the real part of their eigenvalues. Each is listed
below:
• (1, 0, 0, 0) and λ = 0.0107, 0.7778,−0.1333,−1.000000000
• (0, 1, 0, 0) and λ = 0.0081, 1,−0.1747,−0.7778
• (1, 1, 0, 0) and λ = 0.0081, 0.0137,−0.7778,−1
• (0.867, 0, 0.259, 0), and λ = 0.6625,−0.0130,−0.1333,−0.7779
• (0, 0.866, 0, 0.203), and λ = 1,−0.0098,−0.1750,−0.6048
• (1, 0.866, 0, 0.203) and λ = −1, 0.0135,−0.0098,−0.6048
• (0.835, 0.937, 0.315, 0) and λ = 0.0045,−0.0175,−0.6972,−0.7249
By looking at each of the steady states with their corresponding Eigenvalues,
it is easy to see that all of the semi-trivial steady states are unstable.
For this system there is one “coexistence steady state” whereby each of
the steady state values are greater than zero. The stability of the steady
state is stable as each of the eigenvalues are negative.
detJ(0.836,0.866,0.314,0.103) − λI = 0 and λ = −0.0049,−0.0174,−0.6063,−0.7262.
(3.4.26)
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In order to change the stability of the trivial and semi-trivial steady states,
the parameter values would have to be modified to achieve stability. This
however was not of interest in this PhD as the most interesting and important
dynamics are realised by examining the co-existence steady state.
3.4.4 Results
The results in this section will be worked out using ODE45 in Matlab, a black
box solver, which utilises a 4th/5th order Runge Kutta method. Further
details can be found in Chapter 1.3. It should also be noted that the initial
conditions for this system are (T1, T2, E1, E2) = (1, 1, 1, 1).
3.4.5 Oscillations/bifurcations
Limit cycles, derived from Hopf bifurcations, are extremely interesting to
have in a model. By varying a parameter, a Hopf bifurcation may become
apparent, showing that the variable will have some degree of control on the
dynamics of the system. The steady state moves from a steady state of sta-
ble coexistence to an unstable steady state, which gives rise to oscillatory
dynamics. A stable limit cycle will display oscillations, which have the same
amplitude or damped oscillations, which get progressively smaller, gravitat-
ing towards the attractor. An unstable limit cycle will lead to oscillations
whose amplitude get progressively bigger. Biologically, stable limit cycles,
in the context of this model, mean that the immune system has managed
to keep the tumour population under check, and a dormancy situation has
become apparent. Parameter values for the results are shown in section 3.4.2.
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There is a Hopf bifurcation when s1 = 0.279. The bifurcation diagrams for
T1 and T2 are shown in Figures 3.1-3.2 and similar diagrams can be obtained
for the other two variables. A Hopf bifurcation is a critical point where the
stability of the system switches and this gives rise to a periodic solution. The
bifurcation diagrams have been generated using the computer programme,
XPP AUTO. The red line indicates that the solution is stable, while the
black line indicates the solution is unstable. The blue circles represent an
unstable limit cycle and the green a stable limit cycle. Stable limit cycles are
essentially attractors, where any small perturbation will cause the system to
return to the attractor. Looking at the bifurcation diagrams, it can be seen
that the limit cycles are stable in this case. Any value of parameter s1, which
is within the arc of the periodic, will give stable limit cycles. The amplitude
of the Hopf bifurcation, within the arc, can be determined by looking at
the difference between the maximum and minimum values for that given
parameter value. For example, when looking at Figure 3.1 when s1 = 0.21,
this will give much larger amplitudes than if s1 = 0.24.
Moreover, Figures 3.3-3.6 show the stable oscillatory dynamics for s1 =
0.225. In these figures, the differences in the amplitude can be seen more
clearly. Looking at the bifurcation diagram for the T1 population, it can
be seen that there is a much larger amplitude than in the figure for the
T2 population. Referring back to system 3.4.1-3.4.4, the T1 population is
attacked only by the E1 cells, whereas the E2 population is killed by both
immune cell types. As previously discussed, reducing the parameter s1 will
cause the immune cells to reach saturation at a much faster rate. This could
possibly be thought as the E1 cells being more adept in cell-cell interactions.
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However, if one looks at Figures 3.3-3.6, the T2 tumour cell bulk is higher
than the T1 tumour cell bulk. This is due to the extra recruitment terms for
the E1 population. As the E1 cells’ recruitment term is much higher, they
are better able to deal with the T1 tumour bulk than the E2 cells are with the
T2 tumour bulk. Although there is a Hopf bifurcation in E2, the oscillations
are too small to see. In Figure 3.6, it can be seen that there is a very low
level of E2 population, supporting the evidence that the recruitment of the
E2 cells is not high enough to provide T2 clearance. Moreover, the value of
the parameter γ2 is much smaller than that of γ1, therefore the E1 population
is also unable to lower the T2 tumour bulk significantly from the steady state
size. It should also be noted that the amplitude of the oscillations for T1
and E1 is much higher than for the other two. This is because the curve for
the recruitment of the E1 population and T1 population is steeper due to the
decrease in parameter s1.
116
00.2
0.4
0.6
0.8
1
T1
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
s1
Figure 3.1: Bifurcation diagram showing a hopf bifurcation in T1 at s1 =
0.279. The line in the diagram represents how the steady state changes as s1
changes. The black part of the line indicates instability of the equilibria and
the red, stability. Moreover, green dots indicate that the hopf bifurcation is
stable and blue dots represent instability.
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Figure 3.2: Bifurcation diagram showing a hopf bifurcation in T2 at s1 =
0.279. The line in the diagram represents how the steady state changes as s1
changes. The black part of the line indicates instability of the equilibria and
the red, stability. Moreover, green dots indicate that the hopf bifurcation is
stable and blue dots represent instability.
117
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Time
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
T1
Figure 3.3: Plot showing T1 where oscillations are derived from the param-
eter space when the hopf bifurcation is present at s1 = 0.225 at times 0 to
2000 seconds.
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Figure 3.4: Plot showing T2 where oscillations are derived from the param-
eter space when the Hopf bifurcation is present at s1 = 0.225 at times 0 to
2000 seconds.
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Figure 3.5: Plot showing E1 where oscillations are derived from the param-
eter space when the Hopf bifurcation is present at s1 = 0.225 at times 0 to
2000 seconds.
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Figure 3.6: Plot showing E2 where very small oscillations are derived from
the parameter space when the Hopf bifurcation is present at s1 = 0.225 at
times 0 to 2000 seconds.
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Moreover, there is a Hopf bifurcation when ψ1 = 0.8287, which gives
rise to a stable periodic solution. The bifurcation diagrams for T1 and E1
are shown in Figures 3.7-3.8 and similar figures can be plotted for the other
variables. The parameter ψ1 controls the saturation level of the term for E1.
As the parameter has been increased, the E1 population has been allowed
to grow to a higher level and therefore, the T1 tumour bulk will be reduced.
This is depicted in Figures 3.9 and 3.11. The E1 cells now fluctuate between
roughly 0.25 and 2.25, whereas the T1 cells vary between 0 and 0.4. The
E2 cells, although beginning high, are reduced to a very low level as their
recruitment is not high enough to overcome the effects of the decay term,
leading to a high T2 tumour bulk. This is depicted in Figures 3.10 and 3.12.
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Figure 3.7: Bifurcation diagram showing a hopf bifurcation in T1 at ψ1 =
0.8287. The line in the diagram represents how the steady state changes as
ψ1 changes. The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.8: Bifurcation diagram showing a hopf bifurcation in E1 at ψ1 =
0.8287. The line in the diagram represents how the steady state changes as
ψ1 changes. The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.9: Plot showing T1 where oscillations are derived from the param-
eter space when the Hopf bifurcation is present at ψ1 = 2 at times 0 to 2000
seconds.
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Figure 3.10: Plot showing T2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at ψ1 = 2 at times 0 to
2000 seconds.
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Figure 3.11: Plot showing E1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at ψ1 = 2 at times 0 to
2000 seconds.
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Figure 3.12: Plot showing E2 where E2 → 0 derived from the parameter
space when the Hopf bifurcation is present at ψ1 = 2 at times 0 to 2000
seconds.
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Another Hopf bifurcation is present when ψ3 = 0.4883. The bifurcation
diagram for E2 is shown in Figure 3.13 and similar diagrams can be depicted
for the other variables. Figures showing the oscillatory dynamics can be
seen in Figures 3.14-3.17 when ψ3 = 1. In this case, the ψ3 term, which
governs the saturation level for the E2 cells, has been increased. This leads
to a higher amount of E2 cells and a reduced T2 tumour bulk. The T1 and
E1 cells are largely unaffected by this and moreover, the oscillations are too
small to show.
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Figure 3.13: Bifurcation diagram showing a hopf bifurcation in T1 at ψ3 =
0.4883. The line in the diagram represents how the steady state changes as
ψ1 changes.The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.14: Plot showing T1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at ψ3 = 1 at times 0 to
2000 seconds.
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Figure 3.15: Plot showing T2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at ψ3 = 1 at times 0 to
2000 seconds.
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Figure 3.16: Plot showing E1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at ψ3 = 1 at times 0 to
2000 seconds.
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Figure 3.17: Plot showing E2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at ψ3 = 1 at times 0 to
2000 seconds.
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3.4.6 Discussion
This section has examined an ODE model of two types of immune cells and
two tumour cells. The dynamics of the system has been explored using
bifurcation analysis. By finding the terms that create periodic solutions, the
control parameters and subsequent underlying dynamics of the system can
be elucidated. Here, the parameters s1, ψ1 and ψ3 are varied and periodic
solutions are found by way of Hopf bifurcations. The model allows more
analytical techniques to be used and gives a good understanding of the type of
dynamics, which can become apparent when varying the control parameters.
Although this ODE model has provided a good basis, it is now necessary to
develop a spatial model to study the effects space may have.
3.5 Spatial Model
The model in section 3.4 has been extended in this section into a spatial
system. This allows the exploration of cell-cell dynamics in a 1-D domain.
The spatial system is as follows:
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dT1
dt
= D1∇2T1 + T1(1− T1)− γ1 E1T1
s1 + T1
, (3.5.1)
dT2
dt
= D2∇2T2 + α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s2 + T2
, (3.5.2)
dE1
dt
= D3∇2E1 + ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1, (3.5.3)
dE2
dt
= D4∇2E2 + ψ3E2T2
s2 + T2
− ω2E2, (3.5.4)
where the values of the spatial parameters are:
D1 = D2 = 0.000008 and D3 = D4 = 0.0000075. (3.5.5)
Moreover, these values are generic as the results in this section are concerned
with studying the underlying mathematical dynamics of the system.
System (3.5.1)-(3.5.4) extends the previous ODE model by including dif-
fusion terms for each of the cell types. These describe the random motility
of the cells in the domain, with parameters D1 −D4 defining their velocity.
The results utilise the same parameter values as found in section 3.4.2.
3.5.1 Initial and boundary conditions
Zero flux boundary conditions were imposed and the initial conditions used
are similar to the ones used in Matzavinos et al. [2004] and are defined as:
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T1(x, 0) =

T10(1− exp(−1000(x− l)2)), if 0 ≤ x ≤ l,
0, if l < x ≤ x0,
(3.5.6)
T2(x, 0) =

T20(1− exp(−1000(x− l)2)), if 0 ≤ x ≤ l,
0, if l < x ≤ x0,
(3.5.7)
E1(x, 0) =

0, if 0 ≤ x ≤ l,
E10(1− exp(−1000(x− l)2)), if l < x ≤ x0.
(3.5.8)
E2(x, 0) =

0, if 0 ≤ x ≤ l,
E10(1− exp(−1000(x− l)2)), if l < x ≤ x0.
(3.5.9)
The initial conditions are displayed in Figure 3.18, depicting a tumour
wave front in T1 and T2, which encounter an immune cell front, E1 and E2.
A one-dimensional domain has been created where x ∈ [0, 1] and l represents
the point at which the two fronts interact. It should be noted that the
heterogeneity of the results in this chapter does not result from any changes
in initial conditions. The dynamics here are a well studied feature of reaction-
diffusion equations (Sherratt et al. [1997]; Matzavinos and Chaplain [2004])
and are driven by the presence of a limit cycle.
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Figure 3.18: Plots showing the Initial conditions for each cell type.
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3.5.2 Results
The results in this section have been numerically investigated by using the
Matlab tool, PDEPE. The description of the results will focus on the similar-
ities between that of the ODE model and the findings of the spatial model.
In the ODE model it was found that s1, ψ1 and ψ3 bifurcated and therefore
this section will discuss the impact that the addition of a spatial element has
on the system, with a focus on these specific parameter values.
As previously discussed, s1 determines the steepness of the recruitment
curve for the E1 population while interacting with the tumour cells. The
parameter has been set at the same value as in the ODE case to show a
direct comparison. Figures 3.19-3.26 show the spatial density of the cells at
times 0-2000 seconds and, as previously discussed, the time here is generic.
What can be surmised from these figures is that there is a heterogeneous
distribution of tumour cell density, which is invading the tissue. This is very
similar to the PDE dynamics that were found in Matzavinos et al. [2004].
These type of dynamics are driven by the presence of a Hopf bifurcation in
ODE systems and are deemed heterogeneous type travelling wave solutions.
It can be argued that the immune system is keeping the tumour cells in
check and a co-existence situation has arisen. As a result of higher rate of
recruitment of the E1 population in the ODE model, the amplitude of the
oscillations in T1 and E1 was much higher than that of T2 and E2, and the
spatial results portray similar dynamics. Moreover, the depletion of the E2
cell population is also seen here, where very small oscillations are present,
resulting in a higher T2 tumour density.
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Figure 3.19: Plots showing the spatial density of T1 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.225.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.20: Plots showing the spatial density of T1 at times 800, 1000, 1500
and 2000 seconds. The figures show heterogeneous travelling waves at s1 =
0.225. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.21: Plots showing the spatial density of T2 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.225.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.22: Plots showing the spatial density of T2 at times 800, 1000, 1500
and 2000 seconds. The figures show heterogeneous travelling waves at s1 =
0.225. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.23: Plots showing the spatial density of E1 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.225.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.24: Plots showing the spatial density of E1 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.225. This is derived from the same parameter space as the homoge-
neous system when the Hopf bifurcation is present.
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Figure 3.25: Plots showing the spatial density of E2 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.225.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.26: Plots showing the spatial density of E2 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.225. This is derived from the same parameter space as the homoge-
neous system when the Hopf bifurcation is present.
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The next parameter that was varied in the homogeneous model was ψ1,
which determines the saturation level of the E1 cells when in interaction
with T1. The spatial density of the cells in the domain can be seen in figures
3.27-3.34 and ψ1 = 2, which has been chosen as it was determined that
there was periodic solutions here in the homogeneous model. As ψ1 has been
increased, more E1 cells are in the domain, which subsequently lowers the
T1 tumour density. The figures also show that there is, again, the presence
of heterogeneous type waves in the system, whereby the T1 cells are seen to
invade the tissue whilst in attack by the host immune system. Moreover,
the E2 cells again here do not have a sufficient recruitment rate to make any
significant effect on the T2 tumour density and the T2 cells must be kept
under check by the presence of the E1 cells.
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Figure 3.27: Plots showing the spatial density of T1 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ1 = 2.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.28: Plots showing the spatial density of T1 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ1 = 2. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.29: Plots showing the spatial density of T2 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ1 = 2.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.30: Plots showing the spatial density of T2 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ1 = 2. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.31: Plots showing the spatial density of E1 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ1 = 2.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.32: Plots showing the spatial density of E1 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ1 = 2. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.33: Plots showing the spatial density of E2 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ1 = 2.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.34: Plots showing the spatial density of E2 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ1 = 2. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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3.5.2.1 ψ3 = 1
The parameter, ψ3 has been varied, which determines the recruitment of the
E2 cells when in contact with the T2 tumour population. Again, there is a
Hopf bifurcation in the homogenous system when this parameter is greater
than 0.4883. Here the parameter ψ1 = 1, to reflect the results in the homo-
geneous model. Figures 3.35-3.42 represent the cell densities at times 0-2000
seconds. When looking at the figures for the E2 population, it can be seen
that the boost in the saturation level, allows more cells in the domain, sub-
sequently reducing the T2 tumour density and heterogeneous type waves are
present. Moreover, as before, the T1 and E1 cells display uninteresting type
dynamics, whereby the solutions seem almost stable.
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Figure 3.35: Plots showing the spatial density of T1 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ3 = 1.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.36: Plots showing the spatial density of T1 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ3 = 1. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
3.5.3 Discussion
This section has focused on the extension of the homogeneous model into a
spatial model. Diffusion terms were added and the results were discussed.
The results reflect the findings of the ODE model in that they explore the
variation of the parameter s1, ψ1 and ψ3. In s1 and ψ1 the T1, T2 and E1
and population showed heterogeneous type waves, driven by the presence
of the periodic solutions in the ODE model. ψ3 showed the T2 tumour cell
population invading the tissue and creating heterogeneous type waves while
under attack by the E1 and E2 cells. The model will now be extended into
2-D.
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Figure 3.37: Plots showing the spatial density of T2 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ3 = 1.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.38: Plots showing the spatial density of T2 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ3 = 1. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.39: Plots showing the spatial density of E1 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ3 = 1.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.40: Plots showing the spatial density of E1 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ3 = 1. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.41: Plots showing the spatial density of E2 at times 0, 100, 200
and 400 seconds. The figures show heterogeneous travelling waves at ψ3 = 1.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.42: Plots showing the spatial density of E2 at times 800, 1000,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
ψ3 = 1. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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3.6 2-D spatial model
This section is concerned with extending the spatial model into two dimen-
sions. It is good practice to check whether the system works in higher dimen-
sions to try and ascertain if the model is biologically relevant. The model
has been inputted into the computer programme “Comsol”, utilised to im-
plement the finite element method in time independent PDE systems, over
given domains, to approximate the solutions over a set time. Further details
of Comsol are given in Chapter 1.3.
This model utilises a circular domain for each cell type. The initial tu-
mour cell density has been kept constant throughout the domain and the
immune cells are set occupy the inside of the domain. This is depicted in
Figure 3.43. Moreover, as previously discussed in section 3.5, the chaotic
nature of these results is not driven by the initial conditions, but by the
presence of the limit cycle in addition to the diffusion of the cells.
3.6.1 Results
In the homogenous model it was found that there is a Hopf bifurcation at s1 =
0.225. This was then investigated in the spatial model by setting s1 to a value,
which is in the same parameter space as when oscillations are present in the
homogeneous model, producing heterogeneous travelling waves. Moreover,
the parameter s1 controls the rate of the E1 cells reaching saturation. In
this case the parameter has been decreased, leading to a faster saturation
level. In this section, the model has been extended into 2-D and the same
parameter has been investigated using a value as when oscillations would be
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(a) (b)
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Figure 3.43: Plots showing initial value plots of tumour and immune cells
present in the homogeneous model, s1=0.27. Figures 3.44-3.52 represent the
two-dimensional results at times 100, 200, 400, 800, 1000, 1200, 1600 and
2000 seconds. These pictures mimic the results found in the homogenous
and one-dimensional spatial cases. The E1 immune population is seen to
be attacking the T1 tumour population producing heterogeneous dynamics.
The waves of immune cell and tumour cells interacting with each other show
the oscillatory nature of the system. Moreover, it can be seen that the E2
immune population is very small and has very little heterogeneity, although
it is present. This small population of E2 cells therefore does not make any
significant impact on the T2 tumour density.
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Figure 3.44: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=100. Figures 3.44(a) and
3.44(b) represent tumour type 1 and 2. Figures 3.44(c) and 3.44(d) represent
immune type 1 and 2.
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Figure 3.45: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=200. Figures 3.45(a) and
3.45(b) represent tumour type 1 and 2. Figures 3.45(c) and 3.45(d) represent
immune type 1 and 2.
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Figure 3.46: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=400. Figures 3.46(a) and
3.46(b) represent tumour type 1 and 2. Figures 3.46(c) and 3.46(d) represent
immune type 1 and 2.
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Figure 3.47: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=600. Figures 3.47(a) and
3.47(b) represent tumour type 1 and 2. Figures 3.47(c) and 3.47(d) represent
immune type 1 and 2.
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Figure 3.48: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=800. Figures 3.48(a) and
3.48(b) represent tumour type 1 and 2. Figures 3.48(c) and 3.48(d) represent
immune type 1 and 2.
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Figure 3.49: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=1000. Figures 3.49(a) and
3.49(b) represent tumour type 1 and 2. Figures 3.49(c) and 3.49(d) represent
immune type 1 and 2.
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Figure 3.50: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=1200. Figures 3.50(a) and
3.50(b) represent tumour type 1 and 2. Figures 3.50(c) and 3.50(d) represent
immune type 1 and 2.
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Figure 3.51: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=1600. Figures 3.51(a) and
3.51(b) represent tumour type 1 and 2. Figures 3.51(c) and 3.51(d) represent
immune type 1 and 2.
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Figure 3.52: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when s1 = 0.27 at time=2000. Figures 3.52(a) and
3.52(b) represent tumour type 1 and 2. Figures 3.52(c) and 3.52(d) represent
immune type 1 and 2.
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In the homogeneous model it was found that there is a Hopf bifurcation
at ψ1 = 0.8287. This was then investigated in the spatial model by setting
ψ1 to a value, which is in the same parameter space as when oscillations
are present in the homogeneous model, producing heterogeneous travelling
waves. Figures 3.53-3.61 show the dynamics of the 2-D system when the
parameter ψ1 has been set at 0.08288. This parameter controls the saturation
level of the E1 cells and as it has been increased, from the original parameter
value found in section 3.4.2, more E1 cells are recruited into the domain. The
result of this is a decreased T1 tumour cell density. The figures depict that
the system again displays heterogeneity in E1, T1 and T2, whereby the E1
cells are keeping the T1 and T2 (although at a much lower rate) tumour cells
in check. Furthermore, in the homogenous case the E2 cells were not able to
provide suitable surveillance of the E2 tumour cell population resulting in a
high T2 tumour cell density. Moreover, just as in the homogeneous and 1-D
spatial case the E2 cells do not exhibit a lot of heterogeneity but it is present.
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Figure 3.53: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=100. Figures 3.53(a)
and 3.53(b) represent tumour type 1 and 2. Figures 3.53(c) and 3.53(d)
represent immune type 1 and 2.
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Figure 3.54: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=200. Figures 3.54(a)
and 3.54(b) represent tumour type 1 and 2. Figures 3.54(c) and 3.54(d)
represent immune type 1 and 2.
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Figure 3.55: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=400. Figures 3.55(a)
and 3.55(b) represent tumour type 1 and 2. Figures 3.55(c) and 3.55(d)
represent immune type 1 and 2.
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Figure 3.56: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=600. Figures 3.56(a)
and 3.56(b) represent tumour type 1 and 2. Figures 3.56(c) and 3.56(d)
represent immune type 1 and 2.
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Figure 3.57: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=800. Figures 3.57(a)
and 3.57(b) represent tumour type 1 and 2. Figures 3.57(c) and 3.57(d)
represent immune type 1 and 2.
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Figure 3.58: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=1000. Figures 3.58(a)
and 3.58(b) represent tumour type 1 and 2. Figures 3.58(c) and 3.58(d)
represent immune type 1 and 2.
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Figure 3.59: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=1200. Figures 3.59(a)
and 3.59(b) represent tumour type 1 and 2. Figures 3.59(c) and 3.59(d)
represent immune type 1 and 2.
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Figure 3.60: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=1600. Figures 3.60(a)
and 3.60(b) represent tumour type 1 and 2. Figures 3.60(c) and 3.60(d)
represent immune type 1 and 2.
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Figure 3.61: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ1 = 0.8288 at time=2000. Figures 3.61(a)
and 3.61(b) represent tumour type 1 and 2. Figures 3.61(c) and 3.61(d)
represent immune type 1 and 2.
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In the homogenous model it was found that there is a Hopf bifurcation at
ψ3 = 0.4883. This was then investigated in the spatial model by setting ψ3 to
a value which is in the same parameter space as when oscillations are present
in the homogeneous model, producing heterogeneous travelling waves. Here
the parameter ψ3 has been investigated, which determines the saturation
level of the E2 immune cells. Here the parameter has been increased allowing
more E2 cells to be recruited into the system. Figures 3.62-3.66 represent 2-D
simulations for all cell types at times, 100, 400, 800, 1200 and 2000 seconds.
Again, just as in the homogeneous and 1-D spatial model, the figures show
that the increased recruitment of the E2 cells results in a decreased T2 tumour
cell density and the E1 and T1 populations remain largely unaffected. These
figures, although showing very small heterogeneity has not given the best
results. When increasing this parameter the model struggled to converge
and therefore, the value of the ψ3 that had to be used in this instance was
very close to the bifurcation value in the homogenous case, which produces
very small oscillations.
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Figure 3.62: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ3 = 0.5 at time=100. Figures 3.62(a) and
3.62(b) represent tumour type 1 and 2. Figures 3.62(c) and 3.62(d) represent
immune type 1 and 2.
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Figure 3.63: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ3 = 0.5 at time=400. Figures 3.63(a) and
3.63(b) represent tumour type 1 and 2. Figures 3.63(c) and 3.63(d) represent
immune type 1 and 2.
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Figure 3.64: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ3 = 0.5 at time=800. Figures 3.64(a) and
3.64(b) represent tumour type 1 and 2. Figures 3.64(c) and 3.64(d) represent
immune type 1 and 2.
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Figure 3.65: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ3 = 0.5 at time=1200. Figures 3.65(a) and
3.65(b) represent tumour type 1 and 2. Figures 3.65(c) and 3.65(d) represent
immune type 1 and 2.
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Figure 3.66: Plots showing two dimensional heterogeneous distribution of
tumour and immune cells when ψ3 = 0.5 at time=2000. Figures 3.66(a) and
3.66(b) represent tumour type 1 and 2. Figures 3.66(c) and 3.66(d) represent
immune type 1 and 2.
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3.7 Shortened model with supply terms
The next section is concerned with extending the model in section 3.4,
whereby the immune supply terms, z1 and z2 have been added. This ad-
dition will determine if there is any change in the control parameters found
in the previous model. Steady states of this system and their stability will
be elucidated and bifurcation analysis undertaken. The system still omits
the attack of the E2 tumour cells on the T2 cells and therefore, γ4 = 0 and
ψ4 = 0. The non-dimensional system, becomes:
dT1
dt
= T1(1− T1)− γ1 E1T1
s1 + T1
(3.7.1)
dT2
dt
= α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s3 + T2
(3.7.2)
dE1
dt
= z1 +
ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1 (3.7.3)
dE2
dt
= z2 +
ψ3E2T2
s3 + T2
− ω2E2 (3.7.4)
173
3.7.1 Steady states and stability
For these parameters there are three semi-trivial steady states and one co-
existence steady state. The values of the steady states are:
s1 = (0, 0, 0.25, 0.25), (3.7.5)
s2 = (0, 0.3111, 0.2524, 0.5767) , (3.7.6)
s3 = (0.4199, 0, 0.7980, 0.25) , (3.7.7)
s4 = (0.4147, 0.1783, 0.8012, 0.4011) . (3.7.8)
The stability of each of these steady states is determined by the sign of
their eigenvalues as discussed previously from the Jacobian of the system
where J stands for the Jacobian. The eigenvalues are:
s1 : detJ(0,0,0.25,0.25) − λI = 0 and
λ = 0.7008, 0.3675,−0.1778,−0.1333 (3.7.9)
s2 : detJ(0,0.3111,0.2524,0.5767) − λI = 0 and
λ = 0.6980,−0.0612 + 0.1545I,−0.1759,−0.0612− 0.1545I (3.7.10)
s3 : detJ(0.4199,0,0.7980,0.25) − λI = 0 and
λ = 0.1240,−0.1240 + 0.1959I,−0.1333,−0.1240− 0.1959I (3.7.11)
s4 : detJ(0.4147,0.1783,0.8012,0.4011) − λI = 0
and λ = −0.0364 + 0.1123I,−0.1205 + 0.1977I,−0.1205− 0.1977I,−0.0364− 0.1124I
(3.7.12)
Therefore, all the steady states are unstable aside from the coexistence steady
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state, s4.
3.7.2 Results
The model has been numerically solved using ODE45 in Matlab and the
bifurcation diagrams have been produced using XPP AUTO. The results
will show a reduction in the amount of control parameters, which cause the
system to bifurcate. Initial conditions for the model are the same as in section
3.4.
There is a Hopf bifurcation when s1 = 0.2537 and when s1 = 0.3899,
shown in Figures 3.67 and 3.68. As previously discussed, s1 controls the
rate at which the E1 cell reaches saturation. In this case, the parameter has
been decreased and therefore, the cells reach saturation at a much quicker
rate. s1 is the only parameter, in this model, that gives rise to stable periodic
solutions. The removal of the other two control parameters, which previously
displayed Hopf bifurcations, ψ1 and ψ3, now no longer exhibit these types of
solutions. Figures 3.69-3.72 show the dynamics of the system when s1 = 0.33.
When s1 bifurcated in the previous model, the E2 population was very close
to zero, leaving a high T2 tumour bulk, however with the addition of the
supply terms the E2 cells are now able to mount an effective attack against
the T2 tumour bulk and displays oscillatory dynamics with a much higher
amplitude. The E1 cells also have an enhanced number and are therefore
attributing to the surveillance of the T2 tumour population, with the E1
cells, and are mounting a better attack against the T1 cells. As before, the
model will now be extended to include spatial terms.
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Figure 3.67: Bifurcation diagram showing a hopf bifurcation in T1 at s1 =
0.2537. The line in the diagram represents how the steady state changes as
s1 changes. The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.68: Bifurcation diagram showing a hopf bifurcation in T1 at s1 =
0.3899. The line in the diagram represents how the steady state changes as
s1 changes. The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.69: Plot showing T1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.33 at times 0 to
2000 seconds.
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Time
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
T2
Figure 3.70: Plot showing T2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.33 at times 0 to
2000 seconds.
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Figure 3.71: Plot showing E1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.33 at times 0 to
2000 seconds.
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Figure 3.72: Plot showing E2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.33 at times 0 to
2000 seconds.
3.8 Spatial model
As in section 3.5.2, diffusion terms have been added to the non-dimensional
homogeneous model. The diffusion rates, D1, D2, D3 and D4 are the same
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values as before, and the system will be investigated in the same manner.
dT1
dt
= D1∇2T1 + T1(1− T1)− γ1 E1T1
s1 + T1
(3.8.1)
dT2
dt
= D2∇2T2 + α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s2 + T2
(3.8.2)
dE1
dt
= D3∇2E1 + z1 + ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1 (3.8.3)
dE2
dt
= D4∇2E2 + z2 + ψ3E2T2
s2 + T2
− ω2E2 (3.8.4)
3.8.1 Results
The system in this section has again been numerically investigated using
PDEPE in Matlab. Again the focus is to try and determine what happens
to the system if the parameter value s1 is set to a value in which there are
periodic solutions. Figures 3.73-3.80 show the evolution of the cell densities
at times 100, 200, 400, 800, 1200, 1500 and 2000 seconds. Again the time
is generic, and could be changed to elucidate more biologically relevant time
frames. Initial condition and boundary conditions are the same as in the
previous PDE model. The spatial model here again portrays heterogeneous
waves of all cell types invading the tissue. Both tumour cell densities have
been reduced with the inclusion of more immune cells. In the previous model
where the supply terms for the immune cells were omitted, the E2 cells were
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not able to mount an effective attack against the T2 tumour cells, leading to a
high tumour density. However, in this model, the supply term of more E2 cells
into the system has allowed the E2 cells to mount an effective surveillance
against the T2 tumour cells and therefore they are no longer obsolete.
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Figure 3.73: Plots showing the spatial density of T1 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.33.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
3.8.2 Discussion
This model has extended the system in 3.4 with the inclusion of immune
constant supply terms. The homogeneous system is seen to exhibit periodic
solutions, which arise through the presence of Hopf bifurcations, in parameter
s1. The other two terms in the previous model that didn’t include supply
terms had three control parameters, however the periodic solutions in ψ1 and
ψ3 have disappeared in this model. The inclusion of the supply terms boosts
the numbers of immune cells within the system and therefore the tumour bulk
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Figure 3.74: Plots showing the spatial density of T1 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.33. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
for both tumour types is reduced. The E2 cells are also now able to mount an
effective attack against the T2 tumour cells and are no longer obsolete within
the system. The spatial model, which was developed by adding diffusion to
the homogeneous model, shows heterogeneous type waves that invade the
tissue for all cell types. These come to light due to the presence of the Hopf
bifurcation in the homogeneous model, provided the parameter s1 is in the
correct range where periodic solutions are exhibited. The model will now be
extended to investigate the full system set out in section 3.3.
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Figure 3.75: Plots showing the spatial density of T2 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.33.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.76: Plots showing the spatial density of T2 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.33. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.77: Plots showing the spatial density of E1 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.33.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.78: Plots showing the spatial density of E1 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.33. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.79: Plots showing the spatial density of E2 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.33.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.80: Plots showing the spatial density of E2 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.33. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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3.9 Full immune attack
This section will be concerned with investigating the full system in section
3.3. Here, the E2 cells will be allowed to attack the T1 cell population, albeit
at a lower rate than the E1 cells. The recruitment of the E2 cells has also
been enhanced by their interaction with the T2 cells. This model now includes
two immune specialists whereby each is better at attacking a specific type
of tumour cell and not so good at attacking the other; they both now work
together to achieve tumour dormancy. The non-dimensional system is as
follows:
dT1
dt
= T1(1− T1)− γ1 E1T1
s1 + T1
− γ4E2T1
s4 + T1
(3.9.1)
dT2
dt
= α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s3 + T2
(3.9.2)
dE1
dt
= z1 +
ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1 (3.9.3)
dE2
dt
= z2 +
ψ3E2T2
s3 + T2
+
ψ4E2T1
s4 + T2
− ω2E2 (3.9.4)
As in the previous models, steady states and their stability will be in-
vestigated and bifurcation analysis will be undertaken. Furthermore, it is
necessary to discover if there is any change in the important parameters in
this model as the inclusion of the E2 attack against the tumour may have an
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effect. This will be explored in the results section. All parameter values can
be found in section 3.4.2.
3.9.1 Steady states and stability
For these parameters there are three semi-trivial steady states and one co-
existence steady state. The numerical values of the steady states are:
s1 = (0, 0, 0.25, 0.25), (3.9.5)
s2 = (0, 0.3111, 0.2524, 0.5767) , (3.9.6)
s3 = (0.4063, 0, 0.7646, 0.25) , (3.9.7)
s4 = (0.3911, 0.1963, 0.7447, 0.4216) . (3.9.8)
The stability of each of these steady states is determined by the sign of
their eigenvalues as discussed previously from the Jacobian of the system
where J stands for the Jacobian. The eigenvalues are:
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s1 : detJ(0,0,0.25,0.25) − λI = 0 and
λ = 0.6453, 0.3675,−0.1778,−0.1333 (3.9.9)
s2 : detJ(0,0.3111,0.2524,0.5767) − λI = 0 and
λ = 0.5698,−0.0612 + 0.1545I,−0.1759,−0.0612− 0.1545I (3.9.10)
s3 : detJ(0.4063,0,.7646,0.25) − λI = 0 and
λ = 0.1389,−0.1171 + 0.1949I,−0.1323,−0.1171− 0.1949I (3.9.11)
s4 : detJ(0.3911,0.1963,0.7447,0.4216) − λI = 0 and
λ = −0.0399 + 0.1158I,−0.1065 + 0.1974I,−0.1065− 0.1974I,−0.0399− 0.1158I
(3.9.12)
Again all the steady states are unstable aside from the coexistence steady
state, s4.
3.9.2 Results
The results are generated using ODE45 in Matlab and XPP AUTO for the
bifurcation diagrams. The focus again will be to try and ascertain the dif-
ferences between this model and the two previous models, in terms of the
oscillatory nature of the system and overall cell bulks.
There is a Hopf bifurcation when s1 = 0.3334. The bifurcation diagrams
for T1 and T2 are shown in Figures 3.1-3.2 for cells T1 and T2 and bifurcation
diagrams for the other two cell types can be obtained in a similar fashion.
Here, we see the return of a single bifurcation for the parameter set, giving
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rise to stable periodic solutions. Figures 3.83-3.86 show the oscillatory nature
of the system when s1 = 0.35. As the saturation curve of the E1 cells is less
steep than in the previous homogeneous models, it should be that the T1
tumour population is lower. However, with the E2 cells newfound ability
against the T1 tumour cells, the T1 tumour bulk is lowered. This is also the
case for the T2 cells, as more E2 cells are being recruited into the system.
The amplitude of the oscillations is also much lower, as the immune cells now
have a higher base level value and therefore the simulations do not bounce
between such high and low levels. The system again has managed to keep the
tumour bulk under check, this time keeping the cancer cells at a much lower
level than before. It is now prudent to capture the essence of the system in
1-D.
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Figure 3.81: Bifurcation diagram showing a hopf bifurcation in T1 at s1 =
0.3334. The line in the diagram represents how the steady state changes as
s1 changes. The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.82: Bifurcation diagram showing a hopf bifurcation in E1 at s1 =
0.3334. The line in the diagram represents how the steady state changes as
s1 changes. The black part of the line indicates instability of the equilibria
and the red, stability. Moreover, green dots indicate that the hopf bifurcation
is stable and blue dots represent instability.
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Figure 3.83: Plot showing T1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.35 at times 0 to
2000 seconds.
189
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Time
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
T2
Figure 3.84: Plot showing T2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.35 at times 0 to
2000 seconds.
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Figure 3.85: Plot showing E1 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.35 at times 0 to
2000 seconds.
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Figure 3.86: Plot showing E2 where oscillations are derived from the pa-
rameter space when the Hopf bifurcation is present at s1 = 0.35 at times 0 to
2000 seconds.
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3.10 Spatial model of full immune attack
The model in section 3.9 has been extended again by adding diffusion to each
of the cell types and their coefficients are the same as in previous models.
Furthermore, the results will aim to ascertain a link between the homogenous
findings in section 3.9.2 and to discuss differences between the results from
previous models. The spatial system is as follows:
dT1
dt
= D1∇2T1 + T1(1− T1)− γ1 E1T1
s1 + T1
− γ4 E2T1
s4 + T1
(3.10.1)
dT2
dt
= D2∇2T2 + α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s2 + T2
(3.10.2)
dE1
dt
= D3∇2E1 + z1 + ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1 (3.10.3)
dE2
dt
= D4∇2E2 + z2 + ψ3E2T2
s2 + T2
+ ψ4
E2T1
s4 + T1
− ω2E2 (3.10.4)
3.10.1 Results
The results in this section have been numerically explored using PDEPE in
Matlab. In the homogeneous model it was found that the inclusion of the
E2 cells attacking the T2 cells and the improved recruitment of the T2 cells
reduced the overall tumour cell bulks. There was a Hopf bifurcation present
when parameter s1 = 0.3334 and, therefore the results will explore the impact
this has in the spatial case.
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Figures 3.87-3.94 represent the spatial density of cells at times 100, 200,
400, 800, 1200, 1500 and 2000 seconds. Parameter s1 = 0.35 as this falls
within the periodic solutions of the homogeneous model. The rest of the
parameter values are kept the same. Again, each cell type is exhibiting
heterogeneous type waves, whereby the tumour cells are invading the tissue
and are attacked by the immune population. It can be seen that the tumour
cell densities have been further decreased, compared to the results in the
previous model, in section 3.8.1, even though the E1 cells reach saturation
at a slower rate. The results here are less heterogeneous than in the previous
model, as the periodic solutions show in the homogeneous case, due to a
higher level of immune cells within the system.
0 0.2 0.4 0.6 0.8 1
Distance into tissue
0
0.2
0.4
0.6
0.8
1
T1
 d
en
sit
y
0 0.2 0.4 0.6 0.8 1
Distance into tissue
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
T1
 d
en
sit
y
0 0.2 0.4 0.6 0.8 1
Distance into tissue
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
T1
 d
en
sit
y
0 0.2 0.4 0.6 0.8 1
Distance into tissue
0
0.05
0.1
0.15
0.2
T1
 d
en
sit
y
Figure 3.87: Plots showing the spatial density of T1 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.35.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.88: Plots showing the spatial density of T1 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.35. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
3.10.2 Discussion
This section has modelled the full system first set out in section 3.4. The
homogenous case saw the rise of stable periodic solutions by way of varying
s1 and discovering a Hopf bifurcation. The inclusion of the E2 cells attack
against the T2 cells, as well as their enhanced recruitment, has allowed both
tumour bulks to be lowered, even though s1 has not been reduced as much as
in previous models. The spatial model again exhibited heterogeneous waves
of tumour and immune cell densities and showed reduced heterogeneity in
the system.
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Figure 3.89: Plots showing the spatial density of T2 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.35.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.90: Plots showing the spatial density of T2 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.35. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.91: Plots showing the spatial density of E1 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.35.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.92: Plots showing the spatial density of E1 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.35. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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Figure 3.93: Plots showing the spatial density of E2 at times 0, 100, 200 and
400 seconds. The figures show heterogeneous travelling waves at s1 = 0.35.
This is derived from the same parameter space as the homogeneous system
when the Hopf bifurcation is present.
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Figure 3.94: Plots showing the spatial density of E2 at times 800, 1200,
1500 and 2000 seconds. The figures show heterogeneous travelling waves at
s1 = 0.35. This is derived from the same parameter space as the homogeneous
system when the Hopf bifurcation is present.
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3.11 Conclusion
In this Chapter, two models have been undertaken. The first model, in
section 3.2, was based on de Pillis et al. [2005] where, the system tried to
ascertain the dynamics between CD4+ T-cells, CD8+ T-cells, a tumour pop-
ulation and antigen presenting cells, in a homogeneous model. The model
used Michaelis Mention dynamics to describe the recruitment of the immune
cells, which was enhanced by their interactions with the tumour population.
Moreover, the model also included the action of APCs whereby loaded APCs
activated the CD4+ T-cells; an extra recruitment term. A fractional kill re-
sponse term was used for the killing of the tumour population by the CD8+
T-cells, derived in de Pillis et al. [2005], whereas the CD4+ T-cells used a
simple product term. Moreover, the tumour population could also kill the
immune cells, described again by a product term. Unfortunately, bifurcation
analysis remained elusive and the model was scrapped for the time being.
Another more generic model was then developed in this Chapter.
The second model tried to encapsulate the dynamics of a system with
two tumour populations interacting with two immune populations. The sys-
tem was developed using generic parameter values and utilises some of the
methods from both Matzavinos et al. [2004] and de Pillis et al. [2005]. The ho-
mogenous model, in section 3.3, portrays the dynamics of the system where
the terms describing the immune cells attacking the tumour cells are sur-
mised using Michaelis Menten dynamics. This interaction then creates extra
recruitment for the immune cells. The tumour cells do not kill the immune
cells. The model was then split into two shortened models before analysing
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the full system.
The first reduced model, in section 3.4, omitted the supply terms for
the immune cells, as well as the E2 cells attack against the T1 tumour cell
population. Steady states and their stability were explored and bifurcation
analysis was undertaken. This showed nine steady states of which only the
coexistence steady state was stable. The system was then solved using the
computer programme XPP AUTO to try and find bifurcations. This model
was seen to exhibit periodic solutions arising from Hopf bifurcations when
varying three parameters: s1, controlling the rate at which the E1 population
reaches saturation when in interaction with the T1 cell population; ψ1, the
saturation point of E1 when in interaction with the T1 population; and ψ3,
the saturation point of E2 when interaction with the T2 population. The
system was then investigated using Matlab to show the oscillatory dynamics
of the system.
The reduction of the parameter s1 allowed the system to exhibit stable
periodic solutions. This lowered the T1 tumour bulk, however E1 and T1
exhibited large oscillations. The E2 cells were not able to sufficiently gain
enough momentum to mount an effective surveillance against the T2 cells
and therefore, this lead to a higher T2 tumour bulk, which was only kept
in check by the E1 population. When varying parameter ψ1, the amount of
E1 cells was increased, therefore lowering the T1 cells. Again, the E2 cells
were unable to overcome their decay rate, due to lysis, leading to an almost
unchecked T2 tumour bulk. The last parameter to cause periodic solutions
when varied was ψ3. Here, E1 and T1 remained largely unaltered, but the
E2 cells, due to their enhanced recruitment, were now able to keep the T2
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cells under check. The model was then extended into 1-D by the inclusion
of diffusion terms. The results explored the system by varying the same
parameter values as in the homogeneous model. The results for s1 show a
heterogeneous type distribution of cells throughout the domain for E1, T1
and T2, with an almost obsolete density of E2 cells. Moreover, parameter
ψ1 showed similar results, whereby waves of E1 cells are seen to attack both
tumour cells and the E2 population remains obsolete. The varying of ψ3
shows heterogeneity in E2 and T2, but not in E1 and T1, due to the enhanced
recruitment of the E2 cells. The model was then extended into 2-D using
Comsol, which showed similar heterogeneity when varying all three control
parameters as in the 1-D case.
Biologically, the system was developed with the aim to investigate a more
potent tumour phenotype in the form of the T1 population. With the removal
of the E2 cells surveillance on the T1 population, the T1 cells should thrive,
however as Michaelis mention dynamics are used these terms cause the sys-
tem to exhibit some different dynamics. When removing the supply term
and extra recruitment term for E2, they become almost obsolete within the
system, when s1 is decreased and ψ1 is increased. The removal of the E2 cells
recruitment when in interaction with T2 seems to have the biggest effect on
their performance, however the increasing of the saturation level of the cells,
ψ3, can combat this to a certain degree. The homogeneous model was then
extended, in section 3.7, to include more elements of the immune-tumour
microenvironment.
The supply terms for both immune types, z1 and z2, were added and the
model was investigated in the same way. Steady states, their stability and
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bifurcations were analysed, and the system exhibited two Hopf bifurcations
when s1 was varied. The results show stable periodic solutions. Due to
the introduction of the supply terms, the E2 cells are now able to mount
an attack against the T2 population. The enhanced recruitment and supply
of both immune cells results in lower tumour bulks. This model was then
extended into a PDE model and again, the system exhibited waves of cells,
creating a spatially heterogeneous density throughout the domain. Moreover,
the E2 cells also exhibited this, whereas in the previous model, when varying
s1, they did not. Here, the inclusion of the supply terms has not allowed the
T1 cells to become the dominant cancer cell, as the extra recruitment of the
E1 cells prevents this.
The full system was then examined in section 3.9 and again steady states
and bifurcation analysis was undertaken. Again, the parameter s1 made
the system bifurcate but now only at one point. The inclusion of the E2
cells attack against the T1 cells lowered the overall tumour cell bulk due to
increased recruitment. Furthermore, the system was then extended into a 1-
D spatial model, where the results show a train of waves invading the tissue,
causing a spatial heterogeneous density throughout the domain, which is
met with a host immune system. Moreover, the T2 cell is again the dominant
cancer cell. The recruitment of the E1 cells is higher, therefore allowing the
T2 cells to become the more potent tumour phenotype. Future discussions
on this model and its findings can be found in Chapter 5.
201
Chapter 4
Individual-Based Model of
“Multiple Cell Types”
4.1 Introduction
The next chapter will focus on an avascular tumour, which elicits a response
from a host immune system. Most tumours at this stage are harmless and
grow to around 106 cells in volume (Matzavinos et al. [2004]), whereby cells
at the centre of the tumour die off due to a lack of nutrients and oxygen and
become “necrotic” (Alberts et al. [2008]). However, the prevention of the
tumour mass gaining a regulatory network is paramount in preventing full-
blown cancer spread. It seems prudent, therefore, to delve into the underlying
kinetics of a nascent tumour microenvironment, to try and understand how to
boost an immune cell response, in order to kill the cancer while at the stage
when it poses little threat and can be destroyed. Along with the obvious
issues that reside here, such as lack of accurate machinery and screening,
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which can detect cancer at this small level, there is much discussion as to
how the immune system actually attacks a small tumour mass. As discussed
in Chapter 1.1, the theory of immune surveillance, and subsequently the new
idea of immunoediting, try to describe and portray the way in which cancer
can either be cleared by the immune system, lie dormant or promote tumour
growth. Tumour cells can often harness the immune cells by changing their
phenotype when in a hypoxic state, promoting the growth of a regulatory
blood network. More information can be found in section 1.1.3. This chapter
will use elements of the model and dynamics exhibited in Chapter 2 and
section 3.7. The aim of the model is to try and again detect the three Es
of immunoediting, however this time extending the number of immune and
cancer cells. The model will then proceed to investigate the impact that the
“Warburg Effect”, discussed in section 1.1.4, may have on tumour growth.
4.2 Mathematical Model
This section is an extension to Chapter 2. This chapter concerns an investi-
gation of two immune cells and two tumour cells interacting with one another
in a discrete model using, the previously discussed, CompuCell3D; an open
source software concerned with numerically solving cellular potts models. In
the previous chapter, three models were proposed each with their own set of
differing interactions and results. Here, the second shortened model will be
investigated, from sections 3.7 and 3.8, whereby an immune system is in in-
teraction with different phenotypes of tumour cells. The non-dimensionalised
spatial system from the previous section 3.8 is as follows:
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dT1
dt
= D1∇2T1 + T1(1− T1)− γ1 E1T1
s1 + T1
, (4.2.1)
dT2
dt
= D2∇2T2 + α2T2(1− T2)− γ2 E1T2
s2 + T2
− γ3 E2T2
s2 + T2
, (4.2.2)
dE1
dt
= D3∇2E1 + z1 + ψ1E1T1
s1 + T1
+
ψ2E1T2
s2 + T2
− ω1E1, (4.2.3)
dE2
dt
= D4∇2E2 + z2 + ψ3E2T2
s2 + T2
− ω2E2. (4.2.4)
The above model, (4.2.1)-(4.2.4), describes, mathematically, two tumour
cells being attacked by two immune cells. Tumour type one (T1) is only
attacked by immune type one (E1), whereas tumour type two (T2) is killed by
both (E1 and E2). This is to try and investigate the idea that a tumour, when
in interaction with a host immune system, can become less immunogenic.
The idea stems from the hypothesis of immunoediting. As tumour cells are
not homogeneous and are of mixed type, it is thought that the immune
system actively kills cells that are more immunogenic, allowing cells that are
less immunogenic access to more nutrients and oxygen. Hence, the tumour
mass evades “immune destruction” and can secrete growth factors to gain
a blood network. However, unlike in the previous CompuCell3D model in
Chapter 2, here the tumour cells do not attack the immune cells. This
simplification is to aid in the understanding of the kinetics of this model
that will eventually lead to immune success or failure. The results of section
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3.8 show that there are conditions, whereby a tumour dormant state can
exist where heterogeneous waves are seen throughout the 1-D domain. To
fully investigate the new model, different modelling techniques of Chapters
2 and 3.1 have been used. Again, the hope is to enrich the results that were
found in the previous section 3.8 by using a discrete type model, whereby
more biologically relevant information can be inputted and computed.
The model in this chapter, however, will extend (4.2.1)-(4.2.4) by adding
in some new kinetics. Here, as in the previous CompuCell3D model in Chap-
ter 2, a host immune system is eliciting a response to a nascent tumour
before the tumour cells can secrete growth factors, stimulating an angiogenic
reaction. The immune cell-tumour cell interactions are represented by three
different probabilities to try and mimic the model. The immune cells, like
the model above, do not attack the tumour cells. Immune cell death is cal-
culated by adding in an age term. They are removed from the model if they
have been there for a certain number of MCS.
The model in this chapter has a similar set up to the previous Compu-
Cell3D model. Again, different aspects of CompuCell3D will be utilised to try
and mimic the results found in section 3.8. In this model, as previously dis-
cussed, there are two tumour cell types and two immune cell types. Medium
cells again represent healthy tissue, which is considered to be homogeneous.
This is a simplification of the microenvironment to try and understand the
underlying kinetics involved in the model. A cell is considered to be between
10µm-20µm in diameter (Alberts et al. [2008]), however here a 2-D repre-
sentation is used. Cells are initially determined to be 10µm and divide at
20µm. A newly divided cell is determined to be 5×5 pixels and each pixel
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represents a square element of a cell that is 2µm x 2µm, giving a total area of
4µm2. As in the previous CompuCell3D model, the tumour is represented by
a central 5×5 cell mass, however this time it contains two randomly placed
tumour types: type 1 and type 2. Initially, four immune cells of either type
one or type two are also randomly placed throughout the domain. A generic
type of nutrient feeds the cells in this model, which could be something such
as oxygen or glucose, and is also modelled just as in Chapter 2. Each cell
type has its own random cellular motility and chemotaxis has been omitted.
Figure 4.1: Plot showing the start of the simulation. The domain size is
200×200 pixel grid with each cell being 5×5 pixels. A central initial mass
of tumour cells of type 1 (red) and type 2 (blue) are randomly placed in the
initial MCS. The simulation begins with four immune cells randomly selected
from either type 1 (green) or type 2 (magenta). The tissue is represented by
the grey block of cells called medium cells.
Mitosis is determined in exactly the same way as the previous Compu-
Cell3D model, in that each cell type has an adhesion parameter that de-
termines how strongly each cell type binds to other cell types. Growth is
determined by how much nutrient is available and the tumour growth rate
206
(TGR) determined at every MCS is governed by:
TGR = 0.1× concentration of nutrient at tumour core. (4.2.5)
Both tumour types divide into two daughter cells when they reach 50µm,
20µm in diameter. Quiescent cells of both tumour types form when the
nutrient goes below a certain threshold. They then become necrotic when
there is no oxygen left to support them. When in contact with the medium,
the necrotic cells disintegrate into the “healthy tissue”. Immune cells do not
divide and are supplied to the domain at a constant rate of 25MCS, however
this time there is a random probability as to which type of immune cell is
introduced into the domain.
Cell migration is the same as in Chapter 2 and has a random orientation
for each individual cell type with immune cells having a faster capability
than tumour cells. Quiescent and necrotic cells do not move unless pushed
by a different cell type or by adhesion.
In this model, adhesion is similar, but now has to work with more cell
types. Immune cells of type one and two have a very weak adhesion to one
another and to their own cell type. Proliferating tumour cells of type one
and two adhere together but not as strongly as immune cells of both types
adhere to proliferating tumour cells of type one and two. Immune cells of
both types do not adhere to quiescent or necrotic cells, however tumour cells
do, but weakly. This is to try and allow the two tumour cell types to branch
off and form new local secondary tumour sites.
As before, nutrient is supplied to the domain at a constant rate, secreted
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by the medium cells. Diffusion in the domain is “zero flux” at the boundary
and is modelled by the PDE:
∂c
∂t
= D∇2c− kc+ secrection,
where D is the diffusion rate and k is the decay rate. k represents the uptake
of nutrient in a given cell with rates:
k =

0.5, in the tumour type 1 and 2 cells,
0.25, in the quiescent type 1 and 2 cells,
0.5, in the immune type 1 and 2 cells,
0, in the necrotic cells.
(4.2.6)
Within proliferating tumour and immune cells of both types, the uptake
of nutrient is much higher than quiescent tumour cells of both types. The
tissue, as before, does not uptake nutrient, but instead secretes it. Necrotic
cells do not uptake nutrient. Hypoxic and necrotic effects of cells are not
taken into consideration.
Cell death is one area where this model differs from the previous Com-
puCell3D model. Before, when an immune cell came into contact with a
proliferating tumour cell there were two different outcomes: the proliferating
tumour cell was killed by the immune cell or the immune cell was killed by
the tumour cell. However, in this model, it is only the immune cells that
are able to kill the tumour cells, the tumour cells do not kill. To incorpo-
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rate immune death, an age factor has been introduced, which is user defined.
The age is associated with how many MCS an immune cell can survive for.
After this time, an immune cell is deemed to be “dead” and is turned into a
necrotic cell. The dead cell is then allowed to disintegrate, again only when
in contact with the medium. In biology, differing immune cells have differ-
ent life expectancies, and within this model this has been incorporated. A
generic immune cell death time frame for each cell type was devised and has
been investigated to show qualitative results, in order to try to mimic the
results found in the homogeneous and spatial model from sections 3.7 and
3.8.
To integrate the immune attack against the proliferative tumour cells the
same technique has been used as in the previous CompuCell3D model. In
Matzavinos et al. [2004], a control parameter p was utilised and again has
been introduced into this model. Before, there was only one interaction and
therefore only one probability associated with immune success. This time
there are three interactions stemming from these terms from system (4.2.1)-
(4.2.4):
• in equation ∂T1
∂t
, the term
E1T1
s1 + T1
; (4.2.7)
• in equation∂T2
∂t
,
E1T2
s2 + T2
and
E2T2
s3 + T2
. (4.2.8)
To model these interactions within CompuCell3D, three probabilities have
been introduced. These are:
• the probability of immune 1 killing proliferative tumour 1, E1T1,
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• the probability of immune 1 killing proliferative tumour 2, E1T2,
• the probability of immune 2 killing proliferative tumour 2, E2T2.
The aim of the model is to try and qualitatively model aspects of immuno-
editing, and by modelling cell death in this way it gives the user a good
overall control in order to fully investigate the system. Each probability is
varied and is discussed in the results section.
The simulations run for a user-defined amount of Montecarlo steps (MCS),
laid out in the results section. As before, the simulations will stop if the im-
mune cells kill all of the tumour cells and there are no quiescent cells left. It
will also stop if there are no immune cells left in the domain, due to cells of
other types fully saturating it. Moreover, time can be implemented in a num-
ber of different ways. The most appropriate way for this model to include
time would be to take into consideration the average mitotic rate of a cancer
cell. This is in the region of around 18-34 hours. The age of the tumour cells
does not come into consideration, as one of the main trademarks of cancer
is that tumour cell death is averted by mutations. Time however is generic
in this model.
4.3 Results
The results in this section try to accurately portray the oscillatory dynamics
found in section 3.8, by extending the spatial model into a cellular potts
model, using the computer software package, CompuCell3D. In the homo-
geneous model in section 3.7, a co-existence steady state was identified. By
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varying parameter s1, oscillatory dynamics were found, resulting from a hopf
bifurcation. The model was then extended spatially, by adding in random
motility. Here, heterogeneous waves exist showing the oscillatory nature of
the system. The oscillations represent conditions whereby the immune sys-
tem can engage the tumour cells and keep them under check, albeit in a
dormant situation. Due to the nature of a PDE model, more intricate details
cannot be introduced. In the spatial model, as tumour type 2 was attacked
by two types of immune cells, the hope was for this population to be cleared.
However, the Michaelis Menten dynamics of the system prevented this. This
model will aim to rectify this, producing a coexistence steady state where
the T2 cells are at a lower density than the T1 cells. Moreover, in the PDE
model, quiescent cells and nutrients are not taken into consideration. This
makes it hard to assess how to increase the potency of the tumour cells.
The discrete model begins with a central tumour mass of randomly placed
tumour cells of type one and two, and four randomly selected immune cells
of type one and two. Immune cells do not grow or divide and, as before,
the tumour cells are allowed to grow in relation to how much nutrient is
available at their core. The tumour cells at the rim of the tumour mass,
therefore, will grow much faster than those at the centre, as no nutrient is
available to them, preventing growth. The cells are deemed to turn quiescent
when they fall below a certain threshold value of nutrient level at their core.
Then, the quiescent cells either turn back to being proliferative, if the local
tumour environment improves, or necrotic if the nutrient levels are no longer
sufficient to support it. This creates a “proliferative rim” of very fast growing
tumour cells, with a quiescent zone and a necrotic core.
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Immune cells of type one and two are randomly introduced into the system
at a constant rate of 25MCS. The immune cells have a user defined life
expectancy and the tumour cells do not mount an immune attack in this
model. By introducing an age value for the immune cells, their numbers will
grow to a threshold value, once the life span of the first immune cells has
been reached. This number will stay roughly constant throughout the whole
model, allowing for small differences, due to the model picking a random
immune type to introduce into the domain every 25MCS. When an immune
cell and tumour cell come into contact, their random motility is switched off,
as is their ability to bind to another cell. This means that the immune cells
can only interact with one tumour cell at a time. Each individual reaction
type, depending on which tumour cell is interacting with which immune
cell, has a probability associated with it. In this model, if, for example,
an immune cell has a 10% chance of killing a tumour cell, this means that
it will roughly kill a tumour cell one in every ten MCS. This is provided
that it is in contact with the tumour cell for the whole time. Again, it
should be noted that tumour type one is only attacked by immune type one
whereas, tumour type two is attacked by both immune types. Moreover,
since this modelling technique is stochastic, results will vary every time a
new simulation is undertaken.
As in Chapter 2, this model was used to explore the idea of immunoedit-
ing. The probabilities of each of the tumour-immune interactions have been
examined in order to try and model the three Es of immunoediting; elimi-
nation, equilibrium and escape. Each of the three Es will be identified and
conditions under which they occur will be investigated. The results are split
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into subsections that reflect the type of immune-tumour interaction, which
has been varied, and then will be sub-sectioned according to which immu-
noediting stage they represent.
While undertaking simulations using this model, it became apparent very
quickly that it was necessary to change two of the immune success rates at
one time, rather than just one, as it was difficult to ascertain any results oth-
erwise. A control set of parameters was very difficult to attain and therefore,
this requires more study into achieving a more structured way of showing
how a change in the parameter values dictates a change in the results of the
model. However, this chapter has been able to qualitatively show that it is
possible to simulate the three Es of immunoediting.
4.3.1 E1T1 interactions
As discussed previously, there are three different immune-tumour interac-
tions: tumour one and immune one, E1T1 for simplicity; tumour two and
immune one, E1T2; and tumour two and immune two, E2T2. This section
will focus on the interactions between immune one and tumour one. As tu-
mour cell one only has immune one attacking it, whereas tumour cell two has
both, it was recognised early on that the immune success rate would need
to be reasonably high for equilibrium or elimination of the tumour mass to
occur.
213
4.3.1.1 Cancer cell escape
The simulation in this section was run for 20,000 MCS with the probability
of E1T2 and E2T2 at 22% and 77% respectively. The simulations will stop if
there are no tumour cells, immune cells or quiescent cells left in the domain.
The value of E1T1 has been varied between 70− 89% in order to investigate
the effect of changing immune cell success rate on the tumour cells. Immune
cell death occurs when the immune cell has been in the domain for 1000
MCS. By looking at Figures 4.2-4.15, concentrations of E1, E2, T1 and T2
can be seen in graphical representation in Figures 4.2-4.5 and 4.8-4.13. Here,
T1 is represented by the red line, T2 by the blue line, E1 by the green line
and E2 by the pink line. The spatial representations for E1T1 = 77% and
E1T1 = 88% can be seen in Figures 4.6 and 4.14, where all cell types are
depicted. In the spatial pictures, proliferative tumour type 1 (T1) cells are
red, quiescent tumour type 1 cells are salmon, proliferative tumour type 2
(T2) are blue, quiescent tumour type 2 cells are light blue, necrotic cells are
black, medium cells are grey, immune type 1 cells (E1) are green and immune
type 2 (E2) are magenta. The nutrient concentrations for E1T1 = 77% and
E1T1 = 88% are depicted in Figures 4.7 and 4.15, where the bar at the side
of the figure shows the nutrient concentration in the domain. Looking at
Figures 4.2-4.15, initially the tumour cells and immune cells grow in number.
By 1000 MCS the immune cells start to level off at a rough concentration of
50, 25 of each type, in the domain.
The results show that the T2 cells are killed off very quickly by the immune
cells or, if they do survive, they are kept at a level close to zero. Indeed, this
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was expected as the T2 cells have double the amount of immune cells attacking
them than the T1 cells. This allows more space and nutrient for T1 to invade
the domain and actively evade immune attack. The clearing of the more
immunogenic cells is discussed is discussed in Chapter 1.1. Here, T2 cells are
acting as the more immunogenic cells i.e. cells which are more easily found
by the immune system. As T2 is killed, this allows the less immunogenic (T1)
cells to grow and evade immune destruction. Moreover, the initial makeup
of the tumour mass is also important, as T2 cells that are on the outside of
the tumour mass at the start of the simulation are often killed quickly. If
there are T2 cells present throughout the whole simulation, it is often due to
them hiding as quiescent cells in among proliferating or quiescent T1 cells.
This is portrayed in Figures 4.6 and 4.14. T2 may have small oscillations in
this case, as shown, for example, in Figure 4.13 (top). This is due to the T2
cells either managing to migrate to an area where there is little space for an
immune cell to invade, or if T1 encases the quiescent T2 cells. In the latter
case, as the protective layer of T1 cells are invaded by E1, this allows more
nutrients for T2, enabling them to turn from their quiescent state back into
a proliferative state. However, this is short lived, and the T2 cells generally
lose numbers and lower in peak concentration with every oscillation.
Furthermore, it can be seen, that oscillations are occurring in T1. This is
not due to the immune attack, but rather the oscillatory nature of the T1 cells
seems to be reliant on the clearance of the necrotic cells. This is depicted
in Figures 4.6 and 4.14. This is interesting as it has often been found that
the introduction of inflammatory immune cells into a tumour microenviron-
ment can often have negative effects and actually promote tumour growth,
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discussed in Chapter 1.1. Moreover, the necrotic cells often provide a barrier
for tumour cells against an immune attack, allowing them to grow. Once the
necrotic cells come into contact with the medium they start to disintegrate,
freeing up space and vital nutrient for the tumour cells to regain their former
glory. However, the immune cells are able to clear T2.
Once the immune cells have successfully killed the T2 cells, E2 become
obsolete within the system and now serve to hinder the E1 attack against
T1. This can be attributed to the randomness of immune cell supply every
25MCS. On a smaller scale, the immune cells also provide a physical barrier
as, if they are close to one another, and are not attracted by a tumour cell,
they will often adhere to one another. E2 may also adhere to T1, which it is
not potent to, creating a small barrier for T1.
Looking at the downward trend of E1 success rate, Figures 4.2-4.14 show
that there is no clearance of the T1 cells and full infiltration of the domain
will ensue, albeit over a greater number of MCS than shown here, in some
of the simulations. Indeed, even if the immune success rate is raised further,
it does not have a big impact on tumour cell clearance or tumour bulk. The
simulations that stop before 20,000MCS, such as Figure 4.5 (top), do have a
single oscillation, but, however, this is due to the tumour cells flooding the
domain, using up the nutrients and therefore turning necrotic. Looking at the
figures, T2 does not survive for very long, even if the success rate of the E1T1
interactions is further dropped. This would be counterintuitive however, as
the T1 cells are then allowed to grow much faster due to a smaller immune
success rate giving the T2 cells less nutrient and space to survive. Moreover,
there is no apparent downward pattern in tumour bulk of T1 cells even if the
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success rate of E1 is lowered. One of the ways to combat this is to increase
the number of immune cells in the domain. To do this, more immune cells
could be introduced at a constant rate, however varying the amount of time
the immune cells are in the domain has been investigated. More simulations
can be found in Appendix 6.1, whereby the E1T1 immune success rate has
been lowered, showing no significant effect.
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Figure 4.2: Plots showing the total number of tumour and immune cells for
70 − 71% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape
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Figure 4.3: Plots showing the total number of tumour and immune cells for
72 − 73% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
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Figure 4.4: Plots showing the total number of tumour and immune cells for
74 − 75% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
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Figure 4.5: Plots showing the total number of tumour and immune cells for
76 − 77% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.6: Plots showing the growth of a tumour mass interacting with a host
immune system at 1000MCS immune death rate. The types of cells and their
corresponding colours in Figures 4.6(a)-4.6(i) are as follows: proliferative tumour
type 1 cells in red, quiescent tumour type 1 cells in salmon, proliferative tumour
type 2 in blue, quiescent tumour type 2 cells in light blue, necrotic cells in black,
medium cells in grey, immune type 1 cells in green, immune type 2 in magenta. The
immune success rates are as follows: tumour type 1 and immune type 1 at 77%,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune type 2 at
77%. Figures 4.6(a)-4.6(i) represent the model at 2000MCS, 4000MCS, 6000MCS,
8000MCS, 10000MCS, 12000MCS, 14000MCS, and 16900MCS respectively. The
figures show cancer escape and correspond to Figure 4.5 (bottom).
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.7: Plots showing the nutrient concentration at times 2000MCS,
4000MCS, 6000MCS, 8000MCS, 10000MCS, 12000MCS, 14000MCS, and
16900MCS. The immune success rates are as follows: tumour type 1 and im-
mune type 1 at 77%, tumour type 2 and immune type 1 at 22% and tumour
type 2 and immune type 2 at 77%, corresponding to Figure 4.5 (bottom).
The oxygen concentration is high when it is red and low when it is blue. A
bar on the left hand side of each picture represents the oxygen concentration.
This plot corresponds to Figure 4.5 (bottom). Oxygen is used up by the im-
mune, tumour and quiescent cells leaving areas where tumour cells can longer
be supported leading to necrosis. Once the necrotic cells have disintegrated
oxygen can flow into the area again via medium cells.
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Figure 4.8: Plots showing the total number of tumour and immune cells for
78 − 79% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.9: Plots showing the total number of tumour and immune cells for
80 − 81% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
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Figure 4.10: Plots showing the total number of tumour and immune cells
for 82 − 83% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
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Figure 4.11: Plots showing the total number of tumour and immune cells
for 84 − 85% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
223
Montecarlo Steps
×104
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
To
ta
l n
um
be
r o
f c
el
ls
0
100
200
300
400
86 Percent Immune1 Success Rate
Montecarlo Steps
0 1000 2000 3000 4000 5000 6000 7000 8000 9000
To
ta
l n
um
be
r o
f c
el
ls
0
50
100
150
200
250
300
87 Percent Immune1 Success Rate
Figure 4.12: Plots showing the total number of tumour and immune cells
for 86 − 87% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
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Figure 4.13: Plots showing the total number of tumour and immune cells
for 88 − 89% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line. These plots show cancer escape.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.14: Plots showing the growth of a tumour mass interacting with a
host immune system at 1000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.14(a)-4.14(i) are as follows: proliferative
tumour type 1 cells in red, quiescent tumour type 1 cells in salmon, proliferative
tumour type 2 in blue, quiescent tumour type 2 cells in light blue, necrotic cells
in black, medium cells in grey, immune type 1 cells in green, immune type 2 in
magenta. The immune success rates are as follows: tumour type 1 and immune
type 1 at 88%, tumour type 2 and immune type 1 at 22% and tumour type 2 and
immune type 2 at 77%. Figures 4.14(a)-4.14(i) represent the model at 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS, 12500MCS, 15000MCS, 17500MCS,
and 20000MCS respectively. These figures show cancer escape and correspond to
Figure 4.13 (top).
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(d) (e) (f)
(g) (h) (i)
Figure 4.15: Plots showing the nutrient concentration at times 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS, 12500MCS, 15000MCS,
17500MCS, and 20000MCS, repectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 77%, tumour type 2 and im-
mune type 1 at 22% and tumour type 2 and immune type 2 at 77%, corre-
sponding to Figure 4.13 (top). The oxygen concentration is high when it is
red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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4.3.1.2 Coexistence
The next section is concerned with trying to find an equilibrium state of
immune and tumour cells. Here, the tumour and immune cells should exist
over a long period of time. In section 4.3.1.1, it was identified that in order
to do this, the immune cell concentrations in the domain would need to be
increased. This entails increasing the amount of time the immune cells are
present in the domain i.e. increasing their life expectancy.
In this section, the immune cell rate was increased from 1000MCS to
2500MCS. This means the immune cells are in the domain for 2500MCS
before they are deemed dead, turned into necrotic cells and then allowed
to disintegrate into the medium. The success rates of each of the individual
reactions of the tumour and immune cells, E1T1, E1T2 and E2T2, are 90−99%,
22% and 77%, respectively. The simulations are run for 20,000MCS and again
will stop if there are no immune, tumour or quiescent cells left in the domain.
By increasing the amount of immune cells, the host immune system is now
able to provide a good immune cell attack against the tumour cells. In Fig-
ures 4.16-4.22, the results show that dynamic equilibrium is possible. More
specifically, Figure 4.17 shows the spatial distribution of tumour, immune,
quiescent, medium and necrotic cells in the domain at E1T1 = 90%. In the
spatial figures, the immune cells now have a much bigger presence and the
tumour cells are kept at bay. Figure 4.18 shows the nutrient concentration
at E1T1 = 90%. As an aside, in Figure 4.17 it can be seen that the immune
cells are adhering to one another when tumour cells are not present in the
local area, an observation discussed in section 4.3.1.1. Interestingly, the T2
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tumour cells are now not able to hide among the T1 tumour and quiescent
cells and, therefore, there are no instances of the T2 cells lasting throughout
the entire simulation. As can be seen from Figures 4.16-4.22, the oscillations
are now not driven by the clearance of necrotic cells, however this still plays a
part, allowing the tumour cell bulk to come back. If the death of the immune
cells is lowered further to 3500MCS, a general trend towards elimination can
be seen, whereby the immune cells are able to clear the tumour bulk. To
guarantee tumour cell clearance however, the immune death rate needs to be
lowered. Simulations for the immune death rate at 3500MCS can be found
in the appendix in section 6.2.
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Figure 4.16: Plots showing the total number of tumour and immune cells
for 90 − 91% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.17: Plots showing the growth of a tumour mass interacting with a
host immune system at 2500MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.17(a)-4.17(i) are as follows: proliferative
tumour type 1 cells in red, quiescent tumour type 1 cells in salmon, proliferative
tumour type 2 in blue, quiescent tumour type 2 cells in light blue, necrotic cells
in black, medium cells in grey, immune type 1 cells in green, immune type 2 in
magenta. The immune success rates are as follows: tumour type 1 and immune
type 1 at 90%, tumour type 2 and immune type 1 at 22% and tumour type 2
and immune type 2 at 77%, corresponding to Figure 4.16 (top). Moreover, the
immune death rate is now set to 2500MCS to try and achieve coexistence. Figures
4.17(a)-4.17(i) represent the model at 500MCS, 2500MCS, 5000MCS, 7500MCS,
10000MCS 12500MCS, 15000MCS, 175000MCS and 20000MCS respectively.
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Figure 4.18: Plots showing the nutrient concentration at times 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS 12500MCS, 15000MCS,
175000MCS and 20000MCS, respectively. The immune success rates are
as follows: tumour type 1 and immune type 1 at 90%, tumour type 2 and
immune type 1 at 22% and tumour type 2 and immune type 2 at 77%, cor-
responding to Figure 4.16 (top). The oxygen concentration is high when it is
red and low when it is blue. Moreover, the immune death rate is now set to
2500MCS to try and achieve coexistence. A bar on the left hand side of each
picture represents the oxygen concentration. Oxygen is used up by the im-
mune, tumour and quiescent cells leaving areas where tumour cells can longer
be supported leading to necrosis. Once the necrotic cells have disintegrated
oxygen can flow into the area again via medium cells.
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Figure 4.19: Plots showing the total number of tumour and immune cells
for 92 − 93% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Montecarlo Steps
×104
0
50
100
150
200
To
ta
l n
um
be
r o
f c
el
ls
94 Percent Immune1 Success Rate
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Montecarlo Steps
×104
0
50
100
150
200
To
ta
l n
um
be
r o
f c
el
ls
95 Percent Immune1 Success Rate
Figure 4.20: Plots showing the total number of tumour and immune cells
for 94 − 95% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.21: Plots showing the total number of tumour and immune cells
for 96 − 97% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.22: Plots showing the total number of tumour and immune cells
for 98−99% percent immune 1 kill rate when in interaction with tumour cell
type 1, tumour type 2 and immune type 1 at 22% and tumour type 2 and
immune type 2 at 77%. Tumour cell 1 is represented by the red line, tumour
cell 2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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4.3.1.3 Tumour elimination
In this section cancer destruction by the idealised host immune system is
possible. This is known as the first “E” of immunoediting called “Elimi-
nation”. The immune cell death rate in the following simulations has been
decreased further to 5000MCS i.e. the immune cells will reside in the domain
for 5000MCS before they are killed. Figures 4.23-4.29 show the immune cells
clearing the tumour mass, aside from when the success rate of E1T1 is at
99%. Figures 4.23 (top figure), 4.24 and 4.25 show the E1T1 success rate at
90%. In Figure 4.23 (top figure) the overall concentrations of immune and
tumour cells can be seen with the tumour cells winning out at 11400MCS.
Figure 4.24 depicts the spatial distribution of all cell types and Figure 4.25
shows the nutrient concentration throughout the domain. The tumour mass
is surviving in Figures 4.24(a)-4.24(d), but by 4000MCS the immune cells
have already nearly wiped out the resident T2 tumour population, as well as
cutting into the T1 population. By 6000MCS, in Figure 4.24(f) it has become
apparent that the E1 cells are not allowing the T1 cell’s concentration to pose
a threat. Figures 4.24(g)-4.24(h) show E1 overcoming the tumour cells. Fi-
nally, the simulation ends when there are no tumour cells left, depicted in
Figure 4.24(i).
As the simulation is stochastic in nature, fluctuations in the simulations
are to be expected. This also corresponds to what happened in the elim-
ination section in the previous CompuCell3D model in Chapter 2. Again,
the idea is to try and find a spectrum of results where tumour clearance is
nearly always possible. In this model, the tumour cell population has not
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won out at 99% but is still in equilibrium. This could be attributed to the
adhesion of the tumour cells being set at a low enough level to allow for the
tumour cells to branch off and create new tumour masses locally, evading the
immune system.
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Figure 4.23: Plots showing the total number of tumour and immune cells
for 90 − 91% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.24: Plots showing the growth of a tumour mass interacting with a
host immune system at 5000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.24(a)-4.24(i) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tumour
type 1 and immune type 1 at 90%, tumour type 2 and immune type 1 at 22%
and tumour type 2 and immune type 2 at 77%, corresponding to Figure 4.23
(top). Figures 4.24(a)-4.24(i) represent the model at 500MCS, 1000MCS,
2000MCS, 4000MCS, 6000MCS, 8000MCS, 10000MCS and 11400MCS re-
spectively.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.25: Plots showing the nutrient concentration at times 500MCS,
1000MCS, 2000MCS, 4000MCS, 6000MCS, 8000MCS, 10000MCS and
11400MCS, respectively. The immune success rates are as follows: tumour
type 1 and immune type 1 at 90%, tumour type 2 and immune type 1 at
22% and tumour type 2 and immune type 2 at 77%, corresponding to Figure
4.23 (top). The oxygen concentration is high when it is red and low when
it is blue. A bar on the left hand side of each picture represents the oxygen
concentration. Oxygen is used up by the immune, tumour and quiescent cells
leaving areas where tumour cells can longer be supported leading to necrosis.
Once the necrotic cells have disintegrated oxygen can flow into the area again
via medium cells.
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Figure 4.26: Plots showing the total number of tumour and immune cells
for 92 − 93% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.27: Plots showing the total number of tumour and immune cells
for 94 − 95% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.28: Plots showing the total number of tumour and immune cells
for 96 − 97% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.29: Plots showing the total number of tumour and immune cells
for 98 − 99% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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4.3.2 E2T2 interactions
In section 4.3.1, many different observations became apparent from varying
the success rate of E1 when interaction with T1. Firstly, it can be seen that
either the T2 tumour cells are killed very quickly in the domain or they hide
among the T1 quiescent and tumour cells, allowing them to exist through
the whole simulation, albeit close to zero. Moreover, the T1 cells are seen
to oscillate, driven by clearance of the necrotic cells when the immune life
expectancy is low. Furthermore, in section 4.3.1, the simulations were able
to model each of the three “Es” of immunoediting, by lowering the immune
death rate.
This section will focus on the interactions of the E2 immune cells with T2
tumour cells. To try and allow the T2 cells to grow, the success rate of the E2
cells when in interaction with T2 cells has been lowered (E2T2). As before,
this section will be split into the three different categories for immunoediting.
4.3.2.1 Tumour escape
To increase the potency of the T2 tumour cells, the percentage of E2T2 has
been decreased. The simulations here run for a period of 20,000MCS and, as
before, the simulations will stop if there are no tumour cells, immune cells
or quiescent cells left in the domain. The values of each of the interactions
are as follows: E1T1 = 95%, E1T2 = 22% and E2T2 = 40− 45%. The success
rate of E1T1 has been kept high to try and deplete the T1 cells along with
the hope that the lowered success rate of E2T2 will allow the T2 cells to grow.
Immune cell death for both types occurs at 1000MCS. As in the previous
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investigation into E1T1 in section 4.3.1, the total cell concentration figures,
such as Figure 4.30, show T1 represented by the red line, T2 by the blue line,
E1 by the green line and E2 by the pink line. The spatial representation can
be seen in figures such as Figure 4.31, where all cell types are depicted. In
the spatial pictures, proliferative tumour type 1 (T1) cells are red, quiescent
tumour type 1 cells are salmon, proliferative tumour type 2 (T2) cells are
blue, quiescent tumour type 2 cells are light blue, necrotic cells are black,
medium cells are grey, immune type 1 cells (E1) are green and immune type
2 (E2) are magenta.
Looking at Figures 4.30-4.35, it is clear to see that the T1 tumour popu-
lation has an oscillatory pattern, such as in Figure 4.30 (top) at 40% E2T2
success rate, which is again driven by the clearance of necrotic cells. This
time they are also able to fully invade the domain, such as in Figure 4.30
(bottom) where E2T2 is at 41% success rate. The lowering of the E2T2 success
rate seems to have allowed more space for the T1 cells, as they seem more
potent than when the E2T2 success rate was almost double. The T2 cells
unfortunately have not been able to mount a full attack and are roughly at
the same level as what they were in section 4.3.1.1, where E1T1 = 95% and
immune death was set at 1000MCS. Decreasing the percentage of E1T1 has
little effect on T2 and just increases the T1 tumour bulk. For these simula-
tions see Appendix 3 in section 6.3. T2 does however seem to be occasionally
able to last for the whole simulation. In Figures 4.31-4.32, the spatial pro-
gression of E2T2 at 40% can be seen. Here, as discussed in 4.3.1.1, the initial
makeup of the tumour mass seems to be important. Before, in 4.3.1.1, when
the percentage of E2T2 was higher, the T2 cells were picked off at a faster
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rate. Now, by looking at Figure 4.31, the T2 cells are able to mount an attack
on the immune cells and are able to grow into separate entities away from
the T1 cells and even are able to stay in the system through to the end of the
simulation as shown in Figure 4.32.
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Figure 4.30: Plots showing the total number of tumour and immune cells
for 40 − 41% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
Figure 4.33 shows the progression of all cells in a spatial setting when
E2T2 is at 41% immune success rate. Here, T1 has fully invaded the domain
and T2 has not been able to grow enough to evade the immune cells. The
initial composition seems to need the T2 cells to be placed around the outside
of the tumour bulk and even then it may just be luck that the T2 are able to
gain enough momentum to grow. Again, it is necessary for the immune cell
death rate to be lowered in order to exhibit dormancy and elimination.
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(a) (b)
(c) (d)
Figure 4.31: Plots showing the growth of a tumour mass interacting with a
host immune system at 1000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.31(a)-4.31(d) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tumour
type 1 and immune type 1 at 90%, tumour type 2 and immune type 1 at 22%
and tumour type 2 and immune type 2 at 40%, corresponding to Figure 4.30
(top). Figures 4.31(a)-4.31(d) represent the model at 2500MCS, 5000MCS,
7500MCS and 10000MCS respectively and show cancer escape.
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(a) (b)
(c) (d)
Figure 4.32: Plots showing the growth of a tumour mass interacting with a
host immune system at 1000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.32(a)-4.32(d) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tu-
mour type 1 and immune type 1 at 90%, tumour type 2 and immune type 1
at 22% and tumour type 2 and immune type 2 at 40%, corresponding to Fig-
ure 4.30 (top). Figures 4.32(a)-4.32(d) represent the model at 12500MCS,
15000MCS, 17500MCS and 19900MCS respectively and show cancer escape.
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(a) (b)
(c) (d)
Figure 4.33: Plots showing the growth of a tumour mass interacting with a
host immune system at 1000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.33(a)-4.33(d) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tu-
mour type 1 and immune type 1 at 90%, tumour type 2 and immune type 1
at 22% and tumour type 2 and immune type 2 at 41%, corresponding to Fig-
ure 4.30 (bottom). Figures 4.33(a)-4.33(d) represent the model at 2500MCS,
5000MCS, 7500MCS and 8100MCS respectively and show cancer escape.
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Figure 4.34: Plots showing the total number of tumour and immune cells
for 42 − 43% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.35: Plots showing the total number of tumour and immune cells
for 44 − 45% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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4.3.2.2 Coexistence
By increasing the amount of time the immune cells are allowed in the domain,
an equilibrium state can be found. Even though the value of E2T2 has been
changed, the dynamics of this section are very similar to section 4.3.1. E2T2
has been lowered and varied over 30−36% and the simulation has been run for
40,000MCS, double the amount of time of the previous simulations in section
4.3.1. Extra simulations have also been run for the standard 20,000MCS,
which can be found in the appendix in section 6.4
Figures 4.36-4.45 show equilibrium in most cases, but have also produced
tumour clearance in others. More specifically, when E2T2 = 32% there is
a tumour clearance, which can be seen in Figure 4.37 (top). Initially, both
tumour cell types rise, however after 2000MCS the immune cells begin to
make an attack. This can be seen more closely in Figure 4.38. At 1000MCS,
depicted in Figure 4.38(b), the tumour mass is still growing, however by 2000-
4000MCS, shown in Figures 4.38(d)-4.38(f), the immune cells are mounting
an effective defence, and by 6000MCS the tumour cells have been wiped
out. Figure 4.39 shows the nutrient concentration over time where, even
though the domain is flooded with nutrient, the immune cells are mounting
an effective attack against the tumour cells preventing nutrient uptake.
Conversely, in Figure 4.37 (bottom) the T1, E1 and E2 cells are in equi-
librium. Here, the immune cells are not able to clear the T1 cells, but are
able to keep them at a steady state level. Looking more closely at this par-
ticular simulation, the spatial description in Figures 4.40 and 4.42 show that
again the T2 cells are depleted almost completely by 5000MCS, pictured in
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sub figure 4.40(d). The nutrient concentration over time, for E2T2 = 33%,
is depicted in Figures 4.41 and 4.43. As the simulation progresses, both T1
and T2 tumour cells grow into the space where nutrient is available. After
the T2 tumour cells are depleted by the immune cells, the space left by these
cells is able to produce more nutrient and can therefore support more cells.
Subsequently this gives the T1 cells more space to grow and divide. More-
over, if the T1 cells are already close to this area, it allows them to branch
off and fully proliferate into a new part of the domain. If the immune cell
death is decreased further to 3500MCS, then the simulations tend towards an
“elimination” phase, however equilibrium is still present. These simulations
can be found in the appendix in section 6.5.
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Figure 4.36: Plots showing the total number of tumour and immune cells
for 30 − 31% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.37: Plots showing the total number of tumour and immune cells
for 32 − 33% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.38: Plots showing the growth of a tumour mass interacting with a
host immune system at 2500MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.38(a)-4.38(i) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tu-
mour type 1 and immune type 1 at 95%, tumour type 2 and immune type
1 at 22% and tumour type 2 and immune type 2 at 32%, corresponding to
Figure 4.37 (top). Figures 4.38(a)-4.38(i) represent the model at 500MCS,
1000MCS, 1500MCS, 2000MCS, 3000MCS, 4000MCS, 5000MCS, 5500MCS
and 5900MCS respectively.
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Figure 4.39: Plots showing the nutrient concentration at times 500MCS,
1000MCS, 1500MCS, 2000MCS, 3000MCS, 4000MCS, 5000MCS, 5500MCS
and 5900MCS, respectively. The immune success rates are as follows: tumour
type 1 and immune type 1 at 95%, tumour type 2 and immune type 1 at
22% and tumour type 2 and immune type 2 at 32%, corresponding to Figure
4.37 (top). The oxygen concentration is high when it is red and low when
it is blue. A bar on the left hand side of each picture represents the oxygen
concentration. Oxygen is used up by the immune, tumour and quiescent cells
leaving areas where tumour cells can longer be supported leading to necrosis.
Once the necrotic cells have disintegrated oxygen can flow into the area again
via medium cells.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.40: Plots showing the growth of a tumour mass interacting with a host
immune system at 2500MCS immune death rate. The types of cells and their cor-
responding colours in Figures 4.40(a)-4.40(i) are as follows: proliferative tumour
type 1 cells in red, quiescent tumour type 1 cells in salmon, proliferative tumour
type 2 in blue, quiescent tumour type 2 cells in light blue, necrotic cells in black,
medium cells in grey, immune type 1 cells in green, immune type 2 in magenta.
The immune success rates are as follows: tumour type 1 and immune type 1 at
95%, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune type
2 at 33%, corresponding to Figure 4.37 (bottom). Figures 4.40(c)-4.42(a) repre-
sent the model at 500MCS, 1000MCS, 2500MCS, 5000MCS, 7500MCS, 10000MCS
12500MCS, 15000MCS and 17500MCS respectively.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.41: Plots showing the nutrient concentration at times 500MCS,
1000MCS, 2500MCS, 5000MCS, 7500MCS, 10000MCS, 12500MCS,
15000MCS and 17500MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 22% and tumour type 2 and immune type 2 at 33%, corre-
sponding to Figure 4.37 (bottom). The oxygen concentration is high when it
is red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.42: Plots showing the growth of a tumour mass interacting with a
host immune system at 2500MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.42(a)-4.42(i) are as follows: proliferative
tumour type 1 cells in red, quiescent tumour type 1 cells in salmon, proliferative
tumour type 2 in blue, quiescent tumour type 2 cells in light blue, necrotic cells
in black, medium cells in grey, immune type 1 cells in green, immune type 2 in
magenta. The immune success rates are as follows: tumour type 1 and immune
type 1 at 95%, tumour type 2 and immune type 1 at 22% and tumour type 2 and
immune type 2 at 33% corresponding to Figure 4.37 (bottom). Figures 4.42(a)-
4.42(i) represent the model at 20000MCS, 22500MCS, 25000MCS, 27500MCS,
3000MCS, 32500MCS 35000MCS, 37500MCS and 40000MCS respectively.
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(a) (b) (c)
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Figure 4.43: Plots showing the nutrient concentration at times 20000MCS,
22500MCS, 25000MCS, 27500MCS, 30000MCS, 32500MCS, 35000MCS,
37500MCS and 40000MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 22% and tumour type 2 and immune type 2 at 33% corre-
sponding to Figure 4.37 (bottom). The oxygen concentration is high when it
is red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.44: Plots showing the total number of tumour and immune cells
for 34 − 35% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.45: Plots showing the total number of tumour and immune cells
for 36 − 37% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
255
4.3.2.3 Tumour elimination
This section is concerned with tumour elimination i.e. immune cell destruc-
tion of the tumour cells. Here, the simulations have been run for 20,000MCS,
again unless there are no tumour, quiescent or immune cells left in the do-
main, in which case the simulation will stop. Section 4.3.2.1 focused on the
evasion of the immune destruction by T1 and, in some cases, T2. Section
4.3.2.2 described the simulations that showed steady state dynamics in T1,
E1 and E2 cells. Equilibrium was found by increasing the amount of time
the immune cells of both types were in the domain. In order to allow the
immune cells to have a proficient enough attack against the tumour cells to
fully eradicate them, in the given amount of monte-carlo steps, the immune
cell death rate has again been decreased to 5000MCS. The percentage of
immune success rate for the interactions between E1T1, E1T2 and E2T2 have
been kept the same as in section 4.3.2.2, in order to show a direct comparison.
Figures 4.46-4.51 show that for each individual success rate for E2T2,
ranging from 30− 39%, the immune cells are able to destroy the tumour cell
populations. Figure 4.47 focuses on the spatial dynamics of the simulation
for 30% E1T2 immune success rate. In this figure, the immune cells are seen
to flood the domain fairly quickly by 5000MCS, shown in Figure 4.47(b),
however in Figure 4.47(d), representing 10,000MCS, the T1 cells are trying
to grow a new tumour mass. This is short lived, and is eradicated by the
immune cells by 12900MCS, shown in Figure 4.47(f).
Even though section 4.3.2 has managed to show tumour escape, tumour-
immune equilibrium and tumour elimination, it has not managed to mimic
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the coexistence dynamics from the previous section 3.8 i.e. allowing the T2
to grow so that equilibrium can be found among both tumour and immune
types.
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Figure 4.46: Plots showing the total number of tumour and immune cells
for 30 − 31% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b) (c)
(d) (e) (f)
Figure 4.47: Plots showing the growth of a tumour mass interacting with a
host immune system at 5000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.47(a)-4.47(d) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tu-
mour type 1 and immune type 1 at 90%, tumour type 2 and immune type 1 at
22% and tumour type 2 and immune type 2 at 30%, corresponding to Figure
4.46. Figures 4.47(a)-4.47(d) represent the model at 2500MCS, 5000MCS,
7500MCS, 10000MCS, 11000MCS, 12900MCS respectively and show tumour
elimination.
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Figure 4.48: Plots showing the total number of tumour and immune cells
for 32 − 33% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.49: Plots showing the total number of tumour and immune cells
for 34 − 35% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.50: Plots showing the total number of tumour and immune cells
for 36 − 37% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.51: Plots showing the total number of tumour and immune cells
for 38 − 39% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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4.3.3 E1T2 interactions
In this section, dynamic equilibrium is sought between tumour and immune
cells of both types. Therefore, this section will be only concerned with trying
to get a steady state range of values for the interactions between cells. Again,
the amount of time the immune cells are in the domain is varied, as well as
lowering the success rates of the immune cells, when in contact with the
tumour populations.
4.3.3.1 Coexistence
To try and find a coexistence steady state, the immune success rate of E1T2
and E2T2 has been lowered. The thinking behind this is to try and give
the T2 cells a fighting chance against the dominance of the T1 cells, in order
to understand the dynamics that govern the coexistence steady state. In
Figures 4.52-4.56, E1T1 = 90%, E2T2 = 20% and E1T2 is varied from 10%
to 20%. Both immune cell types die after being in the domain for 3500MCS
and the simulations have been run for 10,000MCS. It was recognised that
this strategy, judging by the simulations in section 4.3.1 and 4.3.2, would
be exposed quickly if it failed to work and, therefore, the shorter simulation
time would be prudent here.
When running the simulations, unfortunately there does not seem to be
any impact on the T2 tumour cell population. There may be more tumour
bulk or less tumour bulk depending on each individual interaction, but find-
ing a equilibrium in this instance seems to be elusive. The amount of time
the immune cells are in the domain has been further decreased to 3000MCS,
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Figure 4.52: Plots showing the total number of tumour and immune cells
for 10 − 11% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
which can be seen in the appendix in section 6.6, which again has no impact
on the length of time the T2 cells are involved.
The next strategy was to try to split the immune death rates i.e. give each
of them a different value. It seemed prudent to give E1 the highest chance
possible of killing the T1 tumour population, therefore the immune death for
T1 was set at 5000MCS. Conversely, the T2 immune death rate was set very
low, with E2 immune cells dying after 500MCS. Again this had no effect, and
only pushed the results of the simulations into a displaying dynamics for the
tumour “elimination” stage. This can be seen in Figures 4.57-4.60, where the
interactions between the tumour and immune cells have the same immune
success rates, but E1T2 has only been varied between 10 − 17%. Therefore,
a new strategy is needed to allow the T2 cells to grow.
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Figure 4.53: Plots showing the total number of tumour and immune cells
for 12 − 13% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.54: Plots showing the total number of tumour and immune cells
for 14 − 15% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.55: Plots showing the total number of tumour and immune cells
for 16 − 17% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.56: Plots showing the total number of tumour and immune cells
for 18 − 19% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.57: Plots showing the total number of tumour and immune cells
for 10 − 11% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.58: Plots showing the total number of tumour and immune cells
for 12 − 13% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.59: Plots showing the total number of tumour and immune cells
for 14 − 15% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 4.60: Plots showing the total number of tumour and immune cells
for 16 − 17% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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4.3.4 The Warburg Effect
In section 4.3.1, 4.3.3 and 4.3.2, the T2 cells are killed by both types of im-
mune cells. Even at a very small rate of immune success, the T2 cells are
killed off very quickly by the immune cells, and it was hard to promote tu-
mour growth. Although the promotion of tumour proliferation seems counter
intuitive, it is necessary in order to understand what causes uncontrollable
growth, even in the presence of a strong immune response. The idea of
modelling some form of the Warburg effect seemed prudent in this situation.
The model has been altered to try and imitate some of the hallmarks of
the Warburg Effect. In this model, as in section 4.3, the nutrient is generic.
If the nutrient here is treated in a similar way, in that it contains oxygen
and glucose, some aspects of the Warburg Effect can be modelled. The T1
cells will still undergo nutrient uptake by way of oxidative mitochondrial
phosphorylation. In the presence of hypoxia the T1 cells will, as in section
4.3, go quiescent, and then necrotic, if the nutrient goes below a critical level.
However, the T2 cells will no longer exhibit quiescence if in a hypoxic region.
The T2 cells will now uptake energy through glycolysis. In an oxidised
environment this is called aerobic glycolysis, however in a hypoxic zone it is
called anaerobic glycolysis. As previously discussed in section 1.1.4, there are
many reasons as to why a tumour cell may favour anaerobic glycolysis over
OXPHOS. In this section, the hypoxic activation of glycolysis will be studied.
As the T2 cells no longer turn quiescent in a limited oxygen environment, the
cells that are at the centre of the tumour mass will still grow. Moreover, in
the necrotic zone, the nutrient is low, stifling tumour growth, however, this
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does not kill the T2 tumour cells under these new circumstances. In a way,
the T2 cells lay in wait until the other cell types around it die off or are killed
by a tumour cell. This will allow it to gain a link to the available nutrient in
the space, in order to continue its uncontrollable growth. The other aspects
of the model, such as cell motility and adhesion, will remain the same.
The aim of this section is to try and focus on evolving the model to
show the three Es of immunoediting. In the following results observations
and conclusions will be drawn as to whether this has been successful. More
importantly, the realisation of a coexistence state through tumour dormancy
has been the outlook of the discrete model from the beginning, and this
extension will hopefully portray it.
4.3.4.1 Tumour escape
When utilising the Warburg Effect for the T2 cells, it is hoped that they will
be able to thrive even in the presence of low oxygen. For the results in this
section both immune types have a death rate of 1000MCS, i.e. the immune
cells die after they have been in the domain for 1000MCS, and the simulations
run for 20,000MCS. The interactions between tumour and immune cells are
still described by the same terms as in sections 4.3.1, 4.3.2 and 4.3.3. Figures
4.61 - 4.67 show the results when E1T1 = 95%, E1T2 = 22% and E2T2 is var-
ied between 30−39%. These figures have been chosen to try and portray the
same values as in section 4.3.2. As before, overall concentrations of immune
and tumour cells can be seen in figures such as 4.61. The spatial distribution
of all cells can be seen in Figure 4.62, and the nutrient concentration can be
seen in Figure 4.63. What is apparent from these figures, is the T2 cells have
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now managed to promote their growth. With the switch to glycolysis, by
means of the turning off of the quiescent/necrotic pathways, the T2 cells are
able to survive in a hostile environment. Furthermore, the figures show that
not only do they survive in the domain, but often out strip the T1 tumour
cells. It should also be noted that as the T2 cells now completely over run
the domain before the simulation has finished. It is still apparent that the
oscillatory dynamics here are determined by the clearance of the necrotic
cells for both tumour types.
Looking more closely at the spatial domain in Figure 4.62, showing the
evolution of the cells at certain time steps, the figures show the oscillatory
nature of the tumour cells. In Figure 4.62(d) the tumour cells seem to be
filling the domain, but by Figure 4.62(e) the necrotic cells have been cleared,
which allows the tumour cells to begin to proliferate into the medium again.
Figure 4.63 shows the nutrient concentration in the domain at certain time
steps. Here, as the T1 cells turn quiescent the T2 cells maintain their prolif-
erative state, allowing growth even when there is no or very little nutrient
available. The T2 cells are therefore able to “hide” from the immune cells
and lie in wait until the T1 cells are either killed or die off due to lack of
nutrient. Once the T2 cells are able to to gain access to more nutrient, they
may be the dominant cell type. Here, the T1 cells may have been killed a the
lack of nutrient therefore can no longer compete for space with so many T2
cells. This is apparent in Figure 4.61 (bottom).
The tumour cells here are evading immune detection just as in the pre-
vious model, however as discussed above, the introduction of the Warburg
Effect allows the T2 cells to thrive in a low oxygen environment. It has
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Figure 4.61: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 30− 31%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
not shown however, dynamic equilibrium for all cells and therefore, further
investigations into this system will need to be performed to elucidate this.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.62: Plots showing the growth of a tumour mass interacting with a host
immune system at 1000MCS immune death rate. The types of cells and their cor-
responding colours in Figures 4.62(a)-4.62(i) are as follows: proliferative tumour
type 1 cells in red, quiescent tumour type 1 cells in salmon, proliferative tumour
type 2 in blue, quiescent tumour type 2 cells in light blue, necrotic cells in black,
medium cells in grey, immune type 1 cells in green, immune type 2 in magenta. The
immune success rates are as follows: tumour type 1 and immune type 1 at 30%,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune type 2
at 77%, corresponding to Figure 4.61 (top). Figures 4.62(a)-4.62(i) represent the
model at 500MCS, 2500MCS, 5000MCS, 7500MCS and 10000MCS, 12500MCS,
15000MCS, 17500MCS, 20000MCS respectively and show tumour escape.
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Figure 4.63: Plots showing the nutrient concentration at times 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS 12500MCS, 15000MCS,
17500MCS and 20000MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 22% and tumour type 2 and immune type 2 at 30%, corre-
sponding to Figure 4.61 (top). The oxygen concentration is high when it is
red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.64: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 32− 33%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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Figure 4.65: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 34− 35%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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Figure 4.66: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 36− 37%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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Figure 4.67: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 38− 39%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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4.3.4.2 Coexistence
To try and portray the results found in section 3.8, a few different modelling
techniques have been utilised. The changing of parameter values and the
addition of the Warburg effect has tried to show accurately the coexistence
state, found in the ODE/PDE models in sections 3.7 and 3.8. In this section,
the simulations will again run for 20,000MCS. Each immune type has been
given a different death rate. E1 cells will be killed in the domain at 2500MCS
from when they were introduced, whereas E2 cells will be killed by 500MCS.
This change has been introduced to give the T2 cells a fighting chance, while
upping the amount of E1 cells in the domain, to try and achieve equilibrium.
The percentage of the tumour immune interactions has also been adjusted.
While, E1T1 = 95% as before, E1T2 = 10% and E2T2 will vary between
12− 20%. This lowering of the immune cell success rate for E1T2 and E2T2
had very little impact in section 4.3.4.1, however the hope is that the T2 cells
will be able to survive even though the E1 cells will have a high concentration.
The lowering of the immune success interaction terms along with the
changing of the immune death has made an impact on the model, in fact
the model now becomes quite changeable. At E2T2 = 12% and E2T2 = 13%,
shown in Figure 4.68, the dynamics are very similar to sections 4.3.1.2 and
4.3.2.2, although the immune cells are now mounting an effective attack
on the tumour cells causing oscillations. Looking at the spatial domain in
Figure 4.69, it is apparent that the immune cells, even when they have a
small success rate, have killed off the T2 cells very quickly. Figure 4.69(a)-
4.69(b) show the T2 cells actually manage, initially, to break off from the
275
main tumour group and form a new mass. However, this exposes them to
immune attack and they are quickly killed off by 5000MCS, shown in Figure
4.69(c). The nutrient concentration can be seen in Figure 4.70. Looking at
both of the spatial figures, while the T2 cells still maintain their proliferative
state in the presence of low nutrient, the T1 cells turn quiescent and then
necrotic.
When E2T2 has been furthered increased to 15%, depicted in Figure 4.71
(bottom), the picture is quite different. In this simulation the T2 cells have
managed to out manoeuvre the T1 cells and have become the dominant tu-
mour phenotype. This would seem odd as the immune cells percentage suc-
cess rate has been increased. However, looking at the spatial description in
Figure 4.72, the T2 have been placed more so around the outer rim of the
tumour allowing its growth to exceed that of the T1 cells. In the fight for
nutrient, as seen in Figure 4.73, the T2 cells, due to their close proximity to
the T1 cells, use up more nutrient as they do not turn quiescent, starving
the T1 cells. Their numbers are far greater by 2500MCS, depicted in Figure
4.72(d), and the T1 cells are picked off by the immune cells and the lack of
nutrient.
At 16% E2T2 success rate, in Figure 4.74 (top), the tumour and immune
cells seem to be living in equilibrium. There is an oscillatory like nature to
the tumour cells as the immune cells begin to attack them. This continues
through the whole simulation. Figure 4.75 shows this oscillatory like nature
in a spatial setting. The existence of all four cell types is now realised.
The nutrient concentration is also portrayed in Figure 4.76. When E2T2 =
17%, the immune cells have managed to kill the tumour cells however, the
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Figure 4.68: Plots showing the total number of tumour and immune cells
for 10% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 12− 13%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
concentration of immune cells will need to be further increased in order for
the immune system to fully eradicate the cancer cells.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.69: Plots showing the growth of a tumour mass interacting with a host
immune system at 2500MCS E1 immune death rate and 500MCS E2 immune death
rate. The types of cells and their corresponding colours in Figures 4.69(a)-4.69(i)
are as follows: proliferative tumour type 1 cells in red, quiescent tumour type 1 cells
in salmon, proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light
blue, necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tumour type
1 and immune type 1 at 95%, tumour type 2 and immune type 1 at 10% and tumour
type 2 and immune type 2 at 12%, corresponding to Figure 4.68 (top). Figures
4.69(a)-4.69(i) represent the model at 500MCS, 2500MCS, 5000MCS, 7500MCS
and 10000MCS, 12500MCS, 15000MCS, 17500MCS, 20000MCS respectively.
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Figure 4.70: Plots showing the nutrient concentration at times 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS 12500MCS, 15000MCS,
17500MCS and 20000MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 10% and tumour type 2 and immune type 2 at 12%, corre-
sponding to Figure 4.68 (top). The oxygen concentration is high when it is
red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.71: Plots showing the total number of tumour and immune cells
for 10% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 14− 15%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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(g) (h) (i)
Figure 4.72: Plots showing the growth of a tumour mass interacting with a host
immune system at 2500MCS E1 immune death rate and 500MCS E2 immune death
rate. The types of cells and their corresponding colours in Figures 4.72(a)-4.72(i)
are as follows: proliferative tumour type 1 cells in red, quiescent tumour type 1
cells in salmon, proliferative tumour type 2 in blue, quiescent tumour type 2 cells
in light blue, necrotic cells in black, medium cells in grey, immune type 1 cells
in green, immune type 2 in magenta. The immune success rates are as follows:
tumour type 1 and immune type 1 at 95%, tumour type 2 and immune type 1
at 10% and tumour type 2 and immune type 2 at 15%, corresponding to Figure
4.71 (bottom). Figures 4.72(a)-4.72(i) represent the model at 500MCS, 1000MCS,
1500MCS, 2500MCS 2500MCS, 7500MCS, 12500MCS, 15000MCS, 17500MCS,
20000MCS respectively.
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4.73: Plots showing the nutrient concentration at times 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS 12500MCS, 15000MCS,
17500MCS and 20000MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 10% and tumour type 2 and immune type 2 at 15%, corre-
sponding to Figure 4.71 (bottom). The oxygen concentration is high when it
is red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.74: Plots showing the total number of tumour and immune cells
for 10% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 16− 17%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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(d) (e) (f)
(g) (h) (i)
Figure 4.75: Plots showing the growth of a tumour mass interacting with a host
immune system at 2500MCS E1 immune death rate and 500MCS E2 immune death
rate. The types of cells and their corresponding colours in Figures 4.75(a)-4.75(i)
are as follows: proliferative tumour type 1 cells in red, quiescent tumour type 1 cells
in salmon, proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light
blue, necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tumour type
1 and immune type 1 at 95%, tumour type 2 and immune type 1 at 10% and tumour
type 2 and immune type 2 at 16%, corresponding to Figure 4.74 (top). Figures
4.75(a)-4.75(i) represent the model at 500MCS, 2500MCS, 5000MCS, 7500MCS
and 10000MCS, 12500MCS, 15000MCS, 17500MCS, 20000MCS respectively.
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Figure 4.76: Plots showing the nutrient concentration at times 500MCS,
2500MCS, 5000MCS, 7500MCS, 10000MCS 12500MCS, 15000MCS,
17500MCS and 20000MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 10% and tumour type 2 and immune type 2 at 16%, corre-
sponding to Figure 4.74 (top). The oxygen concentration is high when it is
red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.77: Plots showing the total number of tumour and immune cells
for 10% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 18− 19%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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4.3.4.3 Tumour elimination
In order to realise the third E of immunoediting, Elimination, the immune
concentrations must be increased. Both immune types have now had their
death rates decreased to 5000MCS. Again, the simulations have been run for
20,000MCS, and the will stop if there are no tumour, quiescent or immune
cells left in the domain. The immune cell success rates have been kept the
same as section 4.3.4.1. In the previous section the immune cell interaction
terms needed to be lowered to achieve equilibrium, however, this time it has
been kept the same as section 4.3.4.1: E1T1 = 95%, E1T2 = 22% and E2T2
is varied between 30− 39%.
The Figures 4.78-4.84 show the results for these set of parameter values.
It is clear from these figures that the immune cells now have enough numbers
to overcome the tumour cells. This could be realised in real life through many
different means, such as, for example, chemotaxis, where local immune cells
are drawn towards the tumour cells; or two different immune types whereby
one signals more immune cells to exit the blood and flow into the domain.
In Figure 4.79 the spatial distribution of all cells is shown. As the tumour
cells divides and grows, the immune cell population also increases, as shown
in Figures 4.79(a)-4.79(c). In Figures 4.79(d)-4.79(f) the immune cells are
killing off the tumour cells and by 13,000MCS, depicted in Figure 4.79(i),
the immune cells have cleared the tumour mass. The nutrient concentration
can be seen in Figure 4.80.
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Figure 4.78: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 30− 31%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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(d) (e) (f)
(g) (h) (i)
Figure 4.79: Plots showing the growth of a tumour mass interacting with a
host immune system at 5000MCS immune death rate. The types of cells and
their corresponding colours in Figures 4.79(b)-4.79(i) are as follows: prolif-
erative tumour type 1 cells in red, quiescent tumour type 1 cells in salmon,
proliferative tumour type 2 in blue, quiescent tumour type 2 cells in light blue,
necrotic cells in black, medium cells in grey, immune type 1 cells in green,
immune type 2 in magenta. The immune success rates are as follows: tumour
type 1 and immune type 1 at 95%, tumour type 2 and immune type 1 at 22%
and tumour type 2 and immune type 2 at 30%, corresponding to Figure 4.78
(top). Figures 4.79(b)-4.79(i) represent the model at 2500MCS, 5000MCS,
7500MCS and 10000MCS respectively and show tumour elimination.
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Figure 4.80: Plots showing the nutrient concentration at times
500MCS, 1000MCS, 2000MCS, 4000MCS, 6000MCS, 8000MCS 10000MCS,
12000MCS, and 13000MCS, respectively. The immune success rates are as
follows: tumour type 1 and immune type 1 at 95%, tumour type 2 and im-
mune type 1 at 22% and tumour type 2 and immune type 2 at 30%, corre-
sponding to Figure 4.78 (top). The oxygen concentration is high when it is
red and low when it is blue. A bar on the left hand side of each picture rep-
resents the oxygen concentration. Oxygen is used up by the immune, tumour
and quiescent cells leaving areas where tumour cells can longer be supported
leading to necrosis. Once the necrotic cells have disintegrated oxygen can flow
into the area again via medium cells.
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Figure 4.81: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 32− 33%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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Figure 4.82: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 34− 35%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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Figure 4.83: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 36− 37%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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Figure 4.84: Plots showing the total number of tumour and immune cells
for 22% immune 1 kill rate when in interaction with tumour cell type 2,
tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 38− 39%. Tumour cell 1 is represented by the red line, tumour cell
2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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4.4 Conclusion
This chapter has focused on extending the models from both of the previ-
ous chapters. The model utilises a discrete CompuCell3D model to try and
surmise the dynamics, which underlie a novel system, whereby two tumour
types are interaction with two immune cell types, before the development of a
tumour blood regulatory network. The aim was to try and find a co-existence
dormant state between all cell types, extending the models in sections 3.7
and 3.8.
The model begins with a central tumour mass containing randomly placed
tumour cells of type one and two, surrounded by four randomly placed im-
mune cells. The model utilises the control parameter set out in Matzavinos
et al. [2004] to employ the killing method used by the immune cells. However,
this time there are three immune-tumour interactions: E1T1, E1T2 and E2T2.
These mimic the ODE/PDE model found in sections 3.7 and 3.8. Unlike the
previous CompuCell3D model in Chapter 2, the tumour cells no longer pose
a threat to the immune cells, therefore an age at which the immune cells die
has been implemented. Immune cell death occurs when they have been in the
domain for a certain number of MCS, defined by the user. Again different
tumour zones can be established, however this time there are two tumour
cells, bringing a whole host of new challenges. Moreover, the tumour cells
are allowed to divide when they reach a certain number of MCS and both
cells have a random motility associated with them.
The model is explored by varying the immune success rates, in order to al-
low the system to exhibit the three Es of immunoediting. Firstly, the immune
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type one success rate when interaction with tumour type one (E1T1), was var-
ied. The three Es of immunoediting were realised and some conclusions can
be drawn. To gain control over the three different state of immunoediting
the amount of time at which the immune cells were in the domain needed
to be increased. Increasing the immune success rate in the interaction, E1T1
did not provide sufficient enough protection against the T1 cells, although
there was a slight decrease in tumour bulk. Moreover, the T2 cells did not
really propagate through the domain and seemed almost obsolete throughout
the system in most simulations. In the dormancy setting, the E1, T1 and E2
cells all exhibited equilibrium, however the T2 did not and were killed in the
domain quickly. The second interaction to be varied was E2T2 and again
the three Es of immunoediting can be realised in T1 but not in T2. Lastly,
an investigation on the interaction of E1T2 was carried out. This section
only focused on trying to get the T2 cells to become more potent within the
system, but this ultimately failed. In order to try and allow the T2 cells to
grow and sustain their mass, a different approach was required. This came
in the form of a phenomenon known as the Warburg Effect.
The Warburg effect allows a cancer cell to utilise glycolysis to try and
gain sufficient nutrient to sustain itself in an often-hostile environment. To
try and promote the growth of the T2 cells, a novel method for implementing
the Warburg effect was employed. When the nutrient level that surrounds
the tumour mass begins to be used up, the T1 cells go quiescent and will
eventually die if they are unable to move into an area where nutrient is
readily available. However, the T2 cells in this situation switch to using
glycolysis in order to maintain their growth and evade immune destruction.
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The three Es of immunoediting have been explored by again varying the
immune cells’ success rate and age. It was shown that the model is able
to generate immune elimination, equilibrium and escape. Moreover, the T2
cells, aided by their ability to survive in a low nutrient environment, now
have sufficient enough numbers to allow them to be present throughout the
domain for a longer number of MCS. Furthermore, the model for all cell
types can, now demonstrate a dormant state like the one exhibited by the
spatial model in 3.8. Further discussions and details on how the model can
be extended can be found in Chapter 5.
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Chapter 5
Discussion and Future
Directions
This Chapter will be concerned with drawing conclusions and providing dis-
cussion on possible extensions to the models found in Chapter 2, 3 and 4.
It is hoped that these models can eventually provide insightful reasons as to
why the dynamics exhibited are present.
The model in Chapter 2, was developed to try and explore the dynamics
between CD8+ T-cells and tumour cells. An individual based model was ex-
amined in CompuCell3D and the Three Es of immunoediting were exhibited.
The model is an extension to the paper Matzavinos et al. [2004], whereby a
parameter variation caused the model to exhibit periodic solutions, driven
by the presence of a limit cycle. The killing mechanism within Matzavinos
et al. [2004] was utilised in the CompuCell3D model, allowing the system
to exhibit different stages of cancer growth. Future work with this model is
quite extensive. The pursuit of a model that is biologically seamless is almost
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impossible, but certain aspects of the tumour-immune environment, as well
as more extensive parameter studies, could be added to hopefully make the
model more biologically realistic.
Firstly, and the most obvious, chemotaxis can be added to the model.
Chemotaxis is when cells move in response to an extracellular chemical gra-
dient. Tumour cells realise these chemicals in order to shape the way the mass
will grow. In response, an immune cell is able to recognise these growth fac-
tors and subsequently are driven toward the tumour mass. This would be
relatively easy to implement within CompuCell3D, with the results probably
showing the immune cells combating the tumour much quicker. Moreover,
immune cells do not live indefinitely as they do in this model. They have a
natural life span, but they also have a limit to how many tumour cells they
can kill. The introduction of both chemotaxis and ageing of immune cells
would be interesting to input in the model. It is possible that these factors
may cancel each other out or the tumour cells may take more of a hold, as the
immune cells could be combating a much bigger tumour, due to the ageing
of immune cells.
Adhesion could also be changed and studied further. In the current model
set up, the immune cells only adhere to one another slightly, however tumour
cells adhere together more, allowing them to stay clustered together. Quies-
cent cells also adhere together more than tumour cells, often creating protec-
tive walls around other tumour masses. The idea would be to investigate if
tumour cell adhesion had any impact on the model or whether it was a sec-
ondary issue that just caused qualitative rather than quantitative changes.
The necrotic core also binds together as a mass and is broken down when
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in contact with the medium. This gives an area where immune cells are not
present, however the area is sucked of nutrient, preventing the tumour mass
from growing into that area. This allows the immune cells to re populate and
when the tumour is able to grow, they can mount an attack. If chemotaxis
was introduced into the model this may have a major impact. However,
the presence of hypoxic and necrotic tumour cells also creates issues. These
cells will let off growth factors to try and gain a regulatory blood network.
Again, this could be implemented using CompuCell3D, but this model is only
concerned with an avascular tumour without a blood supply.
There is also the possibility of investigating tumour cell sub populations.
This is a proposed phenomenon, discussed in the biology section, during
the equilibrium process, where the immune cells and tumour cells oscillate
around a certain level, preventing the tumour cells from gaining a blood
network. The sub population is created by the tumour cells having multiple
interactions with immune cells, killing the immune cells and subsequently
changing their phenotype. While other tumour cells die, these cells are less
immunogenic. Essentially, this type of tumour cell sub population is able to
grow without the immune system driving an effective response, while also
becoming more adept at killing. However, this has been implemented in the
next two Chapters.
In Chapter 3, two models of immune-tumour interactions were developed.
The first model focused on the infiltration of a tumour by CD8+ and CD4+ T-
cells, utilising some of the modelling techniques found in de Pillis et al. [2005].
There is much discussion in the literature, such as in Eftimie et al. [2011],
whereby it is argues that the modelling of the cancer-immune dynamic should
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not solely focus on cytotoxic T-cells, therefore this model was developed
to try and understand the important role T-helper cells play in destroying
MHC I negative tumours. However, the system exhibited no bifurcations
and therefore was shelved. In future, the development of this model could
possibly lie in extracting some of the dynamics, making the model simpler.
This may allow possible problems to be identified with certain terms. The
model was also solved using experimental data values from de Pillis et al.
[2005] and Joshi et al. [2009], therefore it may be prudent to use generic
values to see if the system does exhibit interesting dynamics. In light of this
model, it was determined that it may be interesting to develop a generic
model of two different types of immune cells, interacting with two tumour
population, with a focus on different tumour phenotypes.
The second model in this chapter developed a system whereby two im-
mune populations are attacking two tumour populations. The model utilises
methods from both de Pillis et al. [2005] and Matzavinos et al. [2004]. The
system allows two immune cells to attack both cancer cell populations, how-
ever each is better at killing one and less so the other. The model was then
shortened into two models where certain dynamics were removed. Firstly,
the constant supply terms for the immune cells was removed, as well as the
E2 cells’ attack on the T2 population. The system was seen to bifurcate and
three control parameters were identified. A spatial model was then devel-
oped, which showed heterogeneous type waves throughout the domain. The
second model reintroduced the supply terms, and the system was able to
now exhibit a periodic coexistence steady state, whereby the immune cells
are keeping the tumour cells under check. Within both of these models,
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however, the T2 population remains higher than the T1 population. This is
counter-intuitive as the T1 population is only attacked by one immune cell
type, therefore this should be the dominant cancer cell, however due to the
extra recruitment of the E1 population when interaction with the T1 cells, the
E1 cells are able to lower the T1 tumour cell bulk more effectively. Lastly, the
full system was modelled, and here the extra recruitment of the T2 popula-
tion further reduced the T2 tumour population. This model can be extended
in a number of different ways.
Future work with this model can be quite extensive. First of all, to allow
the T1 cell population to become the dominant cancer cell, certain measures
would need to be put in place. The reduction of their recruitment would need
to be implemented or the E2 cells would need to be very good at killing the T2
cells, increasing their recruitment. Also, the constant supply terms could also
be increased, although these parameters do not seem to pose much control
over the system. Another, and very obvious way to extend the model, would
be to allow both tumour cells to attack the immune cells and terms to describe
this behaviour would need to be explored. Moreover, the model is qualitative
and therefore it would be prudent to try and retain more biologically relevant
solutions by implementing some experimental parameter values. Further
analysis can then be carried out biologically on the system. Furthermore, it
would be interesting to marry both the main models in this chapter, to try
and capture the action of T-helper cells within the environment, along with
the evolution of changing tumour phenotypes.
An individual-based model was developed in Chapter 4 to examine the
dynamics between two immune populations and two tumour populations in
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an avascular tumour, using CompuCell3D. The model extends both models
in Chapters 2 and sections 3.7 and 3.8. Both immune cell populations are al-
lowed to attack the T2 population, however only the E1 immune cells are able
to kill the T1 cells, making them the dominant cancer cell. Tumour cells are
unable to kill the immune cells, however the immune cells die in the model
when in the domain for a user defined amount of Monte Carlo Steps. Nutrient
is supplied to the model by the medium cells and is generic, containing both
oxygen and glucose. The tumour cells are able to grow and divide depending
on how much nutrient is available at their core. Tumour cells turn quiescent
and then necrotic if the nutrient at their core is insufficient to support pro-
liferation. The dynamics of the model are investigated by introducing three
killing terms for the immune cells, and these are varied to try and produce
the three Es of immunoediting. Moreover, a further aim in this model was to
have all of the cell types exhibiting dynamic equilibrium. When simulating
the system, the T2 cells mostly became obsolete very quickly. This was either
due to their destruction by the immune cells or by the exponential growth
of T1 cells, which use up all the available nutrient, preventing T2 growth. In
reality, the cancer cells are thought to undergo the Warburg Effect in order
to deal with low nutrient environments and therefore, the introduction of
this effect seemed the most appropriate way to increase the T2 cells in the
domain. The T2 cells were therefore allowed to continue growth unless there
was absolutely no nutrient at their core. This had the desired effect and the
system was able to produce coexistence. However, many more elements of
the tumour immune environment can be explored using this model.
Further extensions to this model could include some major aspects of
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cancer growth. Most importantly, the immune cells only decay in the domain
due to age, and therefore, the introduction of the tumour attack against
the immune cells should be implemented. Moreover, the E2 cells could be
allowed to kill the T1 cells, just as in the main model in Chapter 3. The
dynamics of the T1 cells could also be extended by allowing them to exhibit
the Warburg Effect. Furthermore, chemotaxis could be implemented in the
model, whereby cells move in response to an extracellular chemical gradient.
Adhesion could also be studied further, with an aim to see if the reduction
of the tumour cells’ adhesion would enable them to grow more in more sites
locally, by breaking off from the main tumour, possibly allowing immune
evasion. Tumour cells also secrete growth factors to try and gain a blood
network especially when in an area where little oxygen is available, known
as hypoxia and again this model could be extended to include this. This
list is only a snapshot of extensions this system could model, however, in
conclusion, these concepts are the most prudent to implement.
In conclusion, this thesis has aimed to model different aspects of immune-
tumour interactions. It has developed two discrete and two classical models
of these dynamics to try and better understand the body’s natural ability to
kill cancer. However, it is of paramount importance that more experimental
human data be used when implementing these models to try and enrich and
validate the results. It is also important to point out that the complexities
of this disease make it impossible to accurately model all aspects of cancer
growth. However, mathematical models are an excellent tool to elucidate the
underlying dynamics of the disease and could lead to the discovery of the most
important biological actions that govern it, with a hope to develop better
302
treatments to extend the host’s life, or to eradicate the cancer completely.
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Chapter 6
Appendices
6.1 Appendix 1
Immune 1, tumour 1 varied
The percentages for the immune-tumour interactions, the number of MCS
and immune death rate in the following results, are as follows:
E1T2 = 22%
E2T2 = 77%
E1T1 = 60− 71%
MCS = 10000
Immune cell death rate: 1000MCS
The results are displayed in Figures 6.1-6.8.
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Figure 6.1: Plots showing the total number of tumour and immune cells for
60 − 61% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b)
(c) (d)
Figure 6.2: Plots showing the growth of a tumour mass interacting with a
host immune system. The types of cells and their corresponding colours in
Figures 6.2(a)-6.2(d) are as follows: proliferative tumour type 1 cells in red,
quiescent tumour type 1 cells in salmon, proliferative tumour type 2 in blue,
quiescent tumour type 2 cells in light blue, necrotic cells in black, medium
cells in grey, immune type 1 cells in green, immune type 2 in magenta. The
immune success rates are as follows: tumour type 1 and immune type 1 at
61%, tumour type 2 and immune type 1 at 22% and tumour type 2 and im-
mune type 2 at 77%. Figures 6.2(a)-6.2(d) represent the model at 2500MCS,
5000MCS, 7500MCS and 10000MCS respectively.
306
0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000
Montecarlo Steps
0
100
200
300
400
500
To
ta
l n
um
be
r o
f c
el
ls
62 Percent Immune1 Success Rate
0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000
Montecarlo Steps
0
50
100
150
200
250
300
350
To
ta
l n
um
be
r o
f c
el
ls
63 Percent Immune1 Success Rate
Figure 6.3: Plots showing the total number of tumour and immune cells for
62 − 63% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.4: Plots showing the total number of tumour and immune cells for
64 − 65% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.5: Plots showing the total number of tumour and immune cells for
66 − 67% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.6: Plots showing the total number of tumour and immune cells for
68 − 69% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.7: Plots showing the total number of tumour and immune cells for
70 − 71% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b)
(c) (d)
Figure 6.8: Plots showing the growth of a tumour mass interacting with a
host immune system. The types of cells and their corresponding colours in
Figures 6.8(a)-6.8(d) are as follows: proliferative tumour type 1 cells in red,
quiescent tumour type 1 cells in salmon, proliferative tumour type 2 in blue,
quiescent tumour type 2 cells in light blue, necrotic cells in black, medium
cells in grey, immune type 1 cells in green, immune type 2 in magenta. The
immune success rates are as follows: tumour type 1 and immune type 1 at
70%, tumour type 2 and immune type 1 at 22% and tumour type 2 and im-
mune type 2 at 77%. Figures 6.8(a)-6.8(d) represent the model at 2500MCS,
5000MCS, 7500MCS and 10000MCS respectively.
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6.2 Appendix 2
Immune 1, tumour 1 varied
The percentages for the immune-tumour interactions, the number of MCS
and immune death rate in the following results, are as follows:
E1T2 = 22%
E2T2 = 77%
E1T1 = 90− 99%
MCS = 10000
Immune cell death rate: 3500MCS
The results are displayed in Figures 6.9-6.13.
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Figure 6.9: Plots showing the total number of tumour and immune cells for
90 − 91% immune 1 kill rate when in interaction with tumour cell type 1,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.10: Plots showing the total number of tumour and immune cells
for 92 − 93% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.11: Plots showing the total number of tumour and immune cells
for 94 − 95% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.12: Plots showing the total number of tumour and immune cells
for 96 − 97% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.13: Plots showing the total number of tumour and immune cells
for 98 − 99% immune 1 kill rate when in interaction with tumour cell type
1, tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 77%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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6.3 Appendix 3
Immune 2, tumour 2 varied
The percentages for the immune-tumour interactions, the number of MCS
and immune death rate in the following results, are as follows:
E1T2 = 22%
E2T2 = 40− 43%
E1T1 = 90%
MCS = 20, 000
Immune cell death rate = 1000MCS
The results are displayed in Figures 6.14-6.17.
315
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Montecarlo Steps
×104
0
100
200
300
400
500
600
700
To
ta
l n
um
be
r o
f c
el
ls
40 Percent Immune2 Success Rate
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Montecarlo Steps
×104
0
100
200
300
400
500
600
To
ta
l n
um
be
r o
f c
el
ls
41 Percent Immune2 Success Rate
Figure 6.14: Plots showing the total number of tumour and immune cells
for 40 − 41% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 90% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.15: Plots showing the total number off tumour and immune cells
for 42−43% percent immune 2 kill rate when in interaction with tumour cell
type 2, tumour type 1 and immune type 1 at 90% and tumour type 2 and
immune type 1 at 22%. Tumour cell 1 is represented by the red line, tumour
cell 2 is represented by the blue line, immune cell 1 is represented by the green
line and immune cell 2 by the pink line.
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(a) (b)
(c) (d)
Figure 6.16: Plots showing the growth of a tumour mass interacting with
a host immune system. The types of cells and their corresponding colours
in Figures 6.16(a)-6.16(d) are as follows: proliferative tumour type 1 cells
in red, quiescent tumour type 1 cells in salmon, proliferative tumour type 2
in blue, quiescent tumour type 2 cells in light blue, necrotic cells in black,
medium cells in grey, immune type 1 cells in green, immune type 2 in ma-
genta. The immune success rates are as follows: tumour type 1 and immune
type 1 at 90%, tumour type 2 and immune type 1 at 22% and tumour type 2
and immune type 2 at 43%. Figures 6.16(a)-6.16(d) represent the model at
2500MCS, 5000MCS, 7500MCS and 10000MCS respectively.
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(a) (b)
(c) (d)
Figure 6.17: Plots showing the growth of a tumour mass interacting with
a host immune system. The types of cells and their corresponding colours
in Figures 6.17(a)-6.17(d) are as follows: proliferative tumour type 1 cells
in red, quiescent tumour type 1 cells in salmon, proliferative tumour type 2
in blue, quiescent tumour type 2 cells in light blue, necrotic cells in black,
medium cells in grey, immune type 1 cells in green, immune type 2 in ma-
genta. The immune success rates are as follows: tumour type 1 and immune
type 1 at 90%, tumour type 2 and immune type 1 at 22% and tumour type 2
and immune type 2 at 43%. Figures 6.17(a)-6.17(d) represent the model at
12500MCS, 15000MCS, 17500MCS and 20000MCS respectively.
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6.4 Appendix 4
Immune 2, tumour 2 varied
The percentages for the immune-tumour interactions, the number of MCS
and immune death rate in the following results, are as follows:
E1T2 = 22%
E2T2 = 30− 39%
E1T1 = 95%
MCS = 20, 000
Immune cell death rate = 2500MCS
The results are displayed in Figures 6.18-6.24.
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Figure 6.18: Plots showing the total number of tumour and immune cells
for 30 − 31% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.19: Plots showing the total number of tumour and immune cells
for 32 − 33% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.20: Plots showing the total number of tumour and immune cells
for 34 − 35% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.21: Plots showing the total number of tumour and immune cells
for 36 − 37% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.22: Plots showing the total number of tumour and immune cells
for 38 − 39% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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(a) (b)
(c) (d)
Figure 6.23: Plots showing the growth of a tumour mass interacting with
a host immune system. The types of cells and their corresponding colours
in Figures 4.47(a)-4.47(d) are as follows: proliferative tumour type 1 cells
in red, quiescent tumour type 1 cells in salmon, proliferative tumour type 2
in blue, quiescent tumour type 2 cells in light blue, necrotic cells in black,
medium cells in grey, immune type 1 cells in green, immune type 2 in ma-
genta. The immune success rates are as follows: tumour type 1 and immune
type 1 at 90%, tumour type 2 and immune type 1 at 22% and tumour type 2
and immune type 2 at 38%. Figures 6.23(a)-6.23(d) represent the model at
2500MCS, 5000MCS, 7500MCS and 10000MCS respectively.
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(a) (b)
(c) (d)
Figure 6.24: Plots showing the total number of interacting with a host im-
mune system. The types of cells and their corresponding colours in Figures
6.24(a)-6.24(d) are as follows: proliferative tumour type 1 cells in red, quies-
cent tumour type 1 cells in salmon, proliferative tumour type 2 in blue, qui-
escent tumour type 2 cells in light blue, necrotic cells in black, medium cells
in grey, immune type 1 cells in green, immune type 2 in magenta. The im-
mune success rates are as follows: tumour type 1 and immune type 1 at 90%,
tumour type 2 and immune type 1 at 22% and tumour type 2 and immune
type 2 at 38%. Figures 6.24(a)-6.24(d) represent the model at 12500MCS,
15000MCS, 17500MCS and 20000MCS respectively.
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6.5 Appendix 5
Immune 2, tumour 2 varied
The percentages for the immune-tumour interactions, the number of MCS
and immune death rate in the following results, are as follows:
E1T2 = 22%
E2T2 = 30− 39%
E1T1 = 95%
MCS = 20, 000
Immune cell death rate = 3500MCS
The results are displayed in Figures 6.25-6.29.
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Figure 6.25: Plots showing the total number of tumour and immune cells
for 30 − 31% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.26: Plots showing the total number of tumour and immune cells
for 32 − 33% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.27: Plots showing the total number of tumour and immune cells
for 34 − 35% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.28: Plots showing the total number of tumour and immune cells
for 36 − 37% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
327
0 2000 4000 6000 8000 10000 12000 14000 16000
Montecarlo Steps
0
50
100
150
200
To
ta
l n
um
be
r o
f c
el
ls
38 Percent Immune2 Success Rate
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Montecarlo Steps
×104
0
20
40
60
80
100
120
140
To
ta
l n
um
be
r o
f c
el
ls
39 Percent Immune2 Success Rate
Figure 6.29: Plots showing the total number of tumour and immune cells
for 38 − 39% immune 2 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 1 at 22%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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6.6 Appendix 6
Immune 2, tumour 2 varied
The percentages for the immune-tumour interactions, the number of MCS
and immune death rate in the following results, are as follows:
E1T2 = 22%
E2T2 = 30− 39%
E1T1 = 95%
MCS = 20, 000
Immune cell death rate = 3000MCS
The results are displayed in Figures 6.30-6.34.
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Figure 6.30: Plots showing the total number of tumour and immune cells
for 10 − 11% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.31: Plots showing the total number of tumour and immune cells
for 12 − 13% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.32: Plots showing the total number of tumour and immune cells
for 14 − 15% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.33: Plots showing the total number of tumour and immune cells
for 16 − 17% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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Figure 6.34: Plots showing the total number of tumour and immune cells
for 18 − 19% immune 1 kill rate when in interaction with tumour cell type
2, tumour type 1 and immune type 1 at 95% and tumour type 2 and immune
type 2 at 20%. Tumour cell 1 is represented by the red line, tumour cell 2 is
represented by the blue line, immune cell 1 is represented by the green line
and immune cell 2 by the pink line.
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